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ABSTRACT OF DISSERTATION 
SCIENCE-BASED REGULATION OF PHARMACOLOGICAL SUBSTANCES IN 
COMPETITION HORSES 
Current testing methodologies within equine forensic toxicology focus on arbitrary 
thresholds and zero-tolerance policy.  Modern analytical chemistry’s limits of detection are 
low enough that oftentimes femtogram-per-milliliter amounts of a substance can readily be 
identified in both blood and urine of a horse.  For most pharmacologically relevant 
compounds, these concentrations have no relevance to pharmacological effect.  It is 
therefore crucial that testing methodologies to determine appropriate thresholds and cut-
offs be developed that are driven by biological activity rather than arbitrary limits of 
detection.  This dissertation looks to address this by suggesting a system of calculated 
Effective Plasma Concentrations by which a safety factor may be determined to calculate 
an Irrelevant Plasma Concentration that may act as a regulatory threshold.  In support of 
such pharmacokinetic studies, novel synthetic pathways have been developed to produce 
reference standards and stably isotopically labelled deuterated internal standards. 
The research undertaken in this thesis is comprised of three primary areas 
of focus: (1) the development of novel synthetic pathways for certified reference standards 
and internal reference standards, (2) the pharmacokinetic description of biologically 
relevant compounds using modern techniques so as to guide both horsepersons and 
regulators in the horse industry, and (3) the description of environmental contamination 
risk for compounds and their ability to be taken up by the animals and later detected by 
forensic investigators from these residual exposures. 
Of the first category, three papers are presented, each representing the novel 
synthesis of a different compound of biological importance.  The first compound 
synthesized was deuterated (d6) xylazine as use as an internal standard for quantitation of 
the therapeutic compound xylazine.  The second compound was the novel synthesis and 
purification of barbarin, a naturally occurring glucosinolate which is believed to be 
responsible for the appearance of a DEA Schedule I compound in horse urine.  The 
synthesis of barbarin as described is the first known chemical synthesis of the compound, 
which until this point had only been previously extracted from biological samples.  The 
third paper covers the synthesis of a deuterated (d5) barbarin for use as an internal standard 
in its quantitation. 
The second category covers the pharmacokinetic studies, the first of which is a pilot 
study which looked at the terminal half-life of mepivacaine in thoroughbred horses.  This 
study offers guidance for horsepersons and veterinarians on proper withdrawal times for 
the given regulatory thresholds of the compound when using therapeutic doses up to four-
hundred milligrams as well as describing the pharmacokinetic model developed in 
determining these withdrawal times. The next study looks at methylprednisolone 
administration across multiple joints and the effects of specific joint injections and co-
injections on the detection of the compound out to six days post-administration.  This paper 
also offers guidance to withdrawal of animals after therapy and highlights many of the 
problems in current regulatory guidance.  The final paper looks at betamethasone in harness 
racing and suggests testing thresholds based upon pharmacokinetic and statistical models 
at a six-day withdrawal timeline. 
The final paper discusses the likelihood of the commonly used non-steroidal anti-
inflammatory drug naproxen to contaminate the environment of the horse.  It also looks 
establishes a suggested screening limit of detection for the compound based upon the 
concentrations of a series of innocuous positives that appeared at a racetrack upon changing 
testing facilities.  This paper highlights the importance of consistency between testing 
facilities as well as the need for expanded established limits instead of the zero-tolerance 
regulation of most compounds. 
Finally, the dissertation concludes with a synopsis of the research presented along 
with suggestions on how the racing industry may move forward in its testing of the animals 
in both a way that will be less burdensome in the future as well as more appropriate to 
protecting the health and livelihood of the animals on which it relies. 
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Models, Novel Syntheses, Environmental Contamination 
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CHAPTER 1.  INTRODUCTION 
1.1 The World is Watching 
Equine Forensic science made worldwide news at the 1968 Kentucky Derby.  The 
Sunday before the world-renowned race, the horse Dancer’s Image was reportedly treated 
with phenylbutazone, a common nonsteroidal anti-inflammatory drug [NSAID].  The 
following Saturday, Dancer’s Image would go on to win the Kentucky Derby, only to be 
later disqualified due to testing positive for phenylbutazone (Hackett, 1968).  The 
controversy made world-wide news, including the cover of Sports Illustrated, and brought 
equine forensics to the forefront of many debates.  Current rulings now allow a threshold 
amount of phenylbutazone to be detected in the horse at competition – 0.3 micrograms per 
milliliter of plasma or serum – and these levels are expected to be reached by 48 hours of 
the administration of a single dose (RMTC 2019).  However, in 1968, quantitation of the 
substance was not possible, so any ‘positive’ was disqualifying. 
The ‘positive’ was contested by the owner, Peter D. Fuller.  Theories began to crop 
up with those that believed Fuller, including the likelihood of a malicious dosing of the 
therapeutic compound the day of the racetrack in order to cause a ‘positive’ result to appear 
(Cady, 1970).  While this may sound far-fetched, Fuller had made enemies in the industry 
and the region, as he supported the civil rights movement, including donating the winnings 
from a previous race to Coretta Scott King two days after the assassination of her husband 
earlier that year. 
Only six years later, in 1974, phenylbutazone would be legalized for use in horses 
by the Kentucky Racing Commission, however to this day, Dancer’s Image is officially 
considered a disqualification (Christine, 1988).  With such high stakes on the line, how 
then are stewards of Thoroughbred racing best posed to protect not only the health of their 
horses, but the image of the industry as a fair and balanced community?  Modern testing 
now allows for detection of most therapeutic substances to a much more extreme level and 
understanding the need for regulatory thresholds will only help prevent another such 
scandal from surfacing.  
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1.2 The World is Watching, Again 
Until May 9, 2021, no other horse to cross the finish line at the Kentucky Derby 
tested positive for a substance above the allowed substance limit.  However, international 
attention was brought upon the race once again as the horse to finish first, Medina Spirit, 
would go on to test positive for the glucocorticoid betamethasone at a reported level of 21 
picograms-per-milliliter of blood.  The Association of Racing Commissioners International 
[ARCI] and Racing Medication and Testing Consortium [RMTC] at the time recommended 
a threshold limit of 10 picograms-per-milliliter in blood for betamethasone in harness races 
and zero-tolerance in flats races, lowered from its previous recommended threshold of 100 
picograms-per-milliliter in blood with no citation as to the reason presented by the RMTC. 
The Kentucky Horse-Racing Commission [KHRC] had recently changed the policy 
regarding the pain reliever to a zero-tolerance limitation for detection at the time of the 
race (Paulick Report Staff, 2021). 
Media attention soon swamped the public with reports of a ‘banned steroid’ that 
would disqualify Medina Spirit’s claim to being the Kentucky Derby winner (Managan 
2021).  The world soon came crashing down on the horse-racing industry, as personalities 
ranging from athletes, animal rights’ activists, and more made commentary on the use of 
steroids on animals.  This effect served no positive purpose to the horseracing industry 
besides to tarnish its reputation.  Betamethasone, while technically a steroid, is best 
described as a glucocorticoid and is predominantly used to help with joint pain.  Even if 
levels detected in Medina Spirit were from those introduced to the correct physiological 
structure rather than topically, the reported levels would almost certainly offer no 
pharmacological relevance to the race in question, in my opinion.  Possibly more 
importantly to the public image of horseracing, however, is the fact that betamethasone is 
not banned from the industry and is commonly used to help prevent inflammation and 
immune response in joints that are worked hard during training.  While it is regulated at 
the horse track, at the levels reported, it is far from the performance-enhancing drug [PED] 
as the media painted it but is instead a legitimate therapeutic that is properly used to 
maintain the health and welfare of the animal. 
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The trainer of Medina Spirit, Bob Baffert, would contest the presence of 
betamethasone and request a split sample analysis for confirmation.  Initially, Baffert 
claimed that they had not administered betamethasone to the animal whatsoever and 
suggested that it was perhaps a malicious administration.  This statement would later be 
reversed when it came to his attention that a topical ointment, Otomax, that had been used 
to treat topical dermatitis Medina Spirit had developed on her hindquarter.  Otomax’s 
primary therapeutic compound is gentamicin sulfate, a broad-spectrum anti-yeast and anti-
bacterial compound used to control otitis in canines.  Betamethasone is present in the 
ointment as well to help treat inflammation at the site.  Clotrimazole is an antifungal present 
in the ointment as well.  Baffert claims that the ongoing treatment of Medina Spirit with 
Otomax was likely the cause of the presence of betamethasone in the animal at the time of 
the race and holds that it had no effect on the integrity of the race itself (Frakes, 2021). 
On June 2, 2021, the split sample results were announced, indicating that 25 
picograms-per-milliliter of betamethasone had been detected in the blood of Medina Spirit.  
No further testing has been announced at the time of this writing, though Clark Brewster, 
the attorney representing Baffert, has stated that they plan on testing the samples for other 
compounds in the Otomax ointment to further strengthen their case that the presence of 
betamethasone was due to the use of said ointment rather than a joint injection (Bonesteel, 
2021).  Meanwhile, arguments are being prepared by both parties involved on whether that 
such positives should be considered rules violations or be shown leniency.  Regardless of 
the outcome, the world will more likely remember the ‘drug use in horseracing’ headlines, 
and count this as a strike against the integrity of the sport. 
1.3 Financial Impact of the Industry 
As of a 2017 study, the United States horse industry contributes fifty billion dollars 
in direct economic impact to the U.S. economy and supports approximately one million 
jobs.  Including indirect and induced spending, this impact totals over about 122 billion 
dollars and a combined effect on employment of 1.7 million jobs.  Undoubtedly, these 
numbers have since increased since 2017.  Of the 7 million horses in the United States, 
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approximately 1.2 million are active in horseracing, which comprises one of the largest 
economic impact sectors of the US equine industry (AHC, 2017). 
Over 165 million dollars in wagers were placed on the 2019 Kentucky Derby alone 
(Paulick Report, 2019).  As an indicator for money both generated by the industry and 
wagered within the industry, a focus on the fairness of the sports medicine applied to the 
athletes (the horses) is of utmost importance, both in terms of the protection of the bettor 
and, more importantly, in terms of the protection of the animals themselves.  The key 
discipline in offering regulators a window into the pharmacological mechanisms active 
within the horse at the time of the race, and therefore the leading technology for protecting 
these animals, is equine forensic science. 
1.3.1 Equine Forensic Science 
Current Equine forensic toxicological practice within the United States for the 
sports horse industry focuses on a zero-tolerance regulatory concept, with defined 
exceptions for specific therapeutic medications, and endogenous, dietary, and 
environmental substances.  That is, allowable levels of therapeutic compounds are those 
which are below the analytical level of detection, unless a specific threshold is established.  
However, as of the start of 2020, this extends only to twenty-eight Controlled Therapeutic 
Medications, three of which are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which 
are restricted to a single type being present per forensic sample (RMTC, 2020). 
The thresholds established for the above classes of medications range from 3 
picograms per milliliter (3 parts per trillion) in plasma for glycopyrrolate, an 
anticholinergic, to 10.0 micrograms per milliliter (10.0 parts per million) in plasma for 
dimethyl sulfoxide [DMSO], a topical analgesic and transdermal carrier.   Most 
compounds, however, are regulated in the range of picograms (9 total) to nanograms (17 
total) per milliliter. 
The Association of Racing Commissioners International [ARCI] publishes these 
thresholds and cites the “dosing specifications” from which these thresholds are established 
but does not always provide a direct citation of the studies on which they are based, though 
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a reference chart is offered for some example studies (ARCI 2020; RMTC, 2017).  
However, they do provide for horsepersons a suggested “withdrawal guideline” based on 
these administrations that represent guidance for their estimated time for the experimental 
administration dosage to reach a level that should be below the established threshold, as 
calculated by a “95/95 Tolerance Interval” (RMTC, 2016). 
A 95/95 Tolerance Interval is a statistical interval which predicts the values by 
which 95% of a given population will fall within a range (at 95% confidence).  That is, 
given 100 members of the population, i.e., racehorses, it is assumed that there is a 95% 
chance that 95 of those horses would be predicted to show behavior, i.e., test below the 
given range/threshold.  Within the RMTC case, this is taken as a one-sided interval (that 
is, 95% of the population will fall at or below the threshold).  The guidelines put forth by 
the RMTC also assume that the any residual amounts within the population will follow 
normal (or log-normal) distributions, which is often not statistically proven for any given 
regulated compound.  While this is the case for many biological functions, it fails to take 
account of many confounding sources of variance, such as the potential presence of 
genetically distinct drug metabolizing subpopulations or differences in exercise, diet, 
gender, or other environmental factors.   
On June 12, 2021, Pimlico Racecourse ran eight races, totaling 84 different 
thoroughbreds that ran through the starting gates that day.  The mathematical assumption 
that 5% of those that received legitimate therapeutic medications that end up being tested 
may be disqualified from the race points to an inevitability – the penalizing of innocent 
trainers, owners, and their animals for the presence of a substance that had no effect on the 
integrity of the race itself.  As long as thresholds continue to be based on withdrawal 
windows that are arbitrarily determined rather than on physiologically relevant 
concentrations, this will continue to be a major issue for the health of the animals. 
These realities present several significant challenges and obstacles for 
horsepersons.  Even under ideal circumstances and following these guidelines rigorously, 
it would be predicted that approximately one out of every twenty animals that were 
responsibly treated while following the withdrawal guidelines would potentially be flagged 
as over the limit (‘called’/’identified’ as described later).  While that may seem 
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inconsequential, these horses are athletes and as such should have readily available access 
to certain pharmaceuticals that improve their quality of life when they have no effect on 
the outcome of a competition.  Zero-tolerance policies, however, discourage horsepersons 
from administering these therapeutics when they are in good recommendation but not 
absolutely required. These penalties are assessed against the owners and trainers of these 
horses and the severity of such penalties is only determined by the number of positive tests 
that trainer has received in his recent past (generally a one-year window).  This means that 
a successful trainer that fields one-hundred different racehorses and has two positive tests 
over the course of the year is systemically considered an equally than a trainer that fields a 
single horse and tests positive the same number of times.  
However, it is rare that the ideal circumstances will be met for a therapeutic, and 
so many pharmaceuticals’ pharmacokinetics may be reported based on inappropriate or 
outdated studies.  While subpopulations are one confounding variable, the increased 
detection capabilities of a modern mass spectrometer have allowed for a better 
understanding of ‘terminal’ half-lives, which for most compounds appear to be much 
longer than previously reported.  This decreased rate at which the pharmaceuticals are 
cleared from the body at low concentrations increases the potential for an innocent 
‘positive.’  Guidance from commissions often assumes previous ‘terminal’ half-lives are 
the truly terminal (rather than the half-life that has been measured at the time of sampling), 
which inevitably leads to the innocuous presence of legitimate therapeutics as detection 
levels become increasingly sensitive – leaving the horsepersons penalized for being good 
caretakers of their horses.  This circumstance is a major problem for the industry as a whole, 
and understanding it requires understanding the regulatory processes used by most 
commissions. 
1.4 The Regulatory Process 
“How are these medication regulations implemented?” one is left asking.  Modern 
equine forensic toxicology is primarily governed by state commissions which set the rules 
(in the United States, often in line with those suggested by the RMTC/ARCI).  However, 
testing itself is generally carried out by independent laboratories.  These laboratories test 
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blood and urine samples for therapeutic compounds via an array of methodologies and 
generally confirm their identifications/quantitation via mass spectrometry.  Whenever a 
regulated substance is found to be above the defined threshold it is their task to report these 
findings to the relevant commission, which may then proceed with regulatory action 
against the trainer/owner.    
There are several terms that should be carefully defined for this discussion.  
Oftentimes you will hear the term ‘positive’ used to describe the detection of a 
pharmaceutical or other bioactive compound within a testing environment.  Within the 
context of the racing industry, it is important to differentiate between ‘identifications,’ 
‘calls,’ and a ‘positives.’  An ‘identification’ in this case is the forensic laboratories 
identifying the presence of a compound of interest in the test samples.  A ‘call’ is whenever 
said compound is reported to the commissions for being present above a threshold.  Finally, 
a ‘positive’ is the step when a commission considers a rules violation to have occurred and 
undertakes proceedings against person for violation of rules.  Note that this may differ 
slightly from the ARCI definition of a ‘positive’ which states that a ‘Positive Test’ “is a 
finding certified by the Laboratory that a regulatory analyte from a Prohibited Substance 
is present in the sample in an amount that exceeds the regulatory limit” (ARCI, 2019)  
However, in practice these will often be one and the same, as commissions rarely, if ever, 
decline to pursue penalties against trainers whenever a substance is reported – that is, while 
our definition of a ‘call’ may be closer to the ARCI’s definition of a ‘Positive Test,’ a ‘call’ 
will generally lead to a ‘positive.’ 
1.4.1 In-House Testing Thresholds 
However, a complication in the overall testing process is that some testing facilities 
and jurisdictions have established their own ‘in-house’ thresholds for certain compounds 
that are commonplace – such as naproxen.  These values are not available publicly but 
serve as a means to bypass lengthy legal proceedings and technical questions.   
These in-house thresholds lead to many downstream problems, however.  The lack 
of clarity on what is being reported is a prime source of confusion.  Naproxen, for example, 
has no listed RMTC threshold, and so is supposedly a zero-tolerance offense.  This means 
that while many commissions have a ruling on paper of ‘zero-tolerance’ for the compound, 
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they in practice have a threshold, based upon their testing facilities discretion.  This value 
is rarely known to either the horsepersons or commissioners, and so practical guidance is 
impossible for recommended dosing and withdrawal.  However, the regulators often 
communicate what is viewed as an effective withdrawal guideline to the community, but 
without defined regulatory or scientific support.  Likewise, any ‘positive’ that is called by 
a laboratory with a lower in-house threshold than another can create regulatory problems, 
depending on the concentration reported. 
Just such a problem arose whenever an authority (West Virginia Racing 
Commission) within the United States changed testing facilities from one (Truesdail 
Laboratories) with an in-house testing limit for naproxen to one without (Industrial 
Laboratories).  Suddenly, low-level positives for the compound began being called in the 
region for horsepersons that previously had a clean record of any violation.  Further 
investigation revealed that the change in testing facilities accompanied an alteration to a 
zero-tolerance in-house threshold for the compound.  Statistical work on the low-level 
reports indicated that an appropriate interim threshold of 250 nanograms-per-milliliter of 
urine seemed appropriate.  While this recommendation seems to have been effective for 
the time being, the compound still does not have a recommended threshold by the 
RMTC/ARCI.  However, without an up-to-date pharmacokinetic model, it is unlikely that 
a meaningful withdrawal guideline can be given to the industry. 
Despite the recommendations and guidelines put forth, sporadic ‘positives’ will 
often still occur from members of the racing community with no known history of 
medication abuse that leave both the individual and commissions confounded by their 
origin.  Classic examples include apparent human-to-horse transfers for tramadol, 
dextromethorphan, and cocaine/benzoylecgonine [BZE].  These positives often imply one 
or multiple issues with the current regulatory methodologies, as the source of the 
medication is innocent and inadvertent, while the levels reported are often physiologically 
irrelevant.  In other cases, trace contaminants in the environment may lead to the 
identification of a compound in the forensic sample, either by introduction during or after 
collection or inadvertent exposure to the athlete.  This second point is especially 
problematic for compounds that are ubiquitously used by humans and either 
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environmentally stable or particularly readily detected (cocaine, caffeine/chocolate, 
naproxen). 
These sporadic, environmentally-related ‘positives’ should be of use to regulators 
when appropriately understood, however.  If they occur in large enough numbers with no 
known cause, it is often possible to determine a specific reasonable cut-off threshold.  For 
example, a published paper discussed in more detail later showed an appropriate threshold 
of 250 nanogram-per-milliliter urine for naproxen used outlier analysis to determine an 
interim threshold (Machin, et al 2020).  This not only helps in the absence of studies using 
modern detectors, but also informs the presence of environmental sources and what may 
be considered unobjectionable exposures.  This emphasizes on the need to have ‘in-house’ 
testing thresholds reported so that they may be reviewed.  Meta-analyses of previous 
studies may also offer similar insight, as they allow aggregation of datasets to better 
understand the pharmacology of the population at large. 
‘In-house’ thresholds are not the only problem with lack of clarity presented by the 
methods of regulation in modern equine forensic toxicology: many of the thresholds in 
place cite literature which is either not specified, unpublished, or failed to be cited all 
together.  Even when the citations are publicly available, the interpretation of the data is 
not, resulting in ambiguity with regards to exact methodology used in determination of 
these thresholds and withdrawal timelines. 
Horsepersons often must simply take these rulings as presented by the authority 
that the rules and regulations are not only being formulated appropriately but being 
enforced in a sensible way, as well.  Without access to the studies and interpretations of 
those making the rules, updates to the system are unlikely to occur with haste or accuracy.  
This is especially problematic for legitimate therapeutics that are not listed by the 
RMTC/ARCI, indicating that their allowable levels fall below that of the Limit of 
Detection of a modern mass spectrometer.  It also, however, is a problem for illicit 
substances that may be found in the environment of the athletes and their staff. 
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Ultimately, the application of zero-tolerance detection policies will only cause 
further headaches in the future as detection capabilities increase while the biology of the 
animals remains relatively constant.  Ideally, appropriate thresholds for all compounds will 
be determined based on biological activity rather than simple detection.  In the meantime, 
however, pharmacokinetic studies are of crucial importance in protecting both the animal-
athletes and their caretakers. 
1.4.2 In the Interests of the Horse 
Ultimately, the welfare of the animals would best be served by a governing system 
of rules that allows for the appropriate and legitimate use of therapeutics while restricting 
them from competing while under the effect of such compounds.  Such a system could 
allow for many therapeutics to be at modern detectable levels while disallowing such levels 
that may affect the outcome of a competition.  For instance, if a High No Effect Dose 
[HNED] were to be determined for a compound, then some safety factor below this dose 
could be taken into account when establishing a relevant cut-off for detection.  Not only 
would this system allow for legitimate therapeutic uses that protect the integrity of the 
competition, but it would also act to future-proof many forensic regulations, in that 
increased sensitivity in testing need not be considered for an established threshold.  Certain 
compounds may still receive a “zero tolerance” ruling, such as the use of anabolic steroids, 
but these appear much more straight forward in citing as disallowed than the current 
regulatory state in which only those cited are allowed. 
In fact, such a model has been proposed and is addressed and utilized in our studies 
on naproxen (Machin, et al 2020).  While the safety factor appears to be relatively high in 
this case, using it as a basis from which to expand seems a well-reasoned place to start.  
Appropriate safety factors grounded in current thresholds for differing classes of RMTC 
allowed thresholds may be calculated to determine what is an appropriate interim threshold 
before full HNED, pharmacological, and pharmacokinetic studies may be performed.  For 
these studies to be accomplished, appropriate reference standards need to be synthesized. 
11 
1.4.3 The Need for Reference Standards 
Of critical importance in performing these pharmacological studies is access to 
high-quality reference standards.  While many pharmacological compounds are readily 
available for use in standards, oftentimes their stable-isotopically labelled counterparts are 
not.  Even more of a problem, oftentimes the reference compound of interest to the 
regulator is not the parent drug, but a metabolite of said compound that is not available 
whatsoever for purchasing as pure standards.  The novel syntheses of pharmacologically 
relevant compounds and their labelled forms is an important and often overlooked aspect 
of the forensic toxicologist. 
Horseracing laboratories are generally accredited under the International 
Laboratory Accreditation Cooperation section G7 [ILAC G7].  Under these guidelines, 
identification of a prohibited substance must “normally result from direct comparison with 
a reference material analyzed in parallel or series with the test sample.”  Generally, these 
reference materials should be either a direct chemical reference or a stable isotopically 
labelled form, as required for identification or quantitation, respectively. 
With this in mind, the novel syntheses of many of these small molecular compounds 
is of great import to the regulatory systems currently in place.  Both for the parent 
compounds of pharmaceuticals as well as their metabolites.  While it is often the case that 
in the equine model the molecule is both hydroxylated and then glucuronidated and 
excreted into the urine via this secondary step of metabolism, the parent compound is often 
recovered via cleaving by beta-glucuronidase and hence the regulatory chemical of interest.  
For pharmaceutical compounds these may or may not always be available as ISO-certified 
reference standards, and so the small-scale synthesis is important to establish.  Likewise, 
the development of this type of novel synthesis often opens the door to the synthesis of 
isotopically-labelled forms – generally via deuterium. 
This is just such the case for the novel syntheses developed for xylazine and the 
deuterated d6-xylazine.  Xylazine is an agonist at the alpha-2 class of adrenergic receptors 
generally used for sedation and anesthesia.  It is currently suggested to have a forty-eight-
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hour withdrawal period for a dose of two-hundred milligrams via IV bolus at two hundred 
picograms-per-milliliter in blood plasma or serum.  Prior to our development, there was 
not a reported synthetic pathway to make deuterium-labelled xylazine for use as an internal 
standard, and so quantitation was limited.  While only an incremental step, it is a necessary 
one for proper regulation of xenobiotics accepted to have thresholds. 
Naturally occurring compounds are often a source of possible ‘positives’ as well.  
One unexpected culprit is the compound barbarin, a secondary metabolite and 
glucosinolate found predominately in its namesake plant Barbarea vulgaris, commonly 
Yellow Rocket.  B. vulgaris is endemic to most of the northern hemisphere, and while 
unlikely to be eaten as a food source on its own, evidence has shown that it is readily eaten 
when mixed with feed and that doing so leads to the detection of aminorex in the urine of 
the horse afterwards (Maylin, 2019).  Barbarin itself is not a regulated compound but is 
believed to be the causative agent in the metabolism of B. vulgaris in causing the detection 
of aminorex – a DEA Schedule I substance -- in equine urine. 
Traditionally, barbarin was produced by lysing the cells of B. vulgaris and purifying 
the molecule.  While relatively straightforward, it was unable to be produced in large 
amounts economically.  With that in mind, we developed a novel synthesis of both 
reference standard barbarin as well as the deuterium-labeled equivalent for use as certified 
reference standards. 
Ultimately, having a systematic approach to the development of thresholds for 
every class of pharmacological compounds not only would streamline regulation, but give 
guidance and coverage to horsepersons and veterinarians caring for their animals.  As it is, 
the ‘zero tolerance with exceptions’ is quite the opposite of the ideal situation for 
performance horses and their health. 
1.5 Pharmacokinetic Studies 
With proper pharmacokinetic studies, the availability of certified reference standards, and 
an understanding of environmental exposures, the current system of regulation can be 
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greatly improved as governing bodies move towards a biology-based regulatory model.  In 
the transition, however, a model system needs to be proposed, and that is what follows by 
example. 
Naproxen, as described previously, is a commonly used NSAID that has a long 
half-life in the environment and can be readily taken back up by the equine patients that 
remain in the treatment environment, or those areas contaminated by other treated animals.  
While levels from environmental exposure are unlikely to ever be close to those that are 
biologically relevant, it is important that an appropriate threshold be established for its 
regulation.  A biology-based regulatory model should take into account the ‘Effective 
Plasma Concentration’ [EPC] as described by Toutain (Toutain, 2002a, b) and some safety 
factor to determine what is considered an ‘Irrelevant Plasma Concentration’ [IPC].  This 
IPC should be based upon a hierarchy of knowledge for the compound. 
The best situation would be a safety factor that is based on the known pharmacology 
of the compound; however, this is not always practical.  When in-depth data is not 
available, looking at the class of the therapeutic and safety factors used for these should be 
used as guidance.  Finally, when neither of these datapoints are known, an extremely 
cautious safety factor should be taken. 
Toutain suggested an initial safety factor of approximately 500 to be conservative.  
While this certainly would be an IPC, it is likely too conservative to be universally applied.  
Our work with naproxen (Machin 2020) suggested a factor of approximately fifty, as this 
is within the standard range of actual regulatory thresholds for other NSAIDs.  Our 
suggested threshold also fits well with the data available for the sporadic ‘calls’ that were 
caused by the shifting of testing facilities, so would likely cover most innocent 
identifications. 
Certain compounds, of course, should be regulated even more strongly than a 
standard ‘conservative’ IPC safety factor.  An example of this currently is guaiphenesin – 
an expectorant and skeletal muscle relaxant, which is approximately 1000 times less than 
the effective plasma concentration (or half that of Toutain’s recommended conservative 
IPC). 
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Following are specific examples of related reports and research accomplished with 
a brief summary. 
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CHAPTER 2. STUDY SYNOPSES AND PUBLICATIONS 
The following will consist of a cover page giving a synopsis of a study performed 
followed by the publication, both accepted and submitted.  These articles will be broken 
into three primary categories: Novel Syntheses of Standards, Trace Level Therapeutic 









2.1 Novel Syntheses of Standards 
2.1.1 Synthesis, Purification, and Certification of Xylazine-d6 for Equine Medication 
Regulation 
Abstract: Xylazine, N-(2,6-Dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine, is a 
short-acting alpha-2 agonist tranquilizer approved for therapeutic use in horses. Xylazine 
is also an Association of Racing Commissioners International [ARCI] Controlled 
Therapeutic Medication [CTM] with potential to affect equine performance. As such, in 
the United States its use in competition horses is regulated via a regulatory threshold in 
plasma for parent xylazine. We have therefore synthesized, purified and certified xylazine-
d6, a deuterated analogue of xylazine, for use as an internal standard in quantification of 
xylazine. Xylazine-d6 was prepared commencing with commercially available 2,6-
dimethyl-d6-aniline, which was reacted with thiophosgene to yield the isothiocyanate 
intermediate. Reaction of the isothiocyanate intermediate with 3-amino-1-propanol, 
followed by refluxing in concentrated HCl produced xylazine-d6 in moderate yield (40%) 
which was then purified and fully characterized by NMR, HPLC, GCMS and high-
resolution mass spectroscopy for reference standard certification. 
Introduction:  Xylazine is a rapidly acting alpha-2 agonist and tranquilizer commonly used 
in the horse-racing industry. Regulatory thresholds within the US for xylazine restricted it 
to no more than 200 pg/mL in blood at the time of the race.  Prior to this value, urinary 
concentrations were used to determine xylazine and used its primary metabolite (4-
hydroxyxylazine.  The changing to parent xylazine as the molecule of interest demands the 
need for a deuterated internal standard and reference standard. 
Experimental:  
The first reaction takes the above produced aniline and dissolves it in 
dichloromethane followed by the drop-wise addition of triethylamine and thiophosgene 
under ice-cooled conditions.  The mixture is allowed to stir for an hour at room temperature 
17 
before being poured over ice and extracted into dichloromethane resulting in 2,6-d6-
dimethylphenylisothiocyanate. 
The final step of the preparation is dissolving the produced isothiocyanate in 
dichloromethane with the addition of 3-aminopropanol and allowing to reflux overnight 
with stirring.  Solvent is removed via rotary evaporation and an addition of concentrated 
hydrochloric acid before being allowed to reflux overnight once again.  This final solution 
is then poured over a 10% sodium hydroxide solution and stirred for three hours, the 
xylazine-d6 precipitating out as the hydrochloride salt. 
The reaction and products were characterized via proton nuclear magnetic 
resonance spectroscopy as well as both GCMS and LCMS.  Combustion analysis was used 
to verify composition and purity.  Certificates of analysis are available for the resultant 
product. 
Conclusion: Xylazine-d6 is now available for use in gram quantities and well characterized 
for use as an internal standard in forensic sciences in compliance with ISO analytical 
standards. 
Citation: Machin, J., Kudrimoti, S., Brewer, K., Eisenberg, R., &amp; Tobin, T. (2016). 
Synthesis, Purification and Certification of Xylazine-d6 for Equine Medication Regulation. 
Proceedings of the 21st International Conference of Racing Analysts and Veterinarians, 
Uruguay 2016, 21(1), 102–106. 
Personal Contribution: Development of synthetic scheme based on previous work from 
same laboratory on the synthesis of deuterated hydroxyxylazine, sourcing of materials, 
benchwork/wet chemistry (under guidance of Dr. Sucheta Kudrimoti), assisted in proton-
NMR work for confirmation of product, wrote manuscript. 
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SYNTHESIS, PURIFICATION AND CERTIFICATION OF XYLAZINE-d6 FOR 
EQUINE MEDICATION REGULATION 
J. Machin1*, S. Kudrimoti1, K. Brewer3, R. Eisenberg2 & T. Tobin*
1 The Gluck Equine Research Center, University of Kentucky, Lexington, KY 40546 USA 
2 Frontier BioPharm, LLC, PO Box 614, Richmond, KY, 40476 USA 
31711 Lakefield North Court, Wellington, FL 33414 USA 
*Corresponding author’s email: jmachin@icloud.com & ttobin@uky.edu
ABSTRACT 
Xylazine, N-(2,6-Dimethylphenyl)-5,6-dihydro-4H-1,3- thiazin-2-amine, is a short-acting 
alpha-2 agonist tranquilizer approved for therapeutic use in horses. Xylazine is also an 
Association of Racing Commissioners International [ARCI] Controlled Therapeutic 
Medication [CTM] with potential to affect equine performance. As such, in the United 
States its use in competition horses is regulated via a regulatory threshold in plasma for 
parent xylazine. We have therefore synthesized, purified and certified xylazine-d6, a 
deuterated analogue of xylazine, for use as an internal standard in quantification of 
xylazine. Xylazine-d6 was prepared commencing with commercially available 2,6-
dimethyl-d6- aniline, which was reacted with thiophosgene to yield the isothiocyanate 
intermediate. Reaction of the isothiocyanate intermediate with 3-amino-1-propanol, 
followed by refluxing in concentrated HCl produced xylazine-d6 in moderate yield (40%) 
which was then purified and fully characterized by NMR, HPLC, GCMS and high-
resolution mass spectroscopy for reference standard certification. 
KEYWORDS 
Xylazine-d6, internal standard, synthesis, purification, certification 
INTRODUCTION 
Xylazine, [N-(2,6-Dimethylphenyl)-5,6-dihydro-4H-1,3- thiazin-2-amine, 
C12H16N2S, Molar mass 220.334], is a rapidly acting alpha-2 agonist analgesic and 
tranquilizer that is widely used as a short acting tranquilizer in equine medicine (Greene & 
Thurmon 1988; Tobin et al., 2012). With this in mind, it has been deemed to have the 
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potential to affect performance in racehorses (Wagner et al., 1991). Previously xylazine 
has been regulated via the quantitation of its primary urinary metabolite, 4-
hydroxyxylazine (Spyridaki et al., 2004; Tobin et al., 2012). 
Within the United States, regulations restrict the presence of the parent compound 
(xylazine) in post-race plasma testing to no greater than 200 pg/mL in blood. Such decision 
limits are determined in various ways around the world. In many countries these are based 
upon 6 horse pharmacokinetic studies (IFHA, 2016) and the resulting decision limits are 
termed screening limits. In the United States, a similar strategy is invoked with the use of 
thresholds. In the context of this paper, threshold is intended to mean a concentration of a 
non-endogenous, therapeutic substance in an equine biological specimen below which the 
sample will not be considered to contain that substance in breach of the rules. 
The recommended dose for xylazine is approximately 1 mg/kg, usually 
administered by rapid intravenous injection. Administered in this way, the plasma 
concentration of xylazine initially declines rapidly. This initial decline led to a regulatory 
threshold for xylazine to be set to 10 pg/mL in plasma in the United States but more 
recently this limit has been adjusted to 200 pg/mL in plasma, as this regulatory threshold 
value more appropriately reflects the drug’s longer terminal half-life.  Xylazine use has 
been approved by the US Food and Drug Administration in several species, most 
importantly in horses. Due to its ability to be medicinally used in racehorses, the 
Association of Racing Commissioners International [ARCI] has recognized it as a 
Controlled Therapeutic Medication [CTM] with potential to affect equine performance. 
As earlier approaches to xylazine regulation involved use of the equine urinary 
metabolite 4-hydroxyxylazine [4-OH- xylazine] as the regulatory analyte, we have 
previously synthesized and certified both 4-OH-xylazine and its deuterated analogue 
(Kudrimoti et al. 2014). More recently, however, the preferred regulatory regime has 
favored the testing of plasma over urine and consequently the target analyte has shifted 
from the metabolite to parent drug. During the 20th ICRAV meeting in Mauritius, the 
authors were asked to consider the synthesis of a deuterated xylazine standard to 
complement the deuterated metabolite. To accommodate the request and change in 




Synthesis of N-(2,6-Dimethyl-d6-phenyl)-5,6- dihydro-4H-1,3-thiazin-2-amine (Xylazine-
d6): 
Synthesis of 2,6-d6-dimethylaniline 
Sulphanilic acid (1) (5.19 g, 30 mmol) and sodium carbonate (1.8 g, 17 mmol) were 
dissolved in 50 mL of hot (60o C) water, cooled and sodium nitrite (2.1 g, 30 mmol) was 
slowly added portion-wise. The resultant mixture was left stirring for 1 hour and then 
poured onto 37 % (w/w) hydrochloric acid (6 mL) and ice (30 g), which was left to stir for 
another hour, yielding the required diazonium intermediate (2). 
Next, commercially available 1,5-d6-dimethylxylene ((3), 3.6 g, 30 mmol) was dissolved 
in hot 2.5 M sodium hydroxide (20 mL) and the resultant basic solution poured into the 
acidic solution (2) containing the diazonium intermediate. This solution was left to stir for 
1 hour at room temperature, yielding a red slurry which was heated to 55 °C and sodium 
dithionite (22.8 g, 130 mmol) was slowly added until the color turned yellow. The material 
was left stirring overnight at room temperature and the precipitated product was isolated 
via filtration to obtain 2,6-d6-dimethylaniline (4) as a yellow powder. 
Preparation of 2,6-d6- dimethylphenylisothiocyanate (5): 
The above 2,6-d6-dimethylaniline (4) (0.8 g, 4.47 mmol) was dissolved in 
dichloromethane (10 mL) followed by the addition of triethylamine (0.1 mL, 0.75 mmol) 
and thiophosgene (0.6 mL, 7.83 mmol) under ice-cooled conditions over 20 minutes. The 
resulting solution was allowed to stir for 1 hour at room temperature before being poured 
over ice (50 g) and extracted with dichloromethane to obtain 2,6-d6-
dimethylphenylisothiocyanate (5) as a crude orange powder (yield 90%). 
Preparation of xylazine-d6 (6): 
2,6-d6-dimethylisothiocyanate (5) (1.70 g, 9.50 mmol) was dissolved in a solution 
of dichloromethane (20 mL) and 3-aminopropanol (1.70 mL, 1.67 g, 22.18 mmol). The 
solution was set to reflux overnight with stirring. The following morning it was cooled to 
room temperature and the solvent was evaporated using a rotary evaporator. Concentrated 
hydrochloric acid (8 mL) was added to the product and it was allowed to reflux and stir 
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overnight once again. The solution was then poured into an aqueous solution of 10 % 
sodium hydroxide (50 mL) and stirred for 3 hours. The final product (xylazine-d6, 6) 
precipitated as a hydrochloride salt, which presented as an off-white/yellow powder. 
All organic extracts were dried with sodium sulphate, filtered, and concentrated on 
a rotary evaporator. 
Figure 2.1.1.1 Xylazine-d6 Synthesis 
Figure 1: Xylazine-d6 Synthesis shows the reported synthetic pathway. 
CHARACTERISATION 
General 
NMR spectra were measured on a Varian Unity Inova 400 MHz (CA, USA) 
spectrometer and chemical shifts are reported in ppm relative to DMSO-d6 as internal 
standard. 
GCMS spectra were obtained on an Agilent 6890 GC- 5973 MSD (CA, USA) with 
a Zebron ZB-5MSi 15 m x 0.25 mm I.D. capillary column with a 0.25 µm film thickness 
(Phenomenex, Torrence, CA, USA). Helium carrier gas was used. The injector temperature 
was 250°C, with an injection concentration of 0.1 mg/mL and 1 µL injected with an 
autosampler. Electronic Pressure Control (EPC) was used at a constant flow rate of 1.0 
mL/min carrier gas. Detection was with EI ionization operating in scan mode, 20-550 amu 
scan range with an acquisition rate of 4 samples per second. The detector temperatures 
were source at 250°C and quadrupole at 150°C. 
HPLC UV detection was carried out with an Agilent 1100 HPLC (CA, USA) 
equipped with a column heater, diode array detector and an autosampler. A binary solvent 
system consisting of water with 0.1% formic acid and HPLC grade acetonitrile (Pharmaco-
Aaper, KY, USA) with 0.1 % formic acid was used with a Phenomenex Kinetex C18 HPLC 
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column (150 mm x 2.1 mm, 2.6 µm particle with 100 Å pore size) protected with a matched 
Phenomenex C18 guard cartridge at a constant column temperature at 30°C. 
Xylazine was analyzed by injection of 5 µL of a solution at 0.1 mg/mL 
concentration. The initial solvent mixture used a linear gradient of 5% to 95% acetonitrile 
gradient over 12 minutes after a 2 min isocratic holding time at the initial conditions and 
re-equilibration at the initial conditions for 10 minutes. The flow rate was 0.18 mL/min. 
The diode array detector was monitored at 210 nm. 
Combustion analyses were carried out by Atlanta Microlabs, Atlanta, GA. 
Mass spectra were acquired on a Thermo Scientific Q Exactive Orbitrap mass 
spectrometer (Bremen, Germany). Typically, samples were dissolved in 50% acetonitrile: 
50% water and infused by syringe pump into the electrospray source at 5 uL/min. Spectra 
were acquired at 140,000 mass resolution in the positive ion mode. 
Crystallization of the crude product produced an off-white powder from ether-
hexane with melting point 137-138⁰C; 1H-NMR (400MHz, DMSO-d6): δ 2.01 (m, 2H), 
2.86 (t, 2H), 3.31 (t, 2H), 6.90 (t, 1H), 7.0-7.01 (d, 2H). Characterization data are further 
summarized in Table 1. 
High resolution ESI-MS confirmed the expected M+1 molecular formula: C12H 
2H6N2S, theoretical m/z 227.1484, observed m/z 227.1483, delta mass -0.4486 ppm. The 
corresponding unlabeled xylazine was also analyzed by High Resolution ESI-MS as a 
comparison to the labelled material which corresponded to the expected M+1 molecular 
formula: C12H17N2S, theoretical m/z 221.1107, observed m/z 221.1106, delta mass -
0.6214 ppm. 
Combustion analysis revealed the carbon, hydrogen (corrected for deuterium 
mass), sulphur, and nitrogen percentages to be consistent with the calculated molecular 
formula. 
Expected: Percent (%) C, 63.67; H+D, 7.12; N, 12.38; S, 14.16 
Found: C, 63.70; H+D, 6.94; N, 12.37; S, 14.38 
EI-GCMS indicated a single peak and an apparent molecular ion at m/z 226, 
consistent with the expected molecular mass. Isotopic distribution analysis showed the 
following deuterated compositions: d0, d1, d2, d3 – 0%, d4 – 1.61%, d5 
– 5.84%, d6 – 92.54%. 1H-NMR taken in DMSO-d6 indicated
23 
that the structure was consistent with xylazine-d6. 
Table 2.1.1.1 Characterization Data of Xylazine-d6 










Exact Mass 227.1484 (Calculated) 
227.1483 (Found) 
∆ mass 0.6214 ppm 
Combustion Analysis. 
C, 63.67; H, 7.12; N, 12.38; S, 14.16 
(Calculated) 
C, 63.70; H, 6.94; N, 12.37; S, 14.38 
(Found) 
Volatiles (Headspace GC) <0.1% volatiles 
Micro Ash <0.1% residue on ignition 
Melting Point 137-138⁰C











Table 1: Characterization data shows the tabulated values for the characterization 
acquired for xylazine-d6. 
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Figure 2.1.1.2 1H-NMR Spectra for Xylazine/Xylazine-d6 
Figure 2: 1H-NMR Spectra of unlabeled and labelled xylazine shows the overlaid spectra, 
with the deuterium free spectrum located above the d6-labeled spectrum. The conspicuous 
absence of the 2,6-dimethyl signal at 2.1ppm indicates incorporation of deuterium at the 
target site. 
CONCLUSION 
This synthesis is based on previous work from our group that described the 
synthesis of the labelled phase 1 metabolite of xylazine, namely 4-hydroxy-xylazine. The 
primary difference in this procedure was use of 2,6-dimethyl-d6-aniline as the starting 
material rather than 4-hydroxy-2,6-d6-dimethylaniline, as was used in the previous 4-
hydroxyxylazine synthesis. 
Following the procedure described above, xylazine-d6 was synthesized 
commencing with 2,6-d6-dimethylaniline in dichloromethane via reaction with 
thiophosgene in the presence of triethylamine, yielding 2,6-d6-
dimethylphenylisothiocyanate. This intermediate was then reacted with 3-amino-1-
propanol in dichloromethane. After work-up and extraction, the final product was 
crystallized as an off-white powder from ether-hexane. 
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Successful synthesis of the deuterated compound was then verified via a 
comparison of 1H-NMR to the non- deuterated compound. The noteworthy 2,6-dimethyl 
resonance that appears at 2.1 ppm is absent in the deuterated compound, while all other 
peaks remain present. 
Herein reported is a purified and characterized deuterated xylazine suitable for use 
as an internal standard. The characterization   of   xylazine-d6 meets industry requirements 
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market entities such as these certified reference standards. The University of Kentucky 
owns the Intellectual Property associated with the identification and synthesis of these 
reference standards and Drs. Eisenberg and Tobin are listed as creators of the relevant 
University of Kentucky IP. As such, Drs. Tobin and Eisenberg may benefit from an 
inventor’s portion of any royalty income to UK under the relevant IP/Technology Transfer 
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2.1.2 Synthesis and Characterization of Barbarin, A possible Source of Unexplained 
Aminorex Identifications in Forensic Science 
Abstract: Aminorex is a US DEA Schedule 1 controlled substance occasionally detected 
in racing horses. A number of aminorex identifications in sport horses were thought to have 
been caused by exposure to plant sources of aminorex. Glucobarbarin, found in plants of 
the Brassicaceae family, has been suggested as a potential proximate chemical source by 
being metabolized in the plant or the horse to aminorex. In Brassicaceae, glucobarbarin is 
hydrolyzed by myrosinase to yield barbarin, which serves as an insect repellant and/or 
attractant and is structurally related to aminorex. We now report the synthesis, purification 
and characterization of barbarin for use as a reference standard in aminorex related research 
concerning equine urinary identifications of aminorex and also for possible use in equine 
administration experiments. Synthesis of barbarin was performed via ring closure between 
phenylethanolamine and carbon disulfide in tetrahydrofuran with the catalyst pyridine at 
reflux. The reaction yielded a white crystalline substance that was purified and chemically 
characterized as barbarin for use as a Certified Reference Standard or for studies related to 
equine aminorex identifications. 
Introduction:  Aminorex is a DEA Schedule I substance with amphetamine-like properties.  
Initially available as an anorectic in Europe, it was withdrawn from the market when it was 
linked to deaths related to pulmonary hypertension.  The Association of Racing 
Commissioners International specify aminorex as a Class 1, Penalty class A foreign 
substance, indicating major penalties for those violating its prohibition.  However, it has in 
the past been shown to present in urine when horses are treated with the anthelmintic drug 
levamisole.  Presence of its cometabolite rexamino in the urine can be used to verify this 
defense, but sporadic positives at low levels continue to be identified even when levamisole 
is not an explanatory agent, indicating a likely environmental source of the substance. 
The plant substance barbarin was suggested by Voss in 2018 as a potential source 
of aminorex, and a study undertaken by Maylin, et al showed that the parent plant (B. 
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vulgaris) induced aminorex in urine when fed to thoroughbreds.  Traditional synthesis of 
barbarin is neither economical nor efficient, as it relies on the lysing of cells from the plant 
and allowing the hydrolyzation of glucobarbarin by myrosinase.  With that in mind, the 
need for a Certified Reference Standard of synthetic barbarin was deemed necessary and a 
synthetic pathway developed. 
Experimental:  Barbarin was synthesized via the ring closure of 2-hydroxy-2-
phenylethylamine in tetrahydrofuran with catalytic pyridine and excess carbon disulfide.  
The mixture was allowed to reflux overnight, and the completion of the reaction was 
tracked via Thin-Layer Chromatography in a 19:1 dichloromethane: methanol solution.  
After the reaction was completed, the mixture was concentrated, diluted with 
dichloromethane, and washed with dilute hydrochloric acid, brine, and dried over sodium 
sulfate.  Following filtration, the solution was concentrated under vacuum and then purified 
by re-crystallization to yield the resultant white crystalline material. 
The resultant material was characterized via Proton Nuclear Magnetic Resonance, High 
Resolution Mass Spectrometry, and Combustion Analysis, indicating barbarin at a purity 
of 99.7% purity. 
Conclusion: Barbarin is now available as a Certified Reference Standard via a scalable 
synthetic pathway for the first time. 
Citation: Machin, J., Childers, T., Kudrimoti, S., Eisenberg, R., Fenger, C., Hartmann, P., 
... & Tobin, T. (2020). Synthesis and characterization of barbarin, a possible source of 
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ABSTRACT: 
Aminorex is a US DEA Schedule 1 controlled substance occasionally detected in 
racing horses. A number of aminorex identifications in sport horses were thought to have 
been caused by exposure to plant sources of aminorex. Glucobarbarin, found in plants of 
the Brassicaceae family, has been suggested as a potential proximate chemical source by 
being metabolized in the plant or the horse to aminorex. In Brassicaceae, glucobarbarin is 
hydrolyzed by myrosinase to yield barbarin, which serves as an insect repellant and/or 
attractant and is structurally related to aminorex. We now report the synthesis, purification 
and characterization of barbarin for use as a reference standard in aminorex related research 
concerning equine urinary identifications of aminorex and also for possible use in equine 
administration experiments. Synthesis of barbarin was performed via ring closure between 
phenylethanolamine and carbon disulfide in tetrahydrofuran with the catalyst pyridine at 
reflux. The reaction yielded a white crystalline substance that was purified and chemically 
characterized as barbarin for use as a Certified Reference Standard or for studies related to 
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INTRODUCTION: 
Aminorex, (RS)-5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine, molar mass, 162.19, 
(Figure 1), is an amphetamine-like substance that was at one time marketed in Europe as 
an anorectic for weight control. Aminorex, however, was soon associated with deaths from 
pulmonary hypertension (Poos et al, 1963) and withdrawn from marketing in 1972. 
Aminorex is a more potent anorectic than d-amphetamine and its 4-Methylaminorex 
analogue has central effects comparable with those of methamphetamine and both are 
available as illicit recreational substances. Aminorex is a US DEA Schedule 1 controlled 
substance and an Association of Racing Commissioners International [ARCI] Class 1, 
Penalty class A foreign substance, so findings of aminorex in post event equine samples 
can give rise to significant penalties for horsemen (ARCI Uniform Classification 
Guidelines for Foreign Substances January 2018 (V.13.4)). 
Figure 2.1.2.1 Structure of Aminorex 
 
Figure 1: Aminorex, (RS)-5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine, molar mass, 
162.19, 
A sequence of aminorex identifications in US racing, starting in 2002 (Sams 2006, 
Soma et al 2008, Barker 2009), was shown in 2007 to be the result of administration of 
Levamisole, an anthelmintic and immune stimulant which horses and humans metabolize 
to aminorex (Loganathan et al 2009, Ho et al 2009. Gutierrez et al 2010, Hofmaier et al 
2014). Identification of this unexpected source of aminorex reduced the frequency of 
aminorex identifications in horse-racing but did not eliminate them. Unexplained aminorex 
identifications continued, sometimes appearing as “clusters” of identifications, including 
most recently in a number of sport horses with no history or analytical evidence of exposure 
to either Levamisole, Tetramisole or aminorex itself (Teale and Biddle, 2018). 
Possible Botanical Sources for Aminorex 
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Reviewing the analytical data from these sport horse urine samples a number of 
small nitrogenous molecules were identified, along with aminorex. Based on this analysis, 
the plant substance barbarin as has been suggested (Voss, 2018) as a potential source of 
aminorex. Plants of the genus Barbarea, Brassicaceae family contain glucobarbarin, a 
barbarin precursor. In these plants glucobarbarin is hydrolyzed by myrosinase to an 
intermediate which spontaneously cyclizes to yield barbarin, Figure 2, which functions as 
an insect repellant or attractant when the plant structure is damaged (Kjaer et. al., 1957). 
Barbarin is structurally related to aminorex, so it is possible that either glucobarbarin or 
barbarin or a chemically related substance in Brassicaceae fragments in equine feedstuffs 
may be a source of these unexplained aminorex identifications in horse urine. 
Because of the structural similarities between barbarin and aminorex and the 
possible role of glucobarbarin or barbarin as an aminorex precursor in herbivore diets, we 
have synthesized, purified, and certified barbarin with the goal of making it available as a 
Certified Reference Standard and also as a possible equine administration substance. 
Availability of chemically pure barbarin will allow investigation of the role of barbarin as 
a possible botanical source of aminorex in the matter of unexplained post-race aminorex 
identifications in equine forensic samples, and in such cases where it may serve as a 




Figure 2.1.2.2 Natural Conversion of Glucobarbarin to Barbarin 
 
Figure 2: Glucobarbarin, above left, hydrolyzed by the enzyme myrosinase to the 
intermediate, above center, which then spontaneously cyclizes to barbarin, 5-phenyl-2- 





1/ Barbarin Synthesis 
Barbarin, ((RS)-5-Phenyl-2-oxazolidinethione: C9H9NOS, molar mass:179.237 
g/mol) was prepared based on the previous synthesis of related substances (Santoro et 
al,1976) and personal communications with Dr. Richard Sams. Synthesis commenced by 
taking a solution of 2-hydroxy-2-phenylethylamine (1.0 g, 1 eq.) in tetrahydrofuran [THF] 
(20 mL) and to which was added pyridine (0.59 ml, 1 eq.) and excess carbon-disulfide (6 
ml). The mixture was then refluxed overnight at 70°C. When the synthesis reaction was 
complete as determined by Thin-Layer Chromatography (19:1 dichloromethane (DCM): 
methanol) the reaction mixture was concentrated, diluted with DCM, and washed with 
dilute HCl, brine, and dried over sodium sulfate. Following filtration, the solution was 
concentrated under reduced pressure and then purified by crystallization (9:1 DCM: n-
hexanes) to yield the resultant white crystalline material. 
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Figure 2.1.2.3 Proposed Mechanism for Ring Closure of Barbarin Synthesis 
 
Figure 3: Proposed mechanism for synthesis of barbarin from phenylethanolamine 
and carbon disulfide with pyridine catalyst. Nucleophilic attack of the amino group 
on carbon disulfide results in ring closure, with pyridine acting as a proton shuttle. 
 
2/ Barbarin characterization: 
The white crystalline material resulting from the above-described reactions was 
chemically characterized as barbarin by 1/ Proton nuclear magnetic resonance, 2/ High 
Resolution Mass Spectrometry, and 3/ combustion analysis, as follows: 
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Figure 2.1.2.4 1H-NMR Analysis for Barbarin Product 
 
Figure 4: 1H-NMR analysis 1/ 1H-NMR, (CDCl3,400 MHz) δ (ppm): 7.62 (br s, 1H), 7.35-
7.45 (m, 5H), 5.87 (t, 1H), 4.15(dd, 1H). 3.74(dd, 1H) 
Aromatic protons showing up at 7.35-7.45 ppm as multiplet and the proton Hb of 
five membered ring as a triplet at 5.87 ppm, the Hc proton as double doublet at 4.15pm and 
Hd proton as double doublet at 3.74 ppm and protonated molecule ion peak m/z 180.0477 
in high resolution mass spectrum confirms the structure of barbarin. 
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Figure 2.1.2.5 High-Resolution Mass Spectral Analysis of Barbarin Product 
 
Figure 5: High-Resolution Mass Spectral analysis (ESI, M+1) found: C9H10NOS 
180.0478. 
Peaks are believed to represent as follows: m/z 180, barbarin + H+; m/z 359, barbarin 
noncovalent dimer + H+; m/z 120, barbarin oxazolidinethione ring cleavage product; m/z 
146 = barbarin loss of SH group (S plus a neighboring H). Reversed phase HPLC UV 
detection (C18, methanol water gradient diode array UV detection) indicated a purity of 
approximately 99.5%. 
Another area of regulatory significance is the chirality of barbarin and or aminorex 
originating via the proposed glucobarbarin / barbarin pathway. Review of the literature 
shows that plant barbarin is predominantly found as the R isomer, suggesting that aminorex 
originating from plant barbarin is also likely the be found as the R isomer. Given that 
synthesized aminorex is likely to be racemic, a urinary identification of a small 
concentration of predominantly R aminorex would be entirely consistent with the aminorex 
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identification being of botanical origins, as previously demonstrated to be valuable in 
regulatory evaluation (Barker, 2009). 
 
 
Combustion analysis CHNS, Calc: C, 60.31%, H, 5.06%, N, 7.81%, S, 17.89%. Found: 
C 60.16%, H 4.97%, N 7.77%, S 17.89%, consistent with 99.7% purity. 
 
DISCUSSION: 
The synthesis described in methods proceeded as described and produced a 75% 
yield of a white crystalline substance. This reaction product was purified by 
recrystallization to a chemical purity of 99.5% and the purified product was shown to be 
barbarin suitable for use as a Certified Reference Standard or for equine administration 
experiments. Further work was designed to determine whether or not barbarin was/is the 
actual proximate source of aminorex such as we identified when the Brassicaceae plant 
Barbarea vulgaris, colloquially “Yellow Rocket”, was consumed by horses and aminorex 
identified in the post administration urine samples, as described below. 
In spring 2018, responding to regulatory concerns (Angst, April 17, 2018; Voss, 
April 17, 2018), we harvested flowering Kentucky Barbarea vulgaris and sent it to 
colleagues in New York for equine administration. The experimental horses declined 
consumption when offered the dried plant materials, but readily consumed the plant 
material when mixed with sweet feed. Then, four hours post consumption of Barbarea 
vulgaris showed the presence of aminorex in their urine samples with no evidence for the 
presence of barbarin in the same urine (Maylin, et al 2019). 
At this time, however, it is unclear as to what precisely is the proximate chemical 
source of these post Brassica vulgaris administration urinary aminorex identifications. 
Whatever the mechanism, however, reviewing a number of apparently low concentrations 
aminorex identifications in post-race samples, the Kentucky Horse Racing Commission 
chose to rescind a “positive” identification at their April 17, 2018, meeting in Lexington, 
based on uncertainties concerning the origins of the aminorex identifications (Angst, 2018; 
Voss, 2018). In particular, it appears that as well as aminorex, barbarin was identified in 
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the samples from the horse, giving rise to the possibility that the aminorex identification 
was due to inadvertent exposure of the horse to a plant source of barbarin. 
Our initial working hypothesis was that barbarin formed in the Brassicaceae plant 
associated with harvesting damage to the plant was the likely proximate source of 
aminorex, as set forth in Figure 2. In this model barbarin is present in the plant on ingestion 
and is metabolically transformed in/by the horse to aminorex which is then excreted in the 
urine, leading to urinary aminorex identifications. In this model the metabolic 
transformation from barbarin to aminorex occurs in the horse and is driven by the metabolic 
capabilities of the horse (Tobin, 1981). An alternative hypothesis is that the barbarin is 
excreted in the urine and that the transformation from barbarin to aminorex occurs in the 
urine sample (Voss, 2018), although this seems a less likely possibility. 
The fact that consumption of Brassicaceae plants is associated with aminorex 
identifications in equine urine has significant scientific and forensic implications. 
Aminorex, a substance closely related to Amphetamine has been identified in equine urine 
samples without evidence of exposure to Levamisole. Between the years of 2016 and 2018, 
11 unexplained low level aminorex results have been detected in US sport horses: 3 in 
Illinois between 2016 and 2017, 5 in Massachusetts in 2017, 3 more in Kentucky in 2018, 
and 1 more in 2019 (Holloway, 2019). A proposed source of such urinary aminorex 
identifications is an equine driven metabolic transformation of barbarin or a related 
substance from plants of the Brassicaceae family inadvertently entering equine feedstuffs 
(Teale and Biddle, 2018) to aminorex, as has previously been shown to occur following 
Levamisole administration. Experimental approaches to this question were hindered by the 
lack of availability of chemically pure barbarin, for use both as a research reference 
standard and also in amounts sufficient for equine administration and related experiments. 
Other plants of potential interest include Reseda luteola (colloquially Dyer’s Rocket), a 
known producer of glucobarbarin, and the common Cardamine hirsute (colloquially hairy 
bittercress). 
Barbarin made possible by this research project will allow more in-depth 
investigation of the potential role of glucobarbarin and related substances as chemical 
precursors of aminorex in horses., as recently demonstrated by Machin et al, 2018, and 
possibly also in other mammalian metabolic systems. As such availability of analytical 
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standard quality Barbarin in amounts sufficient for animal administration will be useful in 
the field of equine forensic science. 
 
CONCLUSIONS: 
We now report synthesis, purification, and characterization of the plant 
glucosinolate barbarin in gram quantities. Barbarin, a white crystalline substance is now 
available as a certified reference standard for analytical/forensic toxicological research. 
Additionally, this synthetic method described is readily capable of producing larger 
quantities of Barbarin, such as may be required for equine administration or similar in vivo 
experiments (Machin et al 2018, Tobin, 1981). 
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2.1.3 Synthesis and Characterization of d5-Barbarin for use in Barbarin Related Research 
Abstract: Based on structural similarities and equine administration experiments, Barbarin, 
5-Phenyl-2-oxazolidinethione from Brassicaceae plants is a possible source of equine
urinary identifications of aminorex, (RS)-5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine, an 
amphetamine related US Drug Enforcement Administration (DEA) substance 
considered illegal in sport horses. We now report synthesis and certification of d5- 
barbarin to facilitate research on the relationship between plant barbarin and such 
aminorex identifications. D5-barbarin synthesis commenced with production of d5-oxime 
from d5-Acetophenone via butylnitrite in an ethoxide/ethanol solution.  This oxime was 
then reduced with Lithium Aluminum Hydride to produce the corresponding alcohol-
amine.  Final ring closure of the alcohol amine was performed by addition of carbon 
disulfide with pyridine catalyst. The reaction product was purified by recrystallization and 
presents a stable white crystalline powder. This material was shown to be d5-barbarin by 
proton NMR, Mass Spectrometry, and Elemental Analysis and was purified and chemically 
characterized as 97% pure d5-barbarin for use as an Internal Standard in barbarin related 
equine forensic research. 
Introduction:  Based on structural similarities and equine administration experiments, 
barbarin is a primary candidate to induce the production of the DEA Schedule I substance 
aminorex in horse urine.  Recent studies indicate that the consumption of Barbarea 
vulgaris can induce aminorex in horse urine but does not unequivocally determine barbarin 
as the chemical predecessor.  The need for a deuterated standard fulfills two needs then: 1/ 
the quantification of barbarin in biological samples via use as an internal standard, and 2/ 
effective use of the labelled compound as a precursor in animal administration experiments 
to determine a direct linkage. 
Experimental:  The synthesis took place in three steps.  The first step saw butyl nitrite 
dissolved in ice-cold ethanol, followed by the addition of sodium ethoxide.  D5-
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acetophenone was added to this solution (dissolved in ethanol) dropwise over 30 minutes.  
The solution was maintained at ice cold temperature until the addition was complete, at 
which time it was stirred until reaching room temperature and continued overnight.  The 
following day the precipitate was filtered and washed with ether, dissolved in a minimal 
amount of water, acidified with glacial acetic acid, and the resultant white solid filtered 
and recrystallized with ethanol. 
The second synthetic step was the reduction of the resulting d5-oxime via lithium 
aluminum hydride.  This was done in anhydrous ether under argon at zero degrees Celsius, 
with the oxime being added dropwise (dissolved in anhydrous ether).  The reaction was 
stirred under reflux for 10 hours.  Careful addition of water and moist ether hydrolyzed the 
excess hydride, and the resulting white precipitate was separated by filtration.  The ethereal 
filtrate was dried over sodium sulphate, resulting in a yellow solid. 
The third step of the synthesis was as described in the non-deuterated synthetic paper: the 
d5-2-hydroxy-2-phenylethylamine was dissolved in THF with excess carbon-disulfide and 
catalytic pyridine.  The resultant mixture was refluxed at 70 degrees Celsius for sixteen 
hours and the progress monitored via Thin-Layer Chromatography.  Once the reaction was 
completed, the solution was cooled and concentrated via rotovap, washed in 1N 
hydrochloric acid, and extracted with DCM.  This organic layer was dried with sodium 
sulfate, and the yellow solid product was recrystallized twice, yielding a 99% pure 
substance via combustion analysis. 
All steps of the synthetic pathway were verified via mass spectroscopy as well as proton 
nuclear mass resonance spectroscopy.  The final product was characterized by these 
methods and combustion analysis, and is available, along with its certificate of analysis. 
 
Conclusion: A deuterated reference standard of the plant product barbarin is now available 
commercially, offering a vital point of interest for use in testing facilities and for 
determining appropriate International Residue Limits or Screening Limits of Detection for 
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ABSTRACT: 
 Based on structural similarities and equine administration experiments, Barbarin, 
5-Phenyl-2-oxazolidinethione from Brassicaceae plants is a possible source of equine 
urinary identifications of aminorex, (RS)-5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine, an 
amphetamine related US Drug Enforcement Administration (DEA) substance considered 
illegal in sport horses.  We now report synthesis and certification of d5-barbarin to facilitate 
research on the relationship between plant barbarin and such aminorex identifications.  D5-
barbarin synthesis commenced with production of d5-oxime from d5-Acetophenone via 
butylnitrite in an ethoxide/ethanol solution.   This oxime was then reduced with Lithium 
Aluminum Hydride to produce the corresponding alcohol-amine.   Final ring closure of the 
alcohol amine was performed by addition of carbon disulfide with pyridine catalyst. The 
reaction product was purified by recrystallization and presents a stable white crystalline 
powder. This material was shown to be d5-barbarin by proton NMR, Mass Spectrometry, 
and Elemental Analysis and was purified and chemically characterized as 97% pure d5-
barbarin for use as an Internal Standard in barbarin related equine forensic research.      
 






 Based on structural similarities and equine administration experiments, barbarin, 5-
Phenyl-2-oxazolidinethione from Brassicaceae plants is a possible source of aminorex 
(RS)-5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine, (Figure 1) identifications in race and sport 
horse urines.  Aminorex is an amphetamine related (Hofmaier, et al, 2013) US Drug 
Enforcement Administration (DEA) substance that is considered illegal in racing and sport 
horses.  Aminorex is also an Association of Racing Commissioners International [ARCI] 
Class 1, Penalty class A foreign substance, so identifications of aminorex in equine samples 
can give rise to significant penalties for horsemen (ARCI Uniform Classification 
Guidelines for Foreign Substances January 2018 (V.13.4), the suggested penalties being in 
the order of a 1-year suspension and a $10,000 fine, as has happened at times in US horse 
racing (Whitmore 2017). 
 
Figure 2.1.3.1 Structures of Barbarin and Aminorex 
 
Figure 1.  STRUCTURES OF BARBARIN AND AMINOREX 
 
This possible relationship between plant barbarin and equine urinary aminorex 
identifications was first suggested by Teale and Biddle, 2018, who had identified aminorex 
in English sport horse urines with no known exposure to aminorex or Levamisole, 
Levamisole being an equine anthelmintic and immune stimulant medication known to 
metabolize to aminorex (Barker, S A, 2009, Eiden et al., 2015).  Reviewing their aminorex 
identifications: the absence of any known sources of Aminorex; the presence of a number 
of small plant related molecules in their equine urine samples; and the lack of presence of 
pemoline or rexamino, known metabolites of levamisole (Gutierrez, et al., 2010, Ho, et al, 
2009); Teale and Biddle proposed that the likely source of their aminorex identifications 




 Plants of the genus Barbarea, Brassicaceae family, contain glucobarbarin, a 
barbarin precursor.  In these plants damage to the plant structure triggers hydrolysis of 
glucobarbarin by myrosinase to an intermediate which spontaneously cyclizes to barbarin, 
Figure 2, which functions as an insect repellant or attractant when the plant structure is 
damaged (Kjaer et. al., 1957).  As set forth above, barbarin is related structurally to 
aminorex, and consumption of Brassicaceae plant fragments in equine feed is therefore a 
possible source of such unexplained aminorex identifications, as has been demonstrated in 
our recently published research (Maylin et al., 2019).   
                              
   
Figure 2.1.3.2 Natural Synthesis of Barbarin from Glucobarbarin 
 
 
Figure 2: In plants, glucobarbarin is hydrolyzed by the enzyme myrosinase to the 
intermediate, above center, which spontaneously cyclizes to barbarin. 
 
While this equine administration research (Maylin et al., 2019) links consumption 
of the Brassicaceae plant Brassica vulgaris to urinary aminorex identifications, it does not 
unequivocally identify barbarin as the proximate chemical source of these identifications.  
To address this matter, we therefore now report the synthesis, purification and 
characterization of d5-barbarin, the availability of which will allow more definitive 
identification of the relationship between plant barbarin, and equine consumption of such 





 We have synthesized d5-barbarin for use in barbarin related research, specifically 
to enable more detailed evaluation of the relationship between equine/herbivore 
consumption of Brassicaceae plants containing glucobarbarin and urinary aminorex 
identifications. D5-barbarin was synthesized by a variant of our previously described 
barbarin synthesis method (Machin et al, 2018, Machin et al, 2020), as follows.    
 
D5-barbarin synthesis commenced with production of d5-oxime from d5-
acetophenone via butylnitrite in an ethoxide/ethanol solution, as described by Norman et 
al 1962.  This oxime product was obtained in good yield and next reduced with Lithium 
Aluminum Hydride (Walter, 1952) to produce the corresponding alcohol-amine, again in 
good yield.  Final ring closure of the alcohol amine was performed by addition of carbon 
disulfide with a pyridine catalyst, as described in our earlier barbarin synthesis 
communications (Machin et al, 2018, Machin et al, 2020).  The final d5-barbarin reaction 
product presented as a stable white crystalline powder, was produced in good yield, 
purified by recrystallization and chemically characterized as d5-barbarin by proton NMR, 
Combustion Analysis and Mass Spectrometry and prepared for use as an Internal Standard 
in barbarin related research.    
 
The research need for d5-barbarin comes from the apparent ability of Brassicaceae 
plant consumption by horses to result in low concentration urinary identifications of 
aminorex.  Aminorex being an amphetamine related central nervous stimulant and a US 
DEA schedule 1 substance that is prohibited in racing and sport horses.  A previous and 
unexpected source of aminorex identifications was Levamisole, a veterinary anthelmintic 
and immune stimulant at one time not infrequently prescribed in horses including racing 
horses.  Identification of Levamisole administration as a source of aminorex identifications 
led to a marked reduction in the number of aminorex identifications in racing horses, but 
not to their complete elimination, as noted by Whitmore in 2017 and by Teale and Biddle 
in 2018.  
 
Reviewing their unexpected aminorex identifications, Teale and Biddle noted that 
a number of small nitrogenous compounds were found in the samples, which compounds 
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pointed to plant origins for their aminorex identifications.  Additionally, Teale and Biddle 
reported identification of aminorex itself in sample from some unidentified plants and 
noted that to their knowledge this was the first reported identification of aminorex in a 
plant.  Reviewing these unexpected findings, Teale and Biddle noted that research was 
required to determine the structure of plant derived analytes that might serve as markers of 
plant ingestion and therefore as markers of botanical origins for aminorex identifications 
in equine urine samples.   
 
The major conclusion of the Teale and Biddle findings was that plants of the 
Brassicaceae family contain glucobarbarin which may serve as a plant precursor of 
barbarin, with plant barbarin itself usually serving as an aversive substance to discourage 
herbivory.  Addressing this problem, we first synthesized barbarin as a reference standard 
for barbarin and aminorex related research.  As this synthesis was in progress in Spring 
2018, we observed Kentucky Brassica vulgaris, colloquially Kentucky “Yellow Rocket” 
in flower in Kentucky.  We therefore definitively identified, harvested, cleaned and dried 
these plants and sent them to Professor Maylin in New York for equine administration 
experiments.  The outcome of these experiments was that four hours after consuming 
barbarin the experimental horses produced aminorex containing urines, linking 
consumption of Kentucky Brassica Vulgaris, colloquially “Yellow Rocket”, to urinary 
aminorex identifications.   
 
At this time, however, it is unclear as to what precisely is the proximate chemical 
source of these post Brassica vulgaris administration urinary aminorex identifications.  
Whatever the mechanism, however, reviewing a number of apparently low concentrations 
aminorex identifications in post-race samples, the Kentucky Horse Racing Commission 
chose to rescind a “positive” identification at their April 17th, meeting in Lexington, based 
apparently on uncertainties concerning the origins of the identification (Voss, 2018).  In 
particular, it appears that as well as aminorex, barbarin was identified in the samples from 
the horse, giving rise toe possibility that the aminorex identification was due to inadvertent 




Our initial working hypothesis was that barbarin formed in the Brassicaceae plant 
associated with harvesting damage to the plant was the likely proximate source of 
aminorex, as set forth in Figure 2.  In this model barbarin is present in the plant on ingestion 
and is metabolically transformed in/by the horse to aminorex which is then excreted in the 
urine, leading to urinary aminorex identifications.  In this model the metabolic 
transformation from barbarin to aminorex occurs in the horse and is driven by the metabolic 
capabilities of the horse (Tobin, 1981).  An alternative hypothesis is that the barbarin is 
excreted in the urine and that the transformation from barbarin to aminorex occurs in the 
urine sample, although this seems a somewhat less likely possibility ((Soma, et.al 2008).     
 
The fact that aminorex consumption of Brassicaceae plants is associated with 
aminorex identifications in equine urine has important scientific and forensic implications.  
aminorex has been identified in equine urine samples without evidence of exposure to 
Levamisole.  Between the years of 2016 and 2018, 11 unexplained low level aminorex 
identifications have been reported in US racing horses: 3 in Illinois between 2016 and 2017, 
5 in Massachusetts in 2017, 3 more in Kentucky in 2018, and 1 more in Kentucky in 2019 
(Holloway, 2019).  A proposed source of such urinary aminorex identifications is an equine 
driven metabolic transformation of barbarin or a related substance from plants of the 
Brassicaceae family inadvertently entering equine feedstuffs (Teale and Biddle, 2018) to 
aminorex, as has previously been shown to occur following Levamisole administration.  
Experimental approaches to this question were hindered by the lack of availability of 
chemically pure barbarin and an appropriate internal standard, i.e., d5-barbarin for use both 
as research and internal standards in botanical and equine related research.   
 
A further consideration with respect to these aminorex identifications is that given 
the worldwide distribution of Brassicaceae plants and related glucobarbarin containing 
plants, aminorex appears to meet the definition of a plant related environmental substance 
appearing in post-event urine samples.  As such, these aminorex identifications are in many 
ways equivalent to the Scopolamine identifications that have been sporadically reported 
identified in competition horses worldwide for now thirty or more years, as we reported a 




The most widely used approach to this trace level identification problem is that 
adopted by the International Federation of Horseracing Authorities (IFHA): namely the 
identification of an International Residue Limit or Screening Limit of Detection [SLOD] 
below which defined plasma or urinary concentration the identification is not reported for 
regulatory action.   This approach is set forth in the IFHA website document on this matter 
and as has also recently been communicated with reference to trace level identifications of 
Methamphetamine (Brewer et al 2016) and Naproxen (Machin et al, 2019) identifications 
in equine post-race samples.    
 
In closing, d5-barbarin has now been synthesized, purified and characterized.  D5-
barbarin presents as a stable white crystalline substance and is now available as a stable 
isotope internal standard for analytical, forensic, or toxicological research and, if required, 
in larger quantities such as may be required for other experimental purposes (Maylin et al 




Synthesis of d5-barbarin was a three-step process, The final step of ring closure to 
get the product i.e., d5-barbarin was based on previous report on the synthesis of the 
required substances, unlabeled barbarin (Norman et al, 1962, Walter 1952, Santoro et 
al,1976) and personal communications with Dr. Richard A. Sams, as follows: 
 
Figure 2.1.3.3 Synthesis of d5-Barbarin from d5-Acetophenone 
  
Figure 3: Synthesis of d5-barbarin, started with d5-acetophenone, butylnitrite and sodium 
ethoxide, yielding d5-oxime, then reduced by lithium aluminum hydride, yielding d5-
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alcohol-amine, then reacted with carbon disulfide with catalytic pyridine to yield d5-
barbarin. 
Step 1: Synthesis of d5-oxime from d5-acetophenone, as in the synthesis scheme in Figure 
3 above.  Step 1 commenced when Butyl nitrite (0.96 ml, 1 mole) was taken in ice-cold 
ethanol (50 ml) and to it was added sodium ethoxide (0.565 gm, 1 mole). To this solution 
d5-acetophenone (1 gm, 1 mole) dissolved in 10 ml of ethanol was added dropwise over 
30 minutes, the solution being maintained ice cold until the addition of d5-acetophenone 
was complete and the solution then stirred until it reached room temperature. Stirring then 
continued for 3 hr., following which the solution was held overnight.  The following day 
the formed precipitate was filtered and washed with ether. The washed precipitate was 
dissolved in a minimum quantity of water, acidified with glacial acetic acid and the 
resulting off white solid filtered and recrystallized with ethanol.  The estimated yield from 
this reaction was 45%, and the recovered d5-oxime material was characterized by 1H NMR 
and Mass Spectrometry as appropriate for d5-oxime, m/z 154.0791, H1 NMR(DMSO) in 
ppm: 1H (S, 8.0, 1H), as in Figure 4, below.   
  




Figure 4: The recovered d5-oxime material as characterized by 1H NMR 
 
Step 2: Synthesis of the d5-alcohol-amine:  0.115gm (4eq) LiAlH4 is taken in round 
bottomed flask under argon. The flask was then fitted with a dropping funnel and to it was 
added 30 ml of anhydrous ether under argon and the LIAlH4/ether slurry was stirred at 
0oc.  d5-oxime (0.117 gm, 1eq), dissolved in anhydrous ether(10ml) was added dropwise, 
and the mixture was stirred and refluxed for 10 hr.  Careful addition of water and moist 
ether hydrolyzed the excess hydride, and the resulting voluminous white precipitate was 
separated by filtration and the ethereal filtrate dried over sodium sulfate.  After removal of 
the solvent, the residue yielded a yellowish solid (0.075gm), with an overall reaction yield 
of about 70%.  The resultant material was characterized as d5-alcohol-amine by NMR  1H 
NMR (CDCl3, 400 MHz) δ (ppm): 4.87 (t,1H1), 3.10(dd, 1H2) and 2.85(dd,1H3), 4.80(1H, 
OH), 1.98(2H, NH2) Figure 5, below, and by Mass spectrometry, m/z 142.115 
  




Figure 5: The resultant material was characterized as d5-alcohol-amine by mass 
spectroscopy. 
 
Step 3: Synthesis of d5-barbarin: To the d5-2-hydroxy-2-phenylethylamine (d5-alcohol-
amine) (0.075 gm, 1 eq) in THF (20 ml) was added excess carbon-disulfide (1ml) in the 
presence of 1 equivalent of pyridine.  The resultant mixture was refluxed at 70°C for 16hrs 
and the progress of the reaction monitored by TLC.  Once the reaction was complete, the 
system was cooled and the reaction mixture concentrated on a rotovap, washed with 1N 
HCl, water and the aqueous layer extracted with DCM. The resulting organic layers were 
combined, dried with sodium sulfate and the yellow solid product recrystallized twice using 
a DCM/Hexane solvent system. The final recrystallized product was 99% pure by 
Combustion/Elemental Analysis and its chemical structure was confirmed as d5-barbarin 
by proton NMR 1H NMR (CDCl3, 400 MHz) δ (ppm): 5.85 (t, 1H), 3.71(dd, 1H) and 
4.11(dd, 1H), (Figure 6), and by Mass Spectrometry, (m/z): [M+H] + for C9H4D5NOS 




Figure 2.1.3.6 1H NMR of d5-Barbarin Product 






Figure 2.1.3.7 Mass Spectrum of Resultant d5-Barbarin 
 
Figure 7 The resultant material was also confirmed as d5-barbarin by Mass Spectrometry 




The white crystalline material obtained following purification was characterized as 
follows:   Analysis by proton Nuclear Mass Resonance yielded the following, 1H-NMR, 
(CDCl3,400 MHz) δ (ppm): 5.85 (t, 1H), 3.71(dd, 1H) and 4.11(dd, 1H). and 1.60(1H, NH) 
as shown in Figure 6 above.    Elemental analysis resulted in CHNS, Calc: C, 58.66%, H, 
5.06%, N 7.60%, S, 17.40%. Found: C 57.31%, H 5.24%, N 7.18%, S 16.40%; indicating 
97% purity. High Resolution Mass Spectrometry presented the following: and mass 
spectrometry, (m/z): [M+H] + for C9H4D5NOS 185.0719, as in Figure 7 above. Based on 
NMR, mass and elemental analysis data we have characterized the final product as d5-
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2.2 Trace Level Therapeutic Medication Overages/Positives 
2.2.1 A Pilot Pharmacokinetc / Withdrawal Time Study Using a Full Clinical Dose of 
Mepivacaine in Thoroughbred Horses 
Abstract: Mepivacaine is a widely used local anesthetic and generally approved therapeutic 
medication in performance horses. To guide the racing community with respect to its 
therapeutic use close to regulated events, standard dosing regimens and withdrawal time 
guidelines associated with defined regulatory thresholds are required. The Association of 
Racing Commissioners International [ARCI] schedule recommends a 72-hour withdrawal 
after a dose of 0.07mg/kg, about 35.0 mg/horse, administered subcutaneously [SQ] with a 
regulatory threshold of 10 ng/mL of total 3-hydroxymepivacaine in urine. At times higher 
doses of mepivacaine may be clinically 
required, and the goal of this study was to provide guidance for a 400 mg SQ dose. This 
dose was administered to 6 horses, and the urinary concentrations of total 3-
hydroxymepivacaine determined by liquid chromatography/tandem mass spectrometry for 
out to 5 days. Urinary concentrations of total 3-hydroxymepivacaine exceeded the 10 
ng/mL urinary threshold in all samples collected, including on day 5. Based on these data 
and previous published research, we created a three-compartment model of the urinary 
concentrations of total 3-hydroxymepivacaine and calculated withdrawal time estimates 
following administration of 35 to 400 mg doses of mepivacaine to Thoroughbred horses. 
These data provide best withdrawal time guidelines for veterinarians treating 
Thoroughbreds horses with between 35 and 400 mg SQ doses of mepivacaine, including 
our best calculated projections of withdrawal times out to seven days post administration. 
Introduction:  Current testing recommendations by the RMTC for mepivacaine, a 
commonly used local anesthetic in the equine industry, are 10.0 nanograms total 
hydroxymepivacaine per milliliter of urine or the Limit of Detection of mepivacaine in 
plasma/serum.  These values are associated with a seventy-two-hour withdrawal time for a 
dose of 0.07 mg/kg (approximately 35 mg total) via subcutaneous injection.  However, 
standard doses in practice often reach up to 400 mg total injected.  For such a higher dose, 
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no guidance is provided, and horsemen and veterinarians are left to their own devices for 
determining when is appropriate to enter their horses.  With that in mind, a pharmacokinetic 
study was performed to give guidance for a full clinical dose of mepivacaine. 
 
Experimental:  Six horses were administered 400mg of mepivacaine subcutaneously via 
single injection into the left shoulder.  Pre-injection urine samples were collected and 
stored.  Likewise, urine samples were collected within 2 hours of the injection time each 
day thereafter for five days.  Samples were frozen and analyzed via mass spectrometry for 
urinary 3-hydroxymepivacaine.  Results were analyzed via pharmacokinetic analysis and 
a three-compartment model with an absorption compartment was found to be in best 
agreement with the values observed. 
The pharmacokinetic parameters determined appear to be in good agreement with other 
studies on mepivacaine in horses, though due to the testing facilities much lower limit of 
detection, a much longer terminal-half-life was observed compared to what was previously 
reported, an important detail for determining withdrawal guidelines.  The largest variance 
between the model and the mean plasma concentrations occurred at 24 hours (the model 
being approximately 50% of the observed values) but quickly converges with the observed 
data, and at five days is within 6% of the same value.  At all time-points, it is within one 
standard deviation of the observed datapoints mean. 
Of interest, the relative standard deviation of the population appears to change linearly with 
time, indicating that injection site differences or similar likely play a major role in the early 
variance in plasma concentrations. 
Using said trend in the relative standard deviation, a withdrawal guideline chart was 
developed to guide veterinarians and horsepersons when a dose is most likely to be 
acceptable within a certain amount of time of a race.  As such, the 95/95 tolerance interval 
for a full clinical dose of 400mg is likely to clear the horse at 134 hours (approximately 5.5 




Conclusion: Based on the reported data and the lipophilicity of mepivacaine, the authors 
recommend the following withdrawal guidelines for varying doses: 96 hours for 100mg 
dose, 120 hours for a 200mg dose, and 168 hours for a 400mg dose. 
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Mepivacaine in Thoroughbred Horses. Submitted to International Conference of Racing 
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ABSTRACT 
Mepivacaine is a widely used local anesthetic and generally approved therapeutic 
medication in performance horses.  To guide the racing community with respect to its 
therapeutic use close to regulated events, standard dosing regimens and withdrawal time 
guidelines associated with defined regulatory thresholds are required.  The Association of 
Racing Commissioners International [ARCI] schedule recommends a 72-hour withdrawal 
after a dose of 0.07mg/kg, about 35.0 mg/horse, administered subcutaneously [SQ] with a 
regulatory threshold of 10 ng/mL of total 3-hydroxymepivacaine in urine.  At times higher 
doses of mepivacaine may be clinically required, and the goal of this study was to provide 
guidance for a 400 mg SQ dose.  This dose was administered to 6 horses, and the urinary 
concentrations of total 3-hydroxymepivacaine determined by liquid 
chromatography/tandem mass spectrometry for out to 5 days.  Urinary concentrations of 
total 3-hydroxymepivacaine exceeded the 10 ng/mL urinary threshold in all samples 
collected, including on day 5. Based on these data and previous published research, we 
created a three-compartment model of the urinary concentrations of total 3-
hydroxymepivacaine and calculated withdrawal time estimates following administration of 
35 to 400 mg doses of mepivacaine to Thoroughbred horses.  These data provide best 
withdrawal time guidelines for veterinarians treating Thoroughbreds horses with between 
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35 and 400 mg SQ doses of mepivacaine, including our best calculated projections of 
withdrawal times out to 7 days post administration.    






The objective of this study was to provide guidance for practitioners administering 
the therapeutic medication mepivacaine (Carbocyanine/Polocaine) (Tobin, 1981; Tobin 
2013), Figure 1, at doses higher than the 0.07mg/kg (35 mg) subcutaneous (SQ) dose 
specified in the Association of Racing Commissioners International [ARCI] withdrawal 
guideline.  Current ARCI guidelines recommend withdrawal at least 72 hours prior to 
testing after a SQ dose less than 0.07mg/kg. The ARCI threshold is 10 ng/mL in urine of 
“total 3-hydroxymepivacaine” (RMTC website) and below the Limit of Detection (LOD) 
in plasma (ARCI website), although the Racing Medication and Testing Consortium 
[RMTC] has recently recommended a 50 pg/mL plasma/serum “cut-off” for parent 
mepivacaine (Personal Communication, S.A. Barker). 
 
Figure 2.2.1.1 Structure of Mepivacaine and its Metabolites of Interest 
 
Figure 1: Structure of Mepivacaine and its Metabolites of Interest showing the chemical 
structures and formula weights for mepivacaine, its Phase 1 metabolite, 3-




As noted by Toutain (2010), “one of the most difficult tasks for a veterinarian when 
treating a competition horse is to decide a withdrawal time.” A withdrawal time is a 
recommendation by a veterinarian as when to stop treating/last administer a medication 
prior to a regulated event. The veterinarian reviews regulatory literature, taking care to 
distinguish between European “Detection Times” data and US “Withdrawal Time” data, 
reviews dose, data and the number of experimental animals used and other relevant 
scientific literature. He/she also reviews the clinical data associated with the 
administration, including formulation, route of administration, dosage regimen, duration 
of treatment and sources of animal-related variability, such as age, sex, breed, and 
training/racing history. The veterinarian then estimates a withdrawal time, knowing that 
“the main sources of uncertainty are of biological origin and cannot be reduced by 
managerial options” (Toutain, 2010).  
This study reports a pilot pharmacokinetic evaluation of a 400 mg subcutaneous 
dose of mepivacaine to horses with the goal of guiding veterinarians defining withdrawal 
time guidelines at doses of mepivacaine above the ARCI specified dosage. We selected a 
400 mg subcutaneous dose of mepivacaine, the highest dose routinely required in 
veterinary practice as in, for example, a Caslick’s operation.  This study focused on 
determining the final terminal urinary half-life of total 3-hydroxymepivacaine in urine with 
the goal of guiding veterinarians faced with clinical situations requiring a higher than 35 
mg administration of mepivacaine.       
 
MATERIALS AND METHODS: 
Horses 
Six horses owned by Equine Integrated Medicine, PLC were used in this study (age 
mean ± standard deviation, range 7 ± 5 years, 2 to 16 years, 1 colt, 3 geldings, 2 mares). 
Horses were determined to be healthy by physical examination by an experienced 
practitioner. Caslick’s procedures were performed on 2 mares using 400 mg of 
mepivacaine SQ (CARBOCAINE® V Sterile Aqueous Solution, 2% Mepivacaine 
hydrochloride, USP), provided courtesy of Zoetis (Parsippany, NJ). Colts and geldings 
received 400 mg mepivacaine SQ as a single injection over the left shoulder. 
Overall study design 
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Pre-injection urine samples were collected from the six horses in this study and 
stored pre-drug administration. Horses were trained to urinate by whistling. Urine samples 
were collected by free catch within 2 hours of the injection time each day for five days. 
Samples were frozen and sent frozen overnight to the New York Drug Testing and 
Research Program, 777 Warren Rd., Ithaca, NY 14850, USA for quantitative analysis for 
total urinary 3-hydroxymepivacaine.  
Urinary Hydroxymepivacaine concentration determination 
Quantitative analysis for total urinary 3-hydroxymepivacaine was performed in the 
New York State Racing and Wagering Board Laboratory using their Racing Medication 
and Testing Consortium (RMTC) and ISO-17025 accredited method.  The Limit of 
Detection of the method was 5 pg/mL in urine and the Lower Limit of Quantitation (LLOQ) 
of the method was 10 pg/mL of total 3-hydroxymepivacaine in urine. 
The analytical reference standard for 3-hydroxymepivacaine was purchased as a 
stock solution of 0.102 mg/mL from Frontier BioPharm (Richmond, KY, USA). The 
analytical reference standard for mepivacaine-d3 (used as internal standard) was purchased 
from Toronto Research Chemicals (North York, Ontario, Canada), and prepared as a stock 
solution at 1.00 mg/mL in methanol. Acetonitrile, ethyl acetate, hexane, chloroform, and 
methanol were purchased from EMD Millipore (Billerica, MA, USA).  Mepivacaine-d3 
was used as it is the specified internal standard in the RMTC ISO-77025 approved 
procedure used for Mepivacaine regulation in New York State.  A further consideration is 
that certified 3-hydroxymepivacaine-d3 of adequate purity was not available when the 
approved method was developed/validated.  Methyl tert-butyl ether, ammonium acetate, 
and acetic acid were purchased from Fisher Scientific (Fair Lawn, NJ, USA). β-
glucuronidase, 1140,000 /ml of beta glucuronidase activity, 2,700 units/ml of sulfatase 
activity was purchased from Campbell Science (Logan, UT, USA).  Deionized water was 
produced onsite to the specification of 18.2 mΩ. All reagents were of HPLC grade or better. 
3-Hydroxymepivacaine working solution was prepared by dilution of the 0.102 
mg/mL stock solution with methanol to a concentration of 5.0 ng/µL. Three calibrators 
were prepared by dilution of the working standard solution with drug-free urine to 
concentrations of 50, 500, and 1000 ng/mL. Calibration curves and negative control 
samples were prepared fresh for each quantitative assay. One mL of urine was aliquoted 
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into new, labeled test tubes. To each tube, mepivacaine-d3 stock solution was added 
followed by the addition of 1.0 mL of 1 M ammonium acetate buffer, pH 4.4 and 1.0 mL 
of 10,000 IU/mL β-glucuronidase in water. The pH was verified, and each tube was loosely 
capped. The samples were incubated in a 65°C bath for 2 hours. The samples were cooled 
to room temperature and 2.0 mL of saturated carbonate buffer, 2.0 mL of carbonate buffer, 
pH 9.5, and 5.0 mL of chloroform were added. The samples were mixed by rotation for 10 
min, centrifuged at 2400 rpm for 5 minutes. The upper aqueous layer was aspirated to 
waste. The chloroform layer was transferred to a clean, labeled test tube containing 5.0 mL 
of 1% acetic acid. 1.0 mL of hexane was added, and the samples were capped, mixed by 
rotation for 10 min, and centrifuged at 2400 rpm for 5 min. The acid layer was transferred 
to a clean, labeled test tube and reextracted with 4.0 mL of saturated carbonate buffer and 
5.0 mL of chloroform. The samples were mixed by rotation for 10 min, centrifuged at 2400 
rpm for 5 minutes. The upper organic layer was transferred to a tapered test tube and dried 
under nitrogen at 40°C. Samples were dissolved in 100 µL of 1:1:1 acetonitrile: methanol: 
DI water. 2.5 µL was injected into the LC-MS/MS system, Agilent 6400 series triple 
quadrupole mass spectrometer coupled with an HPLC chromatography system. 
The concentration of total 3-hydroxymepivacaine in urine was measured by LC-
MS/MS using positive electrospray ionization. The mass spectrometer was operated using 
Agilent’s Jet Stream Technology (Agilent Technologies, Palo Alto, CA, USA). 
Chromatography employed a Zorbax SB-CN column (2.1 mm x 150 mm column, 1.8 µm 
particle size, 80Å) (Agilent Technologies) and a linear gradient of 50:50 acetonitrile:10 
mM ammonium acetate in water (Mobile Phase A, MP A) and 45:45:10 acetonitrile: 
methanol: DI H2O (Mobile Phase B, MP B) with a constant flow rate of 0.4 mL/min. The 
initial concentration of MP B was held at 10% for 2.0 min, ramped to 95% over 1.5 min, 
and held at that concentration for 2.0 min before re-equilibrating for 0.5 min at the initial 
concentration. 
Detection and quantification were performed using selective reaction monitoring 
(SRM) of the precursor ion for 3-hydroxymepivacaine (m/z 263) and the internal standard 
(m/z 250). The responses for the product ions for 3-hydroxymepivacaine and mepivacaine-
d3, m/z 98 and 101, were plotted and peaks at the appropriate retention times were 
integrated using MassHunter software (Agilent) (Woods, et al, 2008). MassHunter 
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software was used to generate calibration curves from ion peak area ratios and quantitate 




Concentration versus time evaluations for total 3-hydroxymepivacaine were 
tabulated and mean values were determined for each timepoint. Likewise, data from the 
486 mg dose from the previous study by Harkins, et al (1999) were normalized to a dose 
of 400 mg by multiplying all reported concentrations by a factor of 400/486. The Method 
of Residuals was used to determine an equation to estimate the mean urine total 3-
hydroxymepivacaine concentrations as a function of time after a 400 mg dose.  This 
equation was then again dose-normalized to the 400 mg dose and checked against other 
concentrations (by dividing other SQ doses by 400) from Harkins, et al (1999) to test 






(𝐴𝑒−𝛼𝑡 + 𝐵𝑒−𝛽𝑡 + 𝐶𝑒−𝛾𝑡 − (𝐴 + 𝐵 + 𝐶)𝑒−𝑘𝑎𝑡) 
Where, X = dose administered 
N = normalization factor 
A, B, C, α, β, γ, ka = constants derived from Method of Residuals 
t = time post-administration 
 
Using the constants derived from the Method of Residuals, it was then possible to 

















































In order to predict what the 95/95 tolerance interval’s upper limit in a population 
for a given dose at a specific time post administration, the Relative Standard Deviation 
[RSD] was calculated at each timepoint, and an equation to estimate the RSD was 
determined. One horse (Max) was excluded from the calculation of the RSD as this horse 
showed substantial, unexplained individual variation in the drug absorption and 
elimination patterns. The estimated 95/95 tolerance intervals for a given dose and timepoint 





 𝐶𝑇𝐼,95/95 = (𝑅𝑆𝐷𝑡 ∗ 𝐶𝐸𝑠𝑡,𝑡 ∗ 𝑘) + 𝐶𝐸𝑠𝑡,𝑡, where 
𝐶𝑇𝐼,95/95 𝑖𝑠 𝑡ℎ𝑒 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 95/95 𝑇𝑜𝑙𝑒𝑟𝑎𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑟𝑣𝑎𝑙, 
RSDt = Relative Standard Deviation at time t, 
𝐶𝐸𝑠𝑡,𝑡𝑖𝑠 𝑡ℎ𝑒 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑚𝑒𝑎𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡, and 
k is the k-factor (for 6 horses, k=3.711) 
 
This equation was used to calculate concentrations of total 3-hydroxymepivaciane 
at doses of 35 mg, 50 mg, 100 mg, 200 mg, and 400 mg through 168 hours (7 days). Using 
this equation, we calculated the time post-administration at which urinary concentrations 
of total 3-hydroxymepivaciane drop below the 10 ng/mL threshold. 
 
RESULTS 
The validation of the method employed for the analysis of 3-hydroxymepivacaine 
contained a calibration curve performed encompassing 50, 500 and 1000 ng/mL 3-
hydroxymepivacaine.  The response was linear and gave correlation coefficients (R2) of 
0.99 or better and glucuronidase hydrolysis was at least 95 % complete.  Quality control 
sample replicates were performed (n = 7). The inter-day accuracy was 10.7% for 50 ng/mL 
3-hydroxymepivacaine. The intra-day accuracy was 3.3% for 50 ng/mL 3-
hydroxymepivacaine and the precision was 4.9%.  The limit of detection (LOD) was 5 
ng/mL, and the limit of quantitation (LOQ) was 20 ng/mL, and the method was validated 
with regard to ion suppression and enhancement.     
 
The urinary data for all six horses are presented in Figure 2, including the mean 
concentrations of total urinary 3-hydroxymepivacaine at each timepoint and estimated 
terminal half-lives for total 3-hydroxymepivacaine in urine. The measured total urinary 3-
hydroxymepivacaine concentrations were highest at 24 hours post-administration, 
declining rapidly between 24 and 48 hours, followed thereafter by a slower rate of decline.  
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The apparent half-life was 7.2 hours between 24 and 48 hours followed post 48 hours by 




Figure 2.2.1.2 Total urinary 3-Hydroxymepivacaine, 400mg Dose 
 
Figure 2: Total Urinary 3-Hydroxymepivacaine, 400 mg Dose: The data points show the 
resulting total urinary concentrations of total 3-hydroxymepivacaine over 5 days after a 
400 mg subcutaneous dose in each individual horse.  The maximum total urinary 3-
hydroxymepivacaine concentrations were observed at 24 hours post-administration, with 
a mean urinary concentration of 476 ng/mL.  Total 3-hydroxymepivacaine concentration 
then fell more than ten-fold, with an apparent half-life of about 7.2 hours to yield a mean 
urinary concentration of total 3-hydroxymepivacaine of about 39 ng/mL at 48 hours post 
dosing.  Post 48 hours the rate of decline of the urinary concentrations of total 3-
hydroxymepivacaine slowed considerably, with an apparent terminal half-life of about 38 
hours.   
 
Combining these data with those reported from Harkins, et al. 1999 Figure 3 shows 
that the 400 mg dose data are in good agreement with the earlier study with respect to 






Figure 2.2.1.3 Total 3-Hydroxymepivacaine, Urine 
 
Figure 3: Total 3-Hydroxymepivacaine, Urine: Showing the combined average data from 
the 400 mg study with the data reported by Harkins, et al. 1999.  The data show good 
agreement between both studies on the rate of total 3-hydroxymepivacaine elimination up 
to 48 hours.  
 
 Using the combined data, Equation 6 was determined to provide a satisfactory fit 





(3789𝑒−1.11218𝑡 + 2928𝑒−0.12698𝑡 + 105𝑒−0.01811𝑡 − 6822𝑒−1.05637𝑡), where 
𝐶?̅? is the estimated mean total urinary concentration of 3-hydroxymepivacaine at time t, 
X is the subcutaneous dose of mepivacaine in mg, and t is the time post-treatment in hours 
The Mean Average Percentage Error [MAPE] for this model is calculated at 27.9% 
 
 Graphing Equation 6 and comparing it to the known datasets, there is good overall 
agreement between the available data sets, as shown in Figure 4.  The Mean Average 
Percentage Error [MAPE] being 27.9% for the overall model. 
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Figure 2.2.1.4 Total Urinary 3-Hydroxymepivacaine, Model vs Actual 
 
Figure 4: Total Urinary 3-Hydroxymepivacaine, Model vs Actual shows the fit of the 3-
compartment model with production of 3-hydroxymepivacaine via metabolism of parent 
mepivacaine that was determined by Equation 1 for a 400 mg dose. It shows good 
predictive capabilities. However, adjusting the dose has similar fits that match well with 
the data from Harkins, et al. 1999. 
 
 
Table 2.2.1.1 Predicted vs Total Mean 3-Hydroxymepivacaine 
Day Mean Predicted Difference %Difference Z-Score 
0 0 0 0 0 0 
1 476.383 206.998 -206.9985 -56.6 -0.62125 
2 39.53 50.6213 11.09137 28.1 0.275629 
3 37.5733 28.8172 -8.75608 -23.3 -0.19087 
4 14.6866 18.4710 3.78441 25.8 0.659708 




Table 1: Predicted vs Total Mean 3-Hydroxymepivacaine:  This table shows the predicted 
values and compares them to the mean total urinary 3-hydroxymepivacaine values.  At all 
timepoints measured, the model predictions are within 1 standard deviation of the mean. 
 
These data are well fit by Equation 6, as shown by the data presented in Table # 1, 
where we compare the concentrations predicted from the mathematical model and the 
actual concentrations. By day 5 post-administration, the difference between the predicted 
and the actual values had decreased to -5.9 %, and we also note that total 3-
hydroxymepivacaine concentrations were all higher than the 10 ng/mL ARCI threshold.  
Combining these data into a three-compartment model, Figure 5 presents a general 
interpretation of the pharmacokinetics of mepivacaine after subcutaneous administration. 
 
Figure 2.2.1.5 General Pharmacokinetic Model for Mepivacaine in Thoroughbreds 
 
Figure 5: General Pharmacokinetic Model for Mepivacaine in Thoroughbreds presents 
the model consistent with the available urinary data for 3-hydroxymepivacaine.  Note that 
the “fast” compartment is considered likely to represent well-perfused tissues such as the 
liver and central nervous system, while the “slow” compartment is likely to represent less 
well perfused but high equivalent volume tissues, most likely adipose tissues.  This large 
apparent volume of distribution in the “slow” elimination compartment is presumably 
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responsible for the long apparent terminal half-life of urinary total 3-hydroxymepivacaine 
post subcutaneous administration. 
 
 The Relative Standard Deviation (RSD) of total urinary 3-hydroxymepivacaine 
concentrations also seems to diminish with time in a predictable manner.  Graphing this 
relationship, we see in Figure 6 that the pharmacokinetic parameters from one horse (Max) 
showed significant individual variance, and so the data are presented both including and 
excluding the data points from this horse.  Clinically, the unusual Max data are most likely 
the result of an atypical subcutaneous injection site, as absorption following subcutaneous 
injections can express varying pharmacokinetic behaviors depending on the injection site 




Figure 2.2.1.6 Relative Standard Deviation vs Time 
 
Figure 6: Relative Standard Deviation vs Time shows the relationship between the 
standard deviation of the 3-hydroxymepivacaine concentrations in the graph relative to the 
mean as a function of time. One horse, Max, was characterized by a large amount of 
individual variance, and so the RSD was calculated with and without data from this horse. 
In the data excluding him, a strong trend can be seen showing a narrowing of the relative 
standard deviations between individual urinary concentrations of total 3-
hydroxymepivacaine over time. This trend resembles the dataset with Max after the first 72 
hours. 
Calculating a 95/95 Tolerance Interval requires knowledge of the mean expected 
concentration of the analyte and its variance. Combining Equation 1 with the trend 
calculated from Figure 6 for the RSD, a 95/95 Tolerance Interval and a related withdrawal 
time can be calculated.  This was done by multiplying the mean concentrations predicted 
by Equation 1 by the RSD at the same timepoint predicted by Figure 6 to yield an estimate 
of the Standard Deviation at that timepoint. Doing so for 35 mg, 50 mg, 100 mg, 200 mg, 
and 400 mg doses produced the following withdrawal time guidelines for practicing 




Figure 2.2.1.7 Estimated 95/95 Tolerance Intervals for Various Doses 
 
Figure 7: Estimated 95/95 Tolerance Intervals shows both the predicted mean 
concentrations (solid lines) as well as the predicted times to reach a 95/95 Tolerance 
Interval of 10 ng/mL for various doses over a 7-day (168 hour) time course, post-
administration. Mean concentrations are denoted by solid lines, while predicted Tolerance 
Intervals associated with these doses are color-matched in dotted lines, denoted in the 
legend as “Dose*SF.” Each dosing regimen is for subcutaneous administration. 
 
Of importance for veterinarians is the estimated time at which the urinary concentrations 
following the doses presented in Figure 7 would decline to less than the 10 ng/mL 
regulatory threshold.  This information is presented below in Table 2. All times are 
reported as the minimum time (in hours) for a given dose to reach a mean total urinary 3-
hydroxymepivacaine concentration of 10 ng/mL or until a time at which a 95/95 Tolerance 






Table 2.2.1.2 Withdrawal Guidelines for 95/95 Tolerance Interval for a Regulatory 
Threshold of 10 ng/mL 
Dose (mg) Time (Hours) to Mean Conc.  
10 ng/mL 
Upper Limit of the 95/95 
Tolerance Interval for the Time 
(Hours) to 10 ng/mL 
35 32 50 
50 38 58 
100 57 77 
200 92 103 
400 130 134 
Table 2: Withdrawal Guidelines for a 95/95 Tolerance Interval for a regulatory 
threshold of 10 ng/mL shows the predicted time for various doses to reach a mean 
concentration 10 ng/mL of total 3-hydroxymepivacaine in urine and the time associated 
for that dose in a population to produce a Tolerance Interval of 10 ng/mL for 3-
hydroxymepivacaine in urine. Veterinarians are advised to use the right-hand column as a 
general guideline when estimating withdrawal times. 
 
DISCUSSION 
The goal of this study was to develop best estimates of the urinary concentrations 
of total 3-hydroxymepivacaine that would be expected following administration of 
clinically relevant doses of mepivacaine larger than the ARCI guideline dose of 0.07 
mg/kg., about 35 mg/horse.  Jurisdictions outside the United States recognize that clinically 
relevant doses may at times exceed the ARCI 35 mg dose  Regulatory guidelines for 
mepivacaine administration in other jurisdictions include a 48 hour withdrawal for a SQ 
dose of 300 mg in Canada (Agriculture Canada, 2016), a 48 hour detection time for 400 
mg in Australia (AEVA,1992), and a 4.5 day detection time for SQ dose of 0.395 mg/kg, 
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about 180 mg,   by the European Horseracing Scientific Liaison Committee (EHSLC) 
(European Horserace Scientific Liaison Committee, 1997). These guidelines were 
developed without a reference standard for 3-hydroxymepivacaine, which was first 
synthesized as a research standard by the Kentucky Equine Medication Research Program, 
which research led to an invited review in the Journal of Veterinary Pharmacology and 
Experimental Therapeutics which review supported the use of quantitative urinary 
thresholds as scientifically and forensically appropriate (Tobin et al, 1999).  
The results reported here are in good agreement with published regulatory and 
related research on mepivacaine as well as with current regulatory practice.  Tobin et al 
(1999) reported that dosing with the defined Highest No Effect Dose (HNED) of 2 mg of 
mepivacaine yielded a peak urinary concentration of total 3-hydroxymepivacaine of about 
65 ng/mL.  Similarly, review of the ELISA data obtained following administration of a 
sequence of subcutaneous mepivacaine doses ranging from 2 to 483 mg showed that the 
bulk of an administered dose of mepivacaine is rapidly eliminated in the first hours post 
administration (Harkins, et al 1999).  Consistent with this pattern, the urinary 
concentrations of total 3-hydroxypmepivacaine determined following administration of the 
400 mg dose in this study were all above 10 ng/mL at 72 hours post-dosing and also 
remained above this 10 ng/ml threshold at 120 hours post dosing.    
 
CONCLUSION 
The urinary elimination of total 3-hydroxymepivacaine following subcutaneous 
injection of a 400 mg dose follows a multi-compartmental model with mepivacaine rapidly 
diffusing from the subcutaneous injection site into the central plasma compartment and 
then distributing widely throughout the horse.  Mepivacaine then sequesters into other 
high-volume compartments, most likely adipose tissue, because of the lipophilicity of the 
drug – mepivacaine has a pKa of 7.6 (Becker & Reed 2006), when compared to the pH of 
7.4 of equine blood, this indicates a ratio of the charged-to-uncharged of approximately 
0.63.  That is, approximately 60% of the mepivacaine in blood will be found in the lipid-
soluble form.  The data presented in Table 2 and Figure 7 provide the to date best available 
guidance to veterinarians using higher doses of mepivacaine than the 35 mg dose in the 
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ARCI guidelines.  Based on the data reported herein and rounding out to at least the next 
24-hour time point, it would be unwise to suggest withdrawal times of less than 96 hours 
for a 100 mg dose, 120 hours for a 200 mg dose, and, allowing an extra 24 hours at this 
higher dose, 168 hours for a 400 mg dose. 
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2.2.2 Variability in plasma concentrations of methylprednisolone 6 days after 
intrasynovial injection of methylprednisolone acetate in racing horses: A field study 
Abstract: Background: Methylprednisolone (MP) acetate is a commonly used 
corticosteroid for suppression of inflammation in synovial structures in horses. Its use is 
often regulated in equine sports by plasma MP concentrations. Objectives: This study seeks 
to identify variables that may influence MP clearance when used therapeutically in equine 
athletes in regulated sports. Racing discipline, co-administration with hyaluronic acid (HA) 
and synovial structure were investigated. Study Design: Field study in actively racing 
horses in three disciplines (Thoroughbred, Standardbred and Quarter Horse). Methods: 
Seventy-six horses (15 Thoroughbreds, 20 Standardbreds, 41 Quarter Horses) were 
included in the study. Injection of any synovial structure with a total body dose of 100 mg 
MP acetate was permitted. Coadministration with Hyaluronic acid (HA) was recorded. 
Plasma was collected before injection and at 6 days post-injection within two hours of the 
injection time and analyzed by Liquid Chromatographic tandem Mass Spectroscopy. 
Percent censored data for each synovial structure was determined, and summary statistics 
generated by Robust Regression on Order. Differences between synovial structures and co-
administration with HA were identified by t-test. Results: The plasma concentration for the 
entire group (mean ± standard deviation (sd), pg/mL) was 96 ± 104. The high motion (HM) 
group had a lower plasma MP concentration. 
Experimental: As above, seventy-six horses (15 TB, 20 SB, 41 QH) were included in the 
study.  Injection of any synovial structure with a total dose of 100mg MP acetate was 
permitted.  Co-administration with HA was recorded.  Plasma was collected before 
administration and at 6 days post-injection within two hours of the initial injection time.  
Analysis was via LC-MS/MS.  Robust Regression on Order statistics were generated for 
summary data and censored percentages were included for each injection site.  
Conclusion:  Injection into the Distal Tarsal Subchondral, Chondroitin Carpal Sheath, and 
Medial femorotibial joints as well as combination therapy with Hyaluronic acid may 
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prolong apparent clearance and so longer withdrawal guidelines should be observed when 
appropriate. 
Citation: Machin J, Duer W, Maylin G, Fenger C, Wilson D, Ivey M, Berthold B, Allison 
S, Tobin T. Variability in plasma concentrations of methylprednisolone 6 days after 
intrasynovial injection of methylprednisolone acetate in racing horses: A field study. 
Equine Vet J. 2019 May;51(3):343-348. doi: 10.1111/evj.13003. Epub 2018 Sep 5. PMID: 
30080939. 
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Summary 
Background: Methylprednisolone (MP) acetate is a commonly used corticosteroid for 
suppression of inflammation in synovial structures in horses. Its use is often regulated in 
equine sports by plasma MP concentrations. 
Objectives: To describe variability in MP plasma concentrations after MP acetate injection 
in different synovial structures and with co-administration with hyaluronic acid (HA). 
Study design: Field study in actively racing horses in three disciplines (Thoroughbred, 
Standardbred and Quarter Horse). 
Methods: Seventy-six horses (15 Thoroughbreds, 20 Standardbreds and 41 Quarter Horses) 
were included in the study. Injection of any synovial structure with a total body dose of 
100 mg MP acetate was permitted, data were grouped according to the synovial structure 
injected and co- administration with HA. Plasma was collected before injection and at 6 
days post-injection. Per cent censored data (below the limit of quantification) for each 
synovial structure were determined, and summary statistics generated by Robust 
Regression on Order. Differences between synovial structures and co-administration with 
HA were identified by ANOVA with Tukey’s post hoc testing. 
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Results: The MP plasma concentration at 6 days for injection for the entire group (mean 
standard deviation [s.d.], pg/mL) was 96 104. Metacarpophalangeal (MCP) plasma 
concentrations contained 86% censored data and could not be included in the statistical 
analysis. The carpal joints (CJO) group had a lower plasma MP concentration (P<0.05) 
than the distal tarsal joints (DTJ) or medial femorotibial (MFT), the no HA (NHA) group 
had a lower plasma MP concentration (P<0.05) than HA. 
Main limitations: The synovial structures injected varied by racing discipline, so this study 
was unable to identify any differences between disciplines. Conclusions: Practitioners 
should be aware that injection of DTJ, CS and MFT joints, and combining MP acetate with 
HA may prolong its clearance, and withdrawal times for competition in regulated equine 
sports. 
 
Keywords: horse; methylprednisolone; joint injection; racehorse; threshold; plasma 
concentration 
Introduction 
Methylprednisolone acetate, pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-
dihydroxy-6-methyl-(6a,11b), molecular weight 416.51 g/mol (MP acetate) (Depo-
Medrol®) a is an FDA-approved long-acting, slightly water- soluble corticosteroid prodrug 
for intrasynovial administration in horses where targeted therapy is recommended. The 
marginal water solubility of MP acetate delays its entry into joint fluid, accounting for its 
prolonged therapeutic action. Once dissolved in joint fluid the acetate prodrug moiety is 
catalyzed by alkaline hydrolysis/esterase action, yielding the therapeutically active 
molecule, methylprednisolone. 
Over 53% of racehorses [1] experience lameness during their racing careers, of 
which joint injury is one of the major causes. As many as 27% of Thoroughbred yearlings 
go through public auction with pre-existing arthritis [2], and this problem is not limited to 
Thoroughbreds, as a comparable 33% prevalence is seen in nonracing breeds [3]. Targeted 
joint therapy for these conditions using MP acetate has been a mainstay of equine 
veterinary care since the early 1960s. Use of this specific therapeutic medication is 
accompanied by restrictions in proximity to competition in performance horses with most 
international sports and racing jurisdictions providing withdrawal guidelines without 
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published thresholds. The Canadian Para-Mutuel Agency (CPMA) recommends a 6- day 
withdrawal after 100-mg intra-articular (IA), or a 14-day withdrawal after 200 mg [4], 
whereas the Federation Equestre Internationale provides a detection time of 14 days after 
100-mg IA and 28 days after 200-mg IA [5]. 
In the United States, many jurisdictions have adopted a regulatory threshold of 100 
pg/mL MP in plasma or serum pursuant to a recommendation by the Racing Medication 
and Testing Consortium (RMTC), which is accompanied by a withdrawal recommendation 
of 21 days. The RMTC typically determines thresholds based on the application of a 
statistical method called the 95/95 tolerance [6], although it is not clear whether this 
statistical method was used in the case of MP. The RMTC references a pharmacokinetic 
study of 16 research horses [7], in which MP acetate injection was restricted to a single 
dose of 100 mg without concomitant medication in one antebrachiocarpal joint of 
Thoroughbreds, and these data were used to determine both MP plasma pharmacokinetics 
and support their threshold recommendation. The regulated population of racing horses 
that receive MP acetate may have injections into joints other than the antebrachiocarpal 
joint and is comprised of horses other than Thoroughbreds. In the case of at least one 
therapeutic medication, glycopyrrolate, pharmacokinetic properties differ between 
Thoroughbreds and Standardbreds [8]. 
In order to provide guidance for horsemen and veterinarians operating under 
regulatory restrictions, including the effect of synovial structure being injected and co-
administration of hyaluronic acid, this study was performed. We sought to include horses 
of all three major racing disciplines, Thoroughbreds, Standardbreds and Quarter Horses 
under actual training conditions and to evaluate the effect of the widely used co- 
administration with hyaluronic acid (HA) in order to provide guidance to practitioners for 
practical therapeutic use of MP acetate. We chose 6 days post-MP acetate administration 
for collection of plasma samples because this time frame was likely to minimize the 
censored data points, or data below the limit of quantification (LOQ), based on the previous 
work [7]. 
 




Study facilities and animals 
Privately owned Thoroughbred, Standardbred and Quarter Horse racehorses in race 
training in the practice population of five of the authors (C.F., D.W., M.I., B.B. and S.A.) 
were used throughout. Horses were stabled on the racetrack or at training centers and were 
housed and trained according to standard procedures at racing facilities in Kentucky, Ohio 
and New Mexico. The feed, bedding and water sources were consistent with routine 
management at each facility. Training adhered to regimens consistent with the type of 
racing specific to the racing discipline. Informed consent was obtained for all horses 
enrolled. Inclusion criteria were a full clinical examination and a diagnosis requiring joint 
and/or synovial compartment therapy with 100-mg MP acetate total body dose. Treatment 
was based on the exam and diagnosis by the examining investigator, a signed owner 
consent form, long-term trusted relationships between the investigator and trainer to ensure 
trainer compliance and active participation in racing or fast workouts in preparation for 
racing. Exclusion criteria were previous injections with MP acetate within 1 month, or any 
other medications within the 24 h prior to blood collection. 
 
Experimental design 
All racehorses in the five investigators’ practices which fulfilled the inclusion 
criteria with none of the exclusion criteria were enrolled in the study. In order to replicate 
the usual clinical usage patterns of MP acetate, no restrictions were placed on co-
administered medications. The synovial structure injected was recorded, without any 
restrictions on which structures could be injected. The injected structures were the medial 
femorotibial joint (MFT), distal intertarsal joint and tarsometatarsal joint (DTJ), distal 
interphalangeal (DIP), antebrachiocarpal and intercarpal (combined as CJO), 
metacarpophalangeal joints (MCP) and carpal sheath (CS). Blood was collected into 
lithium heparin tubes prior to synovial structure injection(s), and post-injection blood was 
collected in all cases 6 days (2 h) after synovial structure injection. In five cases where 
preinjection samples were not collected, a complete review of the horse’s medical record 
for the last month was performed to ensure that no prior injection with MP acetate had 
occurred. Blood was kept refrigerated at 4°C and shipped overnight to the New York Drug 





The analytical procedure followed was the ISO 17025/RMTC accredited 
quantitative analytical procedure for Methylprednisolone in place in the New York Drug 
Testing and Research Program. The reference standard for MP was purchased from Sigma 
Aldrich. The analytical reference standard MP-d2 used as internal standard was purchased 
from CDN Isotopes. Stock solutions of MP and the internal standard were prepared at 1 
mg/mL in methanol. Acetonitrile and methanol were purchased from EMD Millipore, and 
methyl-tert-butyl ether and ammonium formate were purchased from Fisher Scientific. 
Deionized water was filtered onsite to the specification of 18.2O. All reagents were HPLC 
grade or better. 
Methylprednisolone working solution was prepared by dilution of the 1 mg/mL 
stock solution with ethanol to the concentration of 25 pg/mL. Plasma calibrators were 
prepared by dilution of the working standard solution with drug-free plasma to 
concentrations of 50, 100 and 200 pg/ mL. Calibration curves and negative control samples 
were prepared fresh for each quantitative assay. 
  
Prior to analysis, 1 mL of plasma was aliquoted into new, labelled test tubes. To 
each tube, MP-d2 stock solution was added along with 5 mL of methyl-tert-butyl ether. 
The samples were mixed by rotation for 10 min, centrifuged at 2400 rpm for 5 min and the 
top ether layer removed and dried under nitrogen. Samples were dissolved in 100 mL of 
1:1:1 acetonitrile: methanol: DI water and a 2.5-lL aliquot injected into the LC-MS/ MS 
system, Agilent 6400 series triple quadrupole mass spectrometer coupled with an HPLC 
chromatography system. 
The concentration of MP was measured in plasma by LC-MS/MS using positive 
electrospray ionization. The mass spectrometer was operated using electrospray combined 
with Agilent’s Jet Stream Technology. Chromatography employed a Zorbax SB-C18 
column with specifications of 10 cm 9 3.0 mm, 3.5 mm, column and a linear gradient of 
acetonitrile (ACN) in water with a constant 5 mmol/L ammonium formate (pH 3.5) at a 
flow rate of 0.5 mL/min. The initial ACN concentration was held at 40% for 
3.0 min, ramped to 95% over 1.0 min and held at that concentration for 
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1.0 min before re-equilibrating for 0.5 min at initial concentration. 
Detection and quantification were conducted using selective reaction monitoring 
(SRM) of initial precursor ion for MP (mass-to-charge ratio 
375.2 m/z) and the internal standard (361.2 m/z). The response for the product ions 
for MP (m/z 339, 321, 293 and 253) and the internal standard (m/z 161) was plotted and 
peaks at the proper retention time integrated using MassHunter software. MassHunter 
software was used to generate calibration curves and quantitate MP in all samples by linear 
regression analysis. 
The validation of the method employed for the analysis of MP contained a 
calibration curve performed encompassing 50, 100 and 200% of the threshold value for 
MP. The response was linear and gave correlation coefficients (R2) of 0.99 or better. 
Quality control samples replicates were performed (n = 7). The interday accuracy was 5.5% 
for 100 pg/mL MP. The intraday accuracy was 0.3% for 100 pg/mL MP. The interday 
precision was 2.5% for 100 pg/mL MP. The intraday precision was 13.9% for 100 pg/mL 
MP. The technique was optimized to provide a lower limit of quantification (LOQ) of 0.05 
ng/mL. The limit of detection (LOD) was 0.025 ng/mL. This analytical method has been 
shown to exclude 20-dihydro-6-methylprednisolone, an isomeric metabolite of 
methylprednisolone in the horse and a possible confounding isomeric metabolite of 
methylprednisolone with respect to the unequivocal identification and confirmation of 
methylprednisolone in post- MP administration equine plasma samples [9]. 
 
Data analysis 
The 6-day post-administration plasma MP concentrations were analyzed for 
percentage of censored (below LOQ) data, effects of number of synovial structures 
injected, specific synovial structure injected and coadministration with HA using Robust 
Regression on Order [10] and General Linear Model statistical methods [11]. Data were 
first grouped as all horses, then subgrouped according to the synovial structure, number of 
synovial structures injected and concomitant administration of HA. Where multiple 
injections resulted in horses being categorized into more than one group, the data from the 
overlapping groups were compared with each individual group in order to determine if 
these data should be compared separately. The effect of HA on plasma clearance was also 
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included as a separate analysis of co-administration with HA (HA) or no co-administration 
with HA (NHA). 
Each dataset was first analyzed for percent censored data, then Normality tests 
(Shapiro-Wilk, Anderson-Darling, Lillefors and Jarque-Bera) were performed on 
uncensored (above LOQ) data in order to determine the most appropriate statistical analysis 
for threshold determination. Summary statistics for each data subgroup were obtained for 
all groups except CS data and MCP data using RROS [11] in R-programming language 
and bootstrap analyses with 100,000 resamplings (XLSTAT®, ADDinsoft 2016 
https://www.xlstat.com/en/ as an Excel® for Mac 2011, Microsoft add- in). Bootstrap with 
resampling was performed to improve estimates of group summary statistics. Comparisons 
of the grouped Synovial structure data were then performed using ANOVA, with Tukey’s 
post hoc testing. 
The use of concomitant HA and no HA groups was compared in a separate analysis 
using a t test. The effect of the number of joints injected was compared using joints as 
count data with a General Linear Model in R being   cognizant   of   the   effects   of   any   
overdispersion [11], and homoscedasticity of variances tested by Bartlett and Brown-
Forsythe tests [12]. Thresholds for each data set were determined using two different 
methods: (95/95) tolerance interval [6] and Gauss-Camp-Meidell (GCM) [13]. 
 
Results 
Seventy-six horses met the inclusion criteria (15 Thoroughbreds, 20 Standardbreds 
and 41 Quarter Horses). Sixty-eight horses had preinjection plasma samples analyzed, and 
all of these plasma samples were below the LOD of the analytical method for MP. Seven 
horses did not have pre- injection plasma samples analyzed, but a review of the medical 
history for these horses showed no previous MP administration or exposure, and these 
horses were included in the analysis. 
The MCP data set had 86% censored data, so no further analysis could be conducted 
[10]. In all cases where the DIP joint was injected, the MCP joint was also injected, so no 
separate conclusions or analyses could be done on this subgroup. There were 13 instances 
of horses categorized into both the MCP and CJO groups. Of these, 12 were censored. 
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There was one instance of a horse categorized into the MFT and CJO group (censored), 
and one instance of a horse categorized into the MFT and DTJ groups (uncensored). All 15 
were included in both groups for analysis. The per cent censored data for each group is 
shown in Table 1. Normality tests (Shapiro-Wilk, Anderson-Darling, Lillefors and Jarque-
Bera) for each data set (All horses, CJO, CS, DTJ, MFT, HA and NHA) indicated that non-
censored data (plasma concentrations above the LOQ) were normally distributed. 
Where censored data in groups fell below 80% (All horses, CJO, CS, DTJ, MFT, 
HA and NHA groups), summary statistics for plasma concentrations arising from MP 
acetate intrasynovial injections were obtained as described above. Standard parametric 
summary statistics were used for CS data, as recommended by Helsel [10]. Box and 
whisker plots (mean, interquartile range and highest and lowest scores, with outliers 
indicated) for these data are shown in Figures 1 and 2, and differences indicated in the 
figures. 
Breed/racing discipline differences were found among which specific synovial 
structures were commonly injected with MP. Insufficient horse numbers were present for 
each joint or synovial structure injected among the different breeds, and not every breed 
was represented in all injection groups (Table 2). Therefore, all breeds were combined, and 
the differences were analyzed by the MP-treated synovial structure. No effect of the 
number of synovial structures injected on the MP plasma concentrations was found (Figure 
3, P = 0.8) with lack of overdispersion. There were 13 instances where CJO and MCP were 
co-injected and one instance where DTJ and MFT were co-injected. In all cases, the 
resulting MP plasma concentrations were within the interquartile range of both groups, so 
the case was included in the analysis of both groups. 
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Table 2.2.2.1 Distribution of censored and Uncensored Data (Methylprednisolone) 
 
TABLE 1: The distribution of censored (plasma concentrations methylprednisolone below 
the limit of quantification) and uncensored (plasma concentrations methylprednisolone at 
or above the limit of quantification) among 6-day methylprednisolone plasma 
concentrations. Horses that were injected into multiple synovial structures are included in 
both groups and include 13 horses in both the metacarpophalangeal and carpal joints, one 
horse in both the medial femorotibial and carpal joints and one horse in both the medial 




Figure 2.2.2.1 Box & Whisker plots for Plasma Methylprednisolone by Joint 
 
Figure 1:  Box   and   whisker    plots   for   plasma   methylprednisolone   
concentrations 6 days post-injection by synovial structure. Concentrations that differ by 
structure are indicated by different letters. *Metacarpophalangeal data are shown for 
comparison but were not included in the analysis because the censored data (below the 




Figure 2.2.2.2 Box and Whisker Plots for Methylprednisolone by Administration of HA 
 
Figure 2:  Box   and   whisker    plots   for   plasma   methylprednisolone   
concentrations 6 days post-injection by concomitant injection of hyaluronic acid compared 
with no hyaluronic acid. The addition of hyaluronic acid to the injection doubled the 
methylprednisolone plasma concentration. 
 
The plasma concentration for the entire group (mean ± s.d., pg/mL) was 96 ± 104.  
The CJO group had a lower plasma MP concentration (53 ± 68, P<0.05) than the DTJ (226 
± 74) and the MFT (177 ± 154) group, and no difference was identified among the other 
groups evaluated.  The NHA (75 ± 96) group had approximately half the MP concentration 
of the HA (147 104, P<0.05) group. Six-day tolerance limits or thresholds generated using 
95/95 or GCM (P = 0.05, P = 0.01) are presented in Table 3. 
 
Table 2.2.2.2 Synovial Structures Injected by Breed 
 




Figure 2.2.2.3 Number of Synovial Structures Injected vs Plasma Methylprednisolone 
 
Figure 3: Number of synovial structures injected and plasma methylprednisolone 





Table 2.2.2.3 Tolerance Limits or Thresholds for 6-day Methylprednisolone 
 
TABLE 3: Tolerance limits or threshold values (pg/mL) for a 6-day methylprednisolone 
plasma concentration for two different statistical methods. The Gauss-Camp-Meidell 
method (P = 0.05) threshold was chosen to match the 95/95 risk of a positive test, and the 
Gauss-Camp-Meidell method (P = 0.01) is included to demonstrate a threshold for a risk 




This population study in racing horses was undertaken to evaluate the post-MP 
acetate administration plasma concentrations of MP under field conditions. Our findings 
provide guidance for practitioners when deciding upon MP acetate use in different synovial 
structures and demonstrate the usefulness of different statistical methods for the 
determination of thresholds for therapeutic substances. The results concur with and support 
previous findings [7] that the pharmacokinetics of MP differs depending upon which 
synovial structures are treated. Knych et al. [7] demonstrated differences in MP plasma 
pharmacokinetics between the antebrachial (AC) joint and the intercarpal (IC) joints, 
whereas our study demonstrates differences among CJO, DTJ and MFT. We were unable 
to repeat the findings of the previous Knych et al. [7] study because the AC and IC joints 
were commonly injected together in the practices of our investigators. Therefore, any 
differences between the pharmacokinetics of MP between these two specific joints would 
not be detected in our study design. 
Metacarpophalangeal joints were associated with the most rapid clearance of MP 
from the plasma in this study (Figure 1), with 85% of the data falling below the LOQ 
(censored), and only a single horse exceeding the 21- day RMTC recommended threshold 
of 100 pg/mL. The high percentage of censored data in this group prevented any statistical 
analysis of this group. The DIP is included in the MCP group because in all cases (N = 5) 
in our study the two structures were injected together. Of these five horses, all were well 
below the 100 pg/mL threshold and 60% of the data were censored. It is likely that this 
joint shares the characteristics of rapid clearance from the plasma with the MCP. This may 
result from its considerable range of motion of 46–47 degrees of flexion/extension despite 
being encased in the hoof [14]. 
Of the joints that could be included in the statistical comparisons, the CJO had the 
lowest MP plasma concentrations. In the MCP, DIP and CJO joints, the low plasma 
concentrations of MP at 6 days post-administration may have been associated with the 
relative ease of the injection procedure resulting in the entire dose being deposited into the 
joint, the motion of the joint which could be associated with increased blood flow or high 
rates of mechanical disruption of the actual MP acetate particles. In contrast, DTJ injections 
were associated with the highest plasma MP concentration at 6 days post-injection. This 
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may have resulted from a larger proportion of the MP acetate being deposited outside of 
the joint in the subcutaneous tissues, reflux of the injectate back out through the needle 
track and into the subcutaneous tissue because of the anatomy of the synovial structure, or 
simply a lower rate of mechanical disruption of the MP acetate particles. The DTJ are 
characterized by minimal joint fluid volume, and even small volumes of medication 
injected into the joint would likely cause sufficiently increased pressure in the joint to result 
in significant reflux. This likelihood that a portion of MP refluxed back through the needle 
track is supported by the narrow standard deviation for plasma MP concentrations for DTJ, 
reflecting the consistency with which this higher plasma concentration is observed. In 
contrast, the plasma MP concentration after injection of the MFT joint was accompanied 
by both a high mean and standard deviation, possibly reflecting the technical difficulty of 
the injection procedure, or variable uptake of the MP into the infrapatellar fat pad. If any 
portion of the dose of MP is inadvertently delivered outside the joint/synovial cavity, a 
longer withdrawal can be expected. Slight movement of the horse during the MFT injection 
procedure could readily result in portions of the dose administered being deposited peri-
articularly. The plasma MP concentrations from horses that had CS synovial structures 
treated had a similar profile to the distribution of MP from those with DTJ injections, 
suggesting a similar mechanism for medication uptake into the systemic circulation from 
the synovial structure. The plasma MP concentration was also higher when the MP was co-
administered with HA than when it was administered alone. The large HA molecules may 
serve to trap the MP in the joint, or the HA may simply add volume to the injection, 
increasing the likelihood of reflux of the injectate into the subcutaneous space. The longer 
withdrawal associated with co-administration of HA has been previously observed with 
other corticosteroid intra-articular targeted therapies [15]. 
In order to provide practitioner guidance on how MP should optimally be used in 
practice, both the 95/95 tolerance limit and GCM method were compared (Table 3). The 
95/95 tolerance limit is defined as a level with which there is 95% confidence that 95% of 
the population will fall below the threshold [6]. Practically, both methods determine the 
probability of violating a threshold given a risk level, in this case 5%. The primary 
differences between these statistical methodologies are the criteria which the data must 
meet for the method to be valid. For example, the 95/95 tolerance method requires 
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normality and a minimum number of data points of 19 [6]. The GCM method does not 
require a normal distribution but does require a unimodal distribution [13]. 
In our MP data set, the calculated threshold varied from 257 to 3160 pg/ mL, 
depending upon which structures were injected and which statistical method was employed 
to determine the threshold. The greatest discrepancy is found between the 95/95 tolerance 
method and the GCM (P = 0.05), with the MFT. Both methods theoretically carry the same 
risk of violating the threshold, but the 95/95 tolerance method is accompanied by a 
considerably higher threshold. Technically, the 95/95 method requires a sample size of at 
least 19 animals [7], and the sample size for the MFT in this study included only 10 horses. 
This exemplifies why it is important that the most appropriate statistical methodology for 
the data be employed in threshold determination. In the case of a sample size less than 19, 
clearly, the 95/95 tolerance level is inappropriate. 
This study provides several important guidelines for veterinarians using targeted 
joint therapy with MP acetate in equine athletes that perform in a regulated environment. 
First, the use of MP in MCP, DIP and CJO joints without the concurrent administration of 
HA is likely to be associated with a shorter withdrawal time before a competitive event 
than other applications of the product. Second, caution should be used in the administration 
of MP to MFT joints because the plasma concentrations of MP are highly variable when 
MP acetate is administered into this synovial structure. Efforts to improve the accuracy of 
MFT injection should be made, including sedation of the patient and injection by 
ultrasound guidance to ensure that the entire dose is deposited within the joint pouch. 
Finally, DTJ and CS require a longer withdrawal for MP acetate administration than when 
used in other joints, likely as a result of their anatomy, and the potential for medication 
reflux out of the synovial structure after injection. For existing thresholds, specific 
withdrawal times before competition for MP acetate injection into disparate synovial 
structures cannot be recommended based on our findings. Additional studies are warranted 
to provide this information. 
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2.2.3 Pharmacokinetics of betamethasone following intra-articular injection of 15mg of 
BTM sodium phosphate/acetate prodrug combination into each medial femorotibial 
joint of Standardbred horses 
Abstract: Betamethasone is an anti-inflammatory corticosteroid frequently used as an 
intra-articular combination of two prodrugs, Betamethasone sodium phosphate 3.15 
mg/ml/mL and Betamethasone acetate 2.85 mg/ml/mL injectable suspension 
administered at a dose of up to 30 mg per horse.   To determine the plasma 
pharmacokinetics and detection times of Betamethasone following BTM combination 
administration, we administered two 15 mg doses of BTM combination, one into each 
medial femorotibial joint of 8 Standardbred horses.   Blood plasma samples were 
collected pre-administration and at selected intervals for ten days.  Concentrations were 
determined using LC-MS/MS and the data analyzed using compartmental 
pharmacokinetic modeling.  Plasma concentrations peaked at 30 minutes at 22 ng/ml/mL, 
with a mean second phase half-life of 7.07 hours until 72 hours post administration.  
After 72 hours, the mean plasma half-life was 123.78 hours, yielding a mean plasma 
concentration of 0.016 ng/ml at 240 hours post administration.  These data fit a three-
compartment model with absorption, with the final terminal plasma half-life of 123.78 
hours.  The initial rapid increase is consistent with rapid bioavailability and distribution 
from Betamethasone sodium phosphate, while the longer terminal phase half-life is 
consistent with the Betamethasone acetate suspension.    Both 95/95 Tolerance and Gauss 
(Camp-Meidell) inequality thresholds were determined at each time point from 72 hours 
to 10 days.   In order to accommodate medial femorotibial joint injections with 30 mg 
total dose of this BTM Combination, these data support a Betamethasone regulatory 
threshold of 0.200 ng/ml with a six-day withdrawal guideline or 0.100 ng/ml/mL with a 
ten-day withdrawal guideline. 
Experimental: Eight standardbred horses (3 geldings, 5 mares) were used in this study.  No 
medication was administered for a minimum of four weeks prior to the beginning of the 
study.  A veterinarian performed the physical and lameness examinations prior.  The horses 
were sedated with detomidine (approximately 10ug/kg, IV).  The MFT joint pouch was 
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identified via ultrasound, and aseptic methods were used to inject 15mg of BTM 
combination (BetaVet) into each joint (30mg total body dose).  Deposition within the joint 
capsules was confirmed via ultrasonography.  Plasma samples were then collected out to 
ten days.  Quantitation was performed via LC-MS/MS.  Pharmacokinetics were performed 
via curve-stripping methodologies, and the Mean Absolute Percentage Error was 8.03%. 
 
Conclusion:  Based on our pharmacokinetic findings, we recommend an interim regulatory 
threshold for Betamethasone of 0.200 ng/mL with a six-day withdrawal guideline, or 0.100 
ng/mL with a ten-day withdrawal guideline for use in racing regulation where bilateral 
MFT injections may be indicated. 
 
Citation: Machin, J., Maylin, G., Duer, W., Fenger, C., Tobin, T. Pharmacokinetics of 
betamethasone following intra-articular injection of 15 mg of BTM sodium 
phosphate/acetate prodrug combination into each medial femorotibial joint of 
Standardbred horses. (2020). Submitted to Journal of Veterinary Pharmacology and 
Therapeutics. 
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ABSTRACT   
Betamethasone is an anti-inflammatory corticosteroid frequently used as an intra-articular 
combination of two prodrugs, Betamethasone sodium phosphate 3.15 mg/ml/mL and 
Betamethasone acetate 2.85 mg/ml/mL injectable suspension administered at a dose of up 
to 30 mg per horse.   To determine the plasma pharmacokinetics and detection times of 
Betamethasone following BTM combination administration, we administered two 15 mg 
doses of BTM combination, one into each medial femorotibial joint of 8 Standardbred 
horses.   Blood plasma samples were collected pre-administration and at selected intervals 
for ten days.  Concentrations were determined using LC-MS/MS and the data analyzed 
using compartmental pharmacokinetic modeling.  Plasma concentrations peaked at 30 
minutes at 22 ng/ml/mL, with a mean second phase half-life of 7.07 hours until 72 hours 
post administration.  After 72 hours, the mean plasma half-life was 123.78 hours, yielding 
a mean plasma concentration of 0.016 ng/ml at 240 hours post administration.  These data 
fit a three-compartment model with absorption, with the final terminal plasma half-life of 
123.78 hours.  The initial rapid increase is consistent with rapid bioavailability and 
distribution from Betamethasone sodium phosphate, while the longer terminal phase half-
life is consistent with the Betamethasone acetate suspension.    Both 95/95 Tolerance and 
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Gauss (Camp-Meidell) inequality thresholds were determined at each time point from 72 
hours to 10 days.   In order to accommodate medial femorotibial joint injections with 30 
mg total dose of this BTM Combination, these data support a Betamethasone regulatory 
threshold of 0.200 ng/ml with a six-day withdrawal guideline or 0.100 ng/ml/mL with a 
ten-day withdrawal guideline. 
Key Words:  Betamethasone, prodrugs, joint injection, horses, Standardbred, 
pharmacokinetics, regulatory thresholds, withdrawal guidelines   
 
1/ INTRODUCTION:  
 
Betamethasone, (11,16β)-9-Fluoro-11,17-dihydroxy-16-methyl-3,20-
dioxopregna-1,4-dien-21-yl, Formula C22H29FO5, Molar Mass 392.5 g·mol−1 (BTM) is 
a corticosteroid widely used in equine medicine as an anti-inflammatory medication 
(Menendez et al., 2016).  Betamethasone is administered by intra-articular injection as a 
combination of BTM sodium phosphate and BTM acetate for a targeted anti-inflammatory 
effect, as a BTM combination product, e.g., 3.15 mg/mL BTM sodium phosphate and 2.85 
mg/mL BTM acetate (BetaVet®, American Regent, Shirley, NY). 
    
Therapeutic medications such as intra-articular BTM are generally subject to 
regulatory restrictions on their use close to competition.  The Canadian Pari-mutuel Agency 
(CPMA) does not publish a plasma/serum threshold but provides guidance of a 6-day 
withdrawal for 18 mg total intra-articular dose of a combination product (CPMA, 2016).  
The Federation Equestrian International (FEI) provides a detection time rather than a 
withdrawal guidance of 7 days for the intra-articular use of 30 mg in up to two joints (FEI, 
2018).  The United Stated Equestrian Federation (USEF) permits the use of BTM in 
competition with the submission of a medication report form (USEF, 2019).  For horse 
racing, a common regulatory threshold in most jurisdictions in the United States for BTM 
is the Association of Racing Commissioners International (ARCI) guideline (ARCI, 2019), 
which is a 0.010 ng/mL plasma or serum threshold with a recommended seven-day 
withdrawal time following intra-articular administration of a single 9 mg dose of the BTM 




Figure 2.2.3.1 Structures of Betamethasone Compounds of Interest 
 
Figure 1: Structural formulae of BTM sodium phosphate (MW 516.40), (11,16β)-9-
Fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl phosphate; BTM 
acetate (MW 434.50), (11,16β)-9-Fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-




BetaVet® is an FDA approved BTM formulation comprised of 3.15 mg/mL of 
BTM sodium phosphate, and 2.85 mg/mL of BTM acetate, or 2.4 mg/mL BTM in the 
sodium phosphate form and 2.6 mg/mL BTM in the acetate form.  The highly water-soluble 
BTM sodium phosphate prodrug acts to provide an initial high intra-articular concentration 
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of BTM while the less water soluble BTM acetate within the suspension dissolves slowly, 
providing a prolonged anti-inflammatory effect (Menendez et al., 2016).   
 
The seven-day ARCI withdrawal time guideline for BTM is based on an 
unpublished study sponsored by the Racing Medication and Testing Consortium [RMTC], 
communicated in the form of an on-line monograph dated January 2019 (ARCI, 2019; 
RMTC, 2019).  That study was conducted using administration of 9 mg of this BTM 
sodium phosphate/acetate combination into a single metacarpophalangeal joint.  Clinically, 
a 9 mg dose is relatively conservative, significantly lower than the clinical doses chosen 
by the CPMA (18 mg), the FEI (30 mg) and published reports (Menendez et al, 2016, 30 
mg).   Furthermore, intra-articular injection of different anatomical structures may be 
associated with different withdrawal times, with targeted therapy of the stifle joint 
representing the most problematic procedure for withdrawal time prediction (Machin et al., 
2019).   
 
In order to provide guidance for horsemen and veterinarians operating under 
regulatory guidelines, a pharmacokinetic study of the clinically relevant dose of 15mg of a 
BTM combination product of BTM acetate and BTM sodium phosphate into each of two 
medial femorotibial joints, total dose 30 mg, was performed.   
 
2/ MATERIALS AND METHODS  
2.1/ Horses  
 
Eight Standardbred horses owned by New York Drug Testing and Research 
Program (3 geldings, 5 mares, age (years) mean ± sd, range 8 ± 4, 4 -13, weight (kg) 454 
± 22.6, 418 - 477) were used in this study.  No medication was administered for a minimum 
of four weeks prior to the beginning of the study.  An experienced veterinary clinician (CF) 
performed the physical and lameness examinations prior to the study, and the horses were 
determined to be healthy and free of lameness.  The study was conducted with the approval 





2.2/ Drug Administration  
 
The horses were sedated with detomidine (Dorm sedan®, Zoetis, Parsippany, NJ), 
approximately 10 mcg/kg, IV.  The medial femorotibial joint pouch was identified by 
ultrasound.  The skin overlying the joint pouch was aseptically prepared using povidone-
iodine scrub (Betadine®, Agri laboratories Ltd., St. Joseph, MO) and rinsed with 70% 
isopropyl alcohol.  Each medial femorotibial joint pouch was injected with 15 mg of the 
combination product of BTM sodium phosphate (3.15mg/mL) and BTM acetate (2.85 
mg/mL) (BetaVet®, American Regent Animal Health, Shirley, NY) using aseptic 
technique with ultrasound guidance.  The deposition of the BTM within the joint pouches 
was confirmed by ultrasonography after completion of each intra-articular injection (Figure 
2).    
 
2.3/ Sample Collection  
 
Blood samples for BTM concentration determination were collected by 
percutaneous venipuncture at time 0, i.e., prior to tranquilization and joint injection, and at 
0, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hours post 
injection.  Samples were collected into heparin tubes and centrifuged at 3,000 x g.  Plasma 
was immediately transferred into storage cryovials and stored at -20C until analysis by 
liquid chromatography tandem mass spectrometry (LC/MS-MS).   
 
2.4/ Quantification of Betamethasone 
 
The analytical procedure followed was the ISO 17025/RMTC accredited 
quantitative analytical procedure for BTM in place in the New York Drug Testing and 
Research Program.  The reference standard for BTM was purchased from Sigma-Aldrich 
Cat. B-7005 at ≥98% purity.  The reference standard for dexamethasone-d4 used as the 
internal standard was purchased from CDN Isotopes Cat. D-5559 at ≥96 atom %D purity.  
Stock solutions of BTM and dexamethasone-d4 were prepared at 1mg/mL in methanol.  
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Acetonitrile and methanol were purchased from EMD Millipore, and methyl tert-butyl 
ether and ammonium formate were purchased from Fisher Scientific. Deionized water was 
filtered on-site to the specification of 18.2MΩ.  All reagents used were HPLC grade or 
better.   
 
The BTM working solution was prepared by dilution of the 1mg/mL stock solution 
with methanol to the concentration of 10pg/mL.  Plasma calibrators were prepared by 
dilution of the working standard solution with drug-free plasma to concentrations of 5, 50, 
100, 1000 and 10,000 pg/mL for the first 48 h of sampling and 5, 10 and 50 pg/mL for 
determination of the terminal elimination portion of the curve.  Quality control samples 
were prepared by dilution of the QC working standard solution with drug-free plasma to 
concentrations of 10pg/mL.  Calibration curves, quality control samples, and negative 
control samples were prepared fresh for each quantitative assay.   
 
Prior to analysis, 2mL of plasma was aliquoted into new, labelled test tubes. To 
each tube dexamethasone-d4 stock solution was added along with 5.0mL methyl tert-butyl 
ether.  The samples were mixed by rotation for 10min, centrifuged at 2400 rpm for 5 
minutes and the top layer removed and dried under nitrogen.  Samples were dissolved in 
50uL of methanol: acetonitrile: deionized water and a 2.5uL aliquot injected into the LC-
MS/MS system, Agilent 6400 series triple quadrupole mass spectrometer coupled with an 
HPLC chromatography system.   
 
The concentration of BTM was measured in plasma by LC-MS/MS using positive 
electrospray ionization.  The mass spectrometer was operated using electrospray combined 
with Agilent’s Jet Stream Technology. Chromatography employed a Zorbax SB-C18, 3.0 
x 100mm and a linear gradient of acetonitrile (ACN) in water with a constant 5mM 
ammonium formate at a flow rate of 0.3mL/min.  The initial ACN concentration was held 
at 50% for 2.75 min, ramped to 95% over 0.5 min, and held at that concentration for 




Detection and quantification were conducted using selective reaction monitoring 
(SRM) of initial precursor ion for BTM (mass-to-charge ratio 393.5 m/z) and the internal 
standard (397.5 m/z).  The response for the product ions for BTM (m/z 373, 355, and 337) 
and the internal standard (m/z 377) was plotted and peaks at the proper retention time 
integrated using MassHunter® software. MassHunter® software was used to generate 
calibration curves and quantitate BTM in all samples by linear regression analysis.   
 
2.5/ Pharmacokinetic analysis:    
 
Compartmental analysis was used for determination of pharmacokinetic parameters 
for intra-articular administered BTM combination with curve-stripping methodologies 
(Gabrielsson & Weiner, 1999). Goodness of fit and the appropriate weighting factor were 
selected based on visual analysis of observed versus predicted concentration graphs as well 
as Mean Absolute Percentage Error [MAPE], which showed the calculated predictive 
power to be 8.03%. 
 
2.6/ Threshold Determination:  
 
Data reduction methods were used for determining thresholds for Plasma BTM 
concentrations at 144, 168, 192, 216 and 240 h (6, 7, 8, 9 and 10 day) post injection.  
Population statistics were determined using a two-step process.  First, all groups contained 
at least 2 censored (BTM concentrations below the LOQ) datapoints, so Robust Regression 
on Order Statistics (Helsel, 2005) were used to obtain imputed datasets as have been 
previously described for equine drug threshold determination (Machin et al., 2019).  
Second, the datasets were subjected to bootstrap analysis with 10,000 re-samplings in order 
to obtain an estimate of population statistics (Maindonald and Braum, 2006).  The dataset 
at each timepoint was tested for Normality (Shapiro-Wilk, Anderson-Darling and Lillefors) 
and threshold determination using a 95/95 tolerance limit (Owen, 1962) and Gauss (Camp-
Meidell) or GCM inequality probability equations (Savage,1961) to obtain thresholds at 
probability levels p= 0.05 and 0.01. The 95/95 tolerance limit corresponds to a value that 
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is at least above 95% of the population (assuming a normal population distribution) with a 
confidence of (95%). The 95/95 tolerance is calculated by: 
     xtol = m + k sx 
Where xtol is the 95/95 tolerance threshold, m is the mean and sx is the standard 
deviation of the sample population.  The k value is a tolerance limit factor equivalent to a 
z-score corrected for probability and sample size (Owen, 1962).   The GCM is a probability 
inequality that provides bounds for the probability that the plasma concentration will fall 
within a given p-value, and requires only a unimodal distribution (Savage, 1961).  All 
calculations for thresholds were performed using an Apple® i-MacPro® computer with 
macOS Catalina 10.15.1 operating system and 3 GHz 10 core Intel Xeon W10 and memory 
32GB 2666MHz DDR4 system.  The performance of this computer was checked by using 
the NIST dataset for the speed of light in air (Dorsey, 1944). The computed speed agreed 
to 7 significant figures with the 299792.5 km/s given by the National Institute of Standard 
and Technology at 
(https://www.itl.nist.gov/div898/handbook/datasets/MICHELSO.DAT)   
 
3/ RESULTS   
 
The response for the calibration curves were linear and gave correlation coefficients 
(R2) of 0.99 or better.  Quality control sample replicates were performed (n = 7). The inter-
day accuracy was 10.7% for 10pg/mL BTM.  The intra-day accuracy was 3.3% for 
10pg/mL BTM. The limit of detection (LOD) was 1pg/mL, and the limit of quantitation 
(LOQ) was 10pg/mL.   
 
Following intra-articular administration of two 15 mg doses of BTM sodium 
phosphate/acetate combination into each stifle joint of eight horses (Fig. 2) the mean 
plasma concentrations of BTM peaked at about 22.0 ng/mL at 30 minutes post 
administration (Figure 3).  Thereafter the plasma concentrations of BTM declined, at first 
rapidly with a 3.85 -hour half-life, soon followed by a slower beta-phase with a mean 
apparent half-life of 7.07 hours.  This slower beta phase half-life held until the plasma 
concentration reached about 0.055 ng/mL at 72 hours post administration.  Then, from 72 
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hours post administration on, the mean terminal plasma half-life became markedly slower, 
at 123.78 hours, as set forth in Figure #3 below.  By ten days post administration the mean 
plasma concentrations of BTM were in the order of 0.016 ng/mL, which was the last time 





Figure 2.2.3.2 Longitudinal Ultrasounds of Medial Femorotibial Joint Injections 
 
Figure 2.  Longitudinal ultrasound images of the medial femorotibial joint pouches of a 
horse prior to injection (a), and immediately after left (b) and right (c) medial femorotibial 
joint injections demonstrating increased echogenicity of the fluid after injection with BTM 






Figure 2.2.3.3 Mean Plasma Betamethasone After Injection of Two Joints 
 
Figure 3.  The mean plasma concentrations of Betamethasone (BTM) following Intra-
articular administration of two doses of 15 mg of BTM sodium phosphate and BTM acetate 
into each stifle joint of eight horses (◊-◊). The X--X symbols show the calculated best fit to 
these data points, as set forth in equation #1 below.  The dashed line (---) shows the 
terminal elimination curve predicted by the terminal plasma half-life fitted to the days 4 to 
10 mean plasma concentrations.   
The data presented in figure #3 above were best fit by a three-compartment model with 
absorption that is well described by the following equation, equation #1, and the relevant 
pharmacokinetic data are presented in Table 1 below. 
𝐶𝑡 = 12.260𝑒
−1.65015𝑡 + 17.177𝑒−0.10671𝑡 + 0.058𝑒−0.00551𝑡 − 29.495𝑒−9.05023𝑡 
Where Ct is the predicted concentration (in ng/mL) at time t (hours post-injection) 
 
The mean terminal plasma half-life based on the day 4 to day 10 data points is 
123.78 hours.  The time predicted for the mean plasma BTM concentration to drop below 
the 0.010 ng/mL plasma threshold set forth by the RMTC following this administration 





Table 2.2.3.1 Betamethasone Population Pharmacokinetic Parameters 
Parameter Mean ± s.d. [range] 
Ka (h
-1) 1.959 ± 1.764 [0.694 – 5.787] 
Kb (h
-1) 0.1111 
± 0.0108 [0.096 – 0.125] 
Kc (h
-1) 0.0088 ± 0.0061 [0.0020 – 0.0183] 
Kabs,I (h
-1) 8.294 
± 4.865 [4.509 – 19.39] 
t1/2,a (h) 0.575 ± 0.322 [0.120 – 0.999] 
t1/2,b (h) 6.276 ± 0.630 [5.545 – 7.22] 
t1/2,c (h) 129.3 ± 112.1 [37.86 – 344.8] 
tdoubling,I (h) 0.101 ± 0.039 [0.0357 – 0.154] 
Cmax (ng/mL) 24.1 ± 3.6 [19.0-2.8] 
Tmax (h) 0.375 ± 0.134 [0.25-0.5] 
Table 1A Population Pharmacokinetic parameters 
 
Table 2.2.3.2 Betamethasone Model Pharmacokinetic Parameters 
Parameter  
Ka (h
-1) 1.6502  
Kb (h
-1) 0.1067 hr-1 
Kc (h
-1) 0.0055 hr-1 
Kabs,I (h
-1) 9.05 hr-1 
t1/2,a (h) 0.42 hr 
t1/2,b (h) 6.49 hr 
t1/2,c (h) 125.8 hr 
tdoubling,I (h) 0.0766 hr 
Table 1B Model Pharmacokinetics 
Table 1A & 1B: Kinetic data as calculated based on the model equation as presented from 
Equation 1.  Ka, Kb, and Kc are the exponential coefficients of each compartment in the 
model.  Kabs,i represents the initial rate of absorption as predicted in the model.  Half-lives 
are calculated based on the exponential coefficients Ka, Kb, and Kc (and doubling time, 
from Kabs,i).  The Area Under the Curve (AUC) was determined using a trapezoidal 
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calculation, and the AUC from the final timepoint (240 hours) to infinity was estimated 
using the terminal half-life.  Population Pharmacokinetics represent the variability of 
individually calculated parameters, as shown in Table 1A.  Table 1B lists those parameters 
as determined by the model alone.  If a horse were to be in the 95th percentile of slowest 
metabolizers in each phase, this study indicates a possible time to 0.010 ng/mL of 45 days 
(due to a terminal half-life of approximately 313 hours). 
 
 
The Gauss(Camp-Meidell) probability curve was used to determine the likelihood 
of a level corresponding to the highest 5% and 1% of the population from 6 days onward.  
These data were considerably higher than the threshold of 0.010 ng/mL, and these values 
are calculated below, Table 2 and presented below along with those for the 95/95 tolerance 






Table 2.2.3.3 Calculated Thresholds and Related Withdrawal Times for Betamethasone 
Withdrawal in Days 95/95 GCM (p = .05) GCM (p=.01) 
6 0.439 0.090 0.167 
7 0.265 0.079 0.143 
8 0.490 0.086 0.161 
9 0.097 0.026 0.034 
10 0.117 0.054 0.094 
Table 2 – Calculated ng/mL Thresholds and related Withdrawal Times for 15mg of 
Betamethasone administered as BTM sodium phosphate/acetate combination into 




This study is the first study that identifies and presents the essentially two-phase 
plasma elimination pharmacokinetics of BTM administered intra-articularly to horses as a 
widely marketed and used clinical formulation BTM sodium phosphate/acetate prodrug 
combination.  This BTM combination is a formulation of two different and chemically 
distinct prodrug forms of BTM, designed to provide an initial high concentration of free 
BTM at the local site of injection followed by a prolonged lower intraarticular 
concentration at the site of injection, and therefore an equivalent prolonged lower plasma 
concentration profile.  The initial high concentration phase is apparently based on the rapid 
bioavailability of the highly water soluble BTM sodium phosphate prodrug component of 
the formulation. This initial phase is followed by a prolonged lower maintenance 
concentration of BTM, based on the slow dissolution of the less water soluble BTM acetate 
prodrug suspension portion of the formulation (Figure 1).   
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Figure 2.2.3.4 Presented Betamethasone Thresholds 
 
Figure 4 shows the calculated thresholds using the two applied statistical methodologies, 
the RMTC 95/95 Tolerance Interval method and Gauss (Camp-Meidell).  The GCM 
calculations are presented at probabilities of 5% and 1%.  All calculations are based on 
plasma concentrations measured at the indicated time post-administration of 15mg of a 
combination of BTM sodium phosphate and BTM acetate to each of the medial femorotibial 
joints (30mg total dose of BTM sodium phosphate/acetate combination across two joints).  
Of note is that the GCM values remain below 0.100 ng/mL between days 9 and 10. 
This biphasic BTM release pattern is demonstrated in Figure 3, where the plasma 
concentrations of BTM peak within less than 30 minutes post-administration at 22 ± 3.7 
ng/ ml.  Thereafter, the plasma concentrations of BTM decline, initially rapidly, with a 
plasma half-life of 3.85 ± 1.52 hours, followed by a well-defined second slower beta phase 
with an apparent plasma half-life of 7.07 ± 1.11 hours which half-life is maintained to about 
72 hours post-administration.  After 72 hours post-administration the plasma half-life slows 
to an apparently final terminal plasma half-life of 123.78 ± 105.44 hours.  This 
predominantly two-phase half-life elimination model is consistent with the above described 
two chemically distinct BTM prodrug components of the formulation.  This is a classic 
sequence of flip-flop pharmacokinetic patterns, where the prolonged 123.78 ± 105.44 h 
126 
 
terminal plasma half-life of BTM is determined by the rate limiting release of BTM from 
the poorly soluble BTM acetate suspension portion of the BTM sodium phosphate/acetate 
prodrug combination formulation.  
This study is in good overall quantitative agreement with the results reported by 
Menendez, et al, 2016, who were the first investigators to report on the plasma 
pharmacokinetics of a similar formulation of BTM after intra-articular administration.  
Menendez et al (2016) administered 30mg of a combination of 3 mg/mL BTM sodium 
phosphate and 3 mg/mL BTM acetate (Celestone Soluspan®, Merck &Co, Inc., 
Whitehouse Station, NJ) intra-articularly, 15 mg into one randomly assigned tarsometarsal 
joint and the second 15 mg dose into the ipsilateral metatarsophalangeal joint.  Following 
these administrations, plasma concentrations of BTM peaked at about 26ng/mL at 48 
minutes post administration and thereafter declined with an apparent plasma half- life of 
9.22 hours, a fully comparable but fractionally longer half-life than the second rapid 
elimination phase plasma half-life (from Kb) of 7.07 hours presented in the data of Figure 
2 above, consistent with the slightly higher proportion of the poorly soluble BTM acetate 
fraction.   
 
Figure 2.2.3.5 Three Compartment Interaction Model for IA Betamethasone 
 
Figure 5:  Three compartment interaction model of intra-articular injection of bilateral 
stifles with a total dose of 30 mg combination BTM sodium phosphate and BTM acetate.  
The large black arrow indicates administration of 15 mg BTM combination into the joint 
compartment(s).  The symbol k
12
indicates the essentially unidirectional diffusion of BTM 
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from the injected joint to the plasma compartment C2, the sampling site for BTM analysis 
and this compartment in equilibrium with C3.    
 
Menendez, et al (2016) reported their last plasma detection of BTM at 64 hours 
post administration, presumably at or about their LOQ of 0.050 ng/mL.  Because of their 
inability to detect BTM concentrations lower than 0.050 ng/mL, Menendez, et al did not 
identify the final slow terminal plasma half-life of BTM reported in our experiments, the 
final terminal mean plasma half-life of BTM being 123.78 hours in our results (that is, what 
our data suggests to be the true terminal half-life).  However, within the limits of the 
available methodology there is good overall agreement between the Menendez data as 
presented and the data presented in our Figure 3 above.   
 
A more recent communication from Knych et al, 2018, reports plasma 
concentrations of BTM following intra-articular administration of BTM combination at the 
product label single joint dose of 9 mg.  We also note that this 9 mg label dose is a 
conservative dose, as shown by the fact that the American Regents Animal Health 
information notes that “BTM sodium phosphate/acetate combination “may be administered 
concurrently in up to two joints per horse” for a total dose of 18 mg.  Similarly, Menendez, 
et al in their study on Intra-articular administration of a similar formulation of BTM as 
Celestone Soluspan® administered a dose of 15 mg/joint into each of two joints, for a total 
I/A dose of 30mg in their pharmacokinetic study, as presented above.   
 Knych et al. studied the pharmacokinetics of a 9 mg right antebrachiocarpal joint 
intra-articular dose of the same BTM combination (BetaVet®) to 12 horses.  In these 
experiments, Knych et al reported peak plasma concentrations of BTM of 3.97 ng/mL at 
1.45 hrs post administration, a somewhat slower time to peak concentration than in our 
experiments.  However, these peak plasma concentrations reported by Knych et al and 
those reported in the current data are in broad agreement.  The small differences may be 
attributed to the higher total dose used in our study, the injection into two joints, and/or the 
anatomy of the different joints injected.  Previous studies have demonstrated that plasma 
concentrations of methylprednisolone vary depending upon the anatomical structure 
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injected (Machin et al., 2019), and it is likely that other pharmacokinetic parameters vary 
as well.    
 
The early phase apparent plasma half-life identified in our study, (Figure 3, Table 
1) is in good agreement with the 7.48 hr. plasma half-life reported by Knych et al.   This 
early rapid phase half-life is presumably driven by the more readily bioavailable BTM 
sodium phosphate in the BTM sodium phosphate/acetate prodrug combination 
formulation.  However, the Limit of Quantitation (LOQ) of the analytical method used in 
the Knych study was, at 0.025 ng/mL in plasma, insufficiently sensitive to allow detection 
of the much longer half-life secondary elimination phase of BTM following administration 
of this relatively low 9 mg dose of their BTM combination formulation.  Knych, et al did 
not identify the longer second phase terminal elimination half-life of BTM that has been 
clearly identified in our higher dose study, however, this is not unexpected because the 
analytical method used in the Knych study had an LOQ of 0.025 ng/mL, as compared to 
the LOQ of 0.010 ng/mL in our study.  Other than this difference in terminal elimination, 
there is good agreement overall between the Knych BTM data and the data of figure #3.  
In particular, the higher dose divided between two joints may account for the earlier Tmax 
and also the higher Cmax reported in this study.  Further, the terminal elimination of 123.78 
± 105.44 h identified in this study could not have been identified using the lower dose and 
less sensitive analytical procedure in the previous study.  
 
The purpose of this study was to identify thresholds for BTM after the use of a 
BTM combination product following intra-articular administration into bilateral 
femorotibial joints at a clinically relevant dose.  Therefore, these data were used to compare 
different methods of threshold calculation, both the 95/95 threshold and also the Gauss 
Camp-Meidell thresholds from each sampling time point from 72 hours on, as presented in 
table 2 and figure 4.  The 95/95 threshold was consistently higher than both the GCM 
(p=0.01 and 0.05).  The 95/95 tolerance method is defined as a level that provides 95% 
confidence that 95% of the population will fall below the threshold.  As has been previously 
shown (Machin et al., 2019), the 95/95 tolerance method is inaccurate when employed with 
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small sample sizes.  The GCM (P=0.01) threshold likely provides a better estimate of a 
true threshold for our data. 
These data show variability in the calculated thresholds from day-to-day post 
administration. Each individual horse exhibits a progressive decline from joint injection to 
96 h post-administration.  After the 96-h point, the plasma BTM concentrations for each 
horse increase and decrease from day to day, with an overall downward trend.  As the 
terminal elimination of the drug is likely due to the rate limiting step of dissolution of the 
BTM acetate component, this is attributable to individual variability, which may include 
the activity of the animal with mechanical disruption of the BTM acetate particles, changes 
in blood supply associated with exercise, or even temperature, affecting the solubility of 
the drug.  In 2 horses that were briefly exercised after the 72-h plasma sample, one horse 
had a four-fold higher BTM plasma concentration after light exercise (data not shown), 
indicating that even light exercise may affect the plasma concentration of BTM.  In our 
study, the 6-day BTM plasma concentrations using the GCM (p=0.01) threshold fell below 
0.200 ng/mL and both the 9- and 10-day GCM (P=0.01) fell below 0.100 ng/mL, indicating 
that 0.200 ng/mL is sufficient for a 6-day threshold and 0.100 ng/mL is sufficient for a 10-
day threshold for bilateral femorotibial joint injection with 15 mg BTM combination.   
 Extrapolation of the elimination equation estimates 14 days for the average 
horse injected with bilateral medial femorotibial joints with 15 mg each of BTM 
combination to drop below the ARCI threshold of 0.010 ng/mL.  However, this is the 
average horse, and a horse that may metabolize intra-articular BTM combination slowly 
may require as much as 45 days to drop below the 0.010 ng/mL ARCI regulatory threshold. 
 
5/ CONCLUSIONS  
Intra-articular administration of 30 mg of BTM combination as a BTM sodium 
phosphate/acetate prodrug combination as two 15 mg/joint intra-articular stifle joint 
injections yielded a rapid initial peak plasma concentration of 22 ± 3.7 ng/mL of BTM at 
about 30 minutes post administration.  Thereafter plasma concentrations of BTM fell 
rapidly, following a three-compartment elimination pharmacokinetic model.  The initial 
plasma half-life was brief, 3.85 hours, followed by a longer second phase half-life of 7.07 
hours.  This second phase half-life was maintained out to about 72 hours, at which point 
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the mean plasma concentration of BTM were on the order of 0.055 ng/mL.  Thereafter, 
plasma concentrations of BTM fell much more slowly, with an apparent mean terminal 
plasm half-life of about 123.78 hours, to reach a mean plasma concentration of 0.016 
ng/mL at ten days post administration.  This terminal elimination half-life was used to 
predict that most horses would fall below the in-place threshold in the United States of 
0.010 ng/mL at 14 days after stifle injection.  This is the first published report describing 
the critically important prolonged terminal plasma half-life of BTM following its intra-
articular administration as a BTM combination formulation in horses, providing guidance 
as to the likely detection times for BTM following its administration at clinically useful 
intraarticular doses of BTM sodium phosphate/acetate combinations to racing horses.  
Based on the available data we calculated the GCM and 95/95 regulatory thresholds at each 
time point from 6 days on and now suggest interim BTM regulatory thresholds of 0.200 
ng/mL with a six-day withdrawal guideline or 0.100 ng/mL with a ten-day withdrawal 
guideline for use in racing regulation where bilateral MFT joint injection may be indicated.    
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2.3 Environmental Sources 
2.3.1 Review and Analysis of an Interim Screening Limit of Detection for Naproxen in 
Post-Race Samples 
Abstract: Starting in August 2015 Thoroughbred racing in Charles Town, West Virginia 
experienced a sequence of intermittent low concentration Naproxen identifications from 
6.3 to 161 ng/ml of plasma (27.3 to 699 nM). These identifications were ongoing, 
indicating the horsemen were unaware of their origins. Naproxen is administered orally to 
horses at substantial doses and is chemically stable in the environment. These 
identifications are therefore most likely associated with exposure of these horses to 
environmental traces of Naproxen. Given the low concentrations of these identifications, 
we were asked to identify a Screening Limit of Detection (SLOD) below which these trace 
level Naproxen identifications would not be reported. Review of the data set suggested an 
SLOD of 200 ng/ml, while outlier analysis suggested an ‘extreme’ outlier level at 247 
ng/ml, which figure was rounded up to 250 ng/ml Naproxen or 1.09 uM. This proposed 
SLOD is in good agreement with other US regulatory thresholds for therapeutic 
medications and this Interim Screening Limit of Detection was presented for review 
Conclusion: Using statistical analyses, including outlier analysis of apparently ‘innocent’ 
positives that were called out of Charles Town racetrack after switching testing locations, 
a suggested interim screening limit of detection was proposed at 250 ng/mL for naproxen. 
Citation: Machin, J., Brewer, K., Catignani, M., Shults, T. F., Fenger, C., Maylin, G. A., 
& Tobin, T. (2020). An interim screening limit of detection for naproxen in equine plasma: 
a review and analysis. Comparative Exercise Physiology, 16(2), 153-160. 
Personal Contribution: Statistical and pharmacokinetic analysis and model development, 
collation of outside data points for meta-analysis, development of environmental 
contamination model and safety factor comparison, and writing of manuscript 
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Starting in August 2015 Thoroughbred racing in Charles Town, West Virginia experienced 
a sequence of intermittent low concentration Naproxen identifications from 6.3 to 161 
ng/ml of plasma (27.3 to 699 nM). These identifications were ongoing, indicating the 
horsemen were unaware of their origins. Naproxen is administered orally to horses at 
substantial doses and is chemically stable in the environment. These identifications are 
therefore most likely associated with exposure of these horses to environmental traces of 
Naproxen. Given the low concentrations of these identifications, we were asked to identify 
a Screening Limit of Detection (SLOD) below which these trace level Naproxen 
identifications would not be reported. Review of the data set suggested an SLOD of 200 
ng/ml, while outlier analysis suggested an ‘extreme’ outlier level at 247 ng/ml, which 
figure was rounded up to 250 ng/ml Naproxen or 1.09 uM. This proposed SLOD is in good 
agreement with other US regulatory thresholds for therapeutic 
medications and this Interim Screening Limit of Detection was presented for review. 
 
Keywords: naproxen, horseracing, environmental contaminant, clinical practice, screening 




Naproxen ((+)-(S)-2-(6-Methoxynaphthalen-2-yl)propanoic acid, C14H14O3, 
230.259 g/mol, (Figure 1) is a non-steroidal anti-inflammatory drug (NSAID) widely used 
in human and equine therapeutic and sports medicines (Tobin, 1981). The dose of 
Naproxen is large, 500 mg in humans twice a day, 2 to 5 g in equines, once or twice per 
day (Lees and Higgins, 1985). Naproxen also plays an important role in both human and 
equine sports training, used both to combat inflammation and exercise-related pain. It has 
been shown to be effective in treating exercise-induced dysfunction, muscle injury, and 
soreness (Dudley et al., 1997). Naproxen has also been shown to be beneficial for aging 
individuals undergoing resistance training by attenuating muscle injury, strength loss, and 
soreness following eccentric muscle actions (Baldwin et al., 2001). Next, Naproxen has 
been shown to be beneficial when used for brief periods of time for short-term recovery of 
muscle function after exercise-induced muscle injuries (Lanier, 2003). In World Anti-
Doping Agency (WADA) regulated human sports, there are no restrictions on the 
presence/use of Naproxen during competition (WADA, 2019) but racehorses are not 
permitted to compete under the influence of pharmacologic levels of most medications. 
Despite this, Naproxen may be administered outside of competition for therapeutic 
purposes. It is orally administered and eliminated at high concentrations in urine resulting 
in a significant environmental presence that is unavoidable in a treatment stall. 
 
Figure 2.3.1.1 Chemical structure of Naproxen 
 
Figure 1 Chemical structure of Naproxen 
 
 Naproxen is stable in the environment, persisting for at least a year (Zuccato et al., 
2000), which means that although administration ceases, a horse remains exposed to 
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significant amounts of environmental Naproxen from the treatment stall. These amounts 
are sufficient to give rise to trace level plasma identifications as long as the animal remains 
in the treatment stall. Additionally, the time for the animal to reach an undetectable 
plasma/urine level after removal from the treatment stall is undefined and largely 
dependent on the sensitivity of the drug testing in place (Tobin et al., 2013). Adding to this, 
there is a significant amount of background contamination as raw drinking water often 
contains small concentrations of Naproxen. In the US 70% of tested Raw Drinking water 
facilities measured between 16 and 44 ng/l of Naproxen in 2008 (Snyder, 2008). The 
amounts of environmental Naproxen to which such horses are exposed are not 
pharmacologically significant, being generally less than 2 μg Naproxen per day. While 
these amounts are much lower than any dose to reach an effective plasma level, estimated 
by Toutain et al. (2002a, b) to be approximately 10 μg/ml, their presence in the environment 
should be noted as a potential source and variable. 
A second potential source of environmental Naproxen is humans that are taking 
Naproxen. Humans may then inadvertently transfer Naproxen to the horse or its 
environment and thereby give rise to trace level Naproxen identifications, as has been 
shown for humans on Tramadol (British Horseracing Authority, 2015). In humans, ~80% 
of Naproxen is excreted as a conjugated metabolite, with 51% of the total excretion being 
a simple acyl-glucuronidated form (Davies and Anderson, 1997). In horses, less than 1% 
of the total compound excreted remains unchanged, with ~40% requiring only hydrolysis 
of glucuronide to be recovered as the parent compound (Soma et al., 1995). Given a full 
course of Naproxen (5g BID for 7 days) has passed through a horse in a single stall, a 
treatment stall could contain up to approximately 28 g of Naproxen. Similarly, the dose of 
Naproxen for humans is approximately 1 g total per day, indicating a total potential daily 
contamination from humans of up to 200 mg parent Naproxen and 510 mg Naproxen 
acylglucuronide. 
Given these circumstances, it should come as no surprise that low-concentration 
trace level identifications of Naproxen may occur associated with therapeutic use of this 
medication, as was first suggested by research on orally administered Naproxen performed 
by our Canadian colleagues (Stevenson et al., 1997), which data we have digitized, 
recalculated, replotted and reanalyzed in Figure 2 below. We note in particular the fact that 
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at 80 hours post-Naproxen administration the plasma concentrations of Naproxen in these 
horses stopped declining and in fact in one case increased after 100 hours post the last dose. 
In addition, all of these post-80-hour plasma concentrations of Naproxen are significantly 
above the 161 ng/ml and lower Charles Town identifications. Consistent with our re-
analysis and interpretation of these Canadian data, later research in Sweden (Wennerlund 
et al., 2000) and Louisiana (Barker, 2008) has made clear that this very slow final 
‘clearance’ of Naproxen from these horses is most likely related to environmental 




Figure 2.3.1.2 Pharmacokinetic Analysis of Reported Naproxen Concentrations 
 
Figure 2. Pharmacokinetic analysis of mean plasma Naproxen concentrations following 2 
g twice daily for 9 days to four horses. In this experiment, published Canadian plasma data 
were recalculated, and replotted, curve fitted and reanalyzed as set forth in methods. The 
overall fit to the data includes an initial plasma half-life of about 8.8 hours, followed by 
an approaching tenfold slower rate of decline from about 80 hours post administration. 
Additionally, and unusually, there was an overall 64% increase in the mean plasma 
concentrations following 96 hours, best explained by significant ongoing exposure of these 
horses to Naproxen. Replotting, reanalysis and reinterpretation of plasma Naproxen data 
from Stevenson et al. (1997). 
 
With regard to the matter of Naproxen being retained in the treatment stall, our 
Swedish colleagues (Wennerlund et al., 2000) emphasize the extreme risk of contamination 
associated with Naproxen use, as follows: ‘An untreated horse put in a box contaminated 
with Naproxen, could not, as far as the urine concentrations were concerned, be 
distinguished from a horse treated with Naproxen’ and ‘Consequently, it is strongly 
suggested that competition/racing horses should be treated in separate treatment boxes and 
then removed. Treatment boxes should only be used for horses undergoing treatment. A 
box cannot be considered clean even if the crib has been scrubbed [emphasis added].’ 
This current sequence of Charles Town Naproxen identifications began in August 
2015 when Industrial Laboratories of Denver, Colorado took over the Charles Town equine 
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drug-testing contract. Previously, no trace level identifications of Naproxen had been 
reported at Charles Town Races, apparently because a plasma regulatory threshold of 1000 
ng/ml in place in the East Coast Mid-Atlantic States was also being used in Charles Town’s 
testing. However, soon after the Colorado laboratory took over testing, the first trace level 
identification of Naproxen at 31 ng/ml was reported, on August 15th, 2015. This sequence 
of sporadic, low concentration Naproxen identifications then continued up until March 




Table 2.3.1.1 Naproxen Positives at Charles Town 
 
Table 1. This table lists our best analysis of the Naproxen ‘positives’ called in Charles 
Town since January 2014.1,2 
 
 Review of Table 1 shows a total of about 14 Naproxen identifications over an 
approximately 21-month period. With the exception of one early 4,200 ng/ml 
identification, all identifications were at or below 161 ng/ml with the majority below 50 
ng/ml. Simply put, with one early exception, this presents as a sequence of low-
concentration identifications with no possibility of pharmacological effect. Furthermore, 
this sequence of identifications continued despite the fact that Charles Town horsemen 
were aware that these trace concentrations of Naproxen were being called ‘positive’, a 
141 
 
pattern consistent with the horsemen involved in these matters being unaware of how to 
prevent these identifications. 
On the other hand, the single 4,200 ng/ml identification occurring early in this 
sequence in September 2015 is consistent with an intentional administration, the Horseman 
then becoming aware that these concentrations of Naproxen were being detected and 
reported, and no further identifications above 161 ng/ml have since been 
reported. This 4,200 ng/ml identification was therefore attributed to an intentional 
administration, and not to being of unknown environmental origin. 
Identifying a Screening Limit of Detection (SLOD) for an environmental substance 
is by definition a ‘bottom-up’ analysis, as follows. Since the data points are the result of 
random environmental exposure of unknown origin, the only data on which such a SLOD 
can be based are actual field data that can reasonably be attributed to an environmental 
source. One reviews the data, performs appropriate statistical analyses and then identifies 
an appropriate SLOD, namely a screening limit of detection which effectively eliminates 
the administrative problem of irrelevant low concentration identifications that are difficult 
or impossible for horsemen, or indeed the industry in general, to control and also are of no 
pharmacological or regulatory significance, as has been determined for a number of trace 
level identifications of methamphetamine and dextrorphan (Brewer et al., 2016; Machin et 
al., 2017). 
 
Materials and methods 
 Data were collected as reported and tabulated in Table 1 before being statistically 
analyzed. Outliers were determined using Tukey’s method. A second statistical analysis 
was constructed without the use of the 4,200 ng/ml datapoint as well and is noted in the 
Results section. The Naproxen plasma data presented in Figure 2 were digitized, re-
analyzed and replotted from Stevenson et al. (1997) as follows. The presented data points 
were pooled, and the mean values obtained at each time point calculated. The mean data 
points were then fitted by standard curve fitting procedures using a two-compartment 
model with absorption. The equation that best fit these data points was Equation 1: 
Equation 1 
𝐶𝑡 = 22.05538
−0.08768𝑡 +  0.62269−0.00842𝑡 −  16.05961−0.77502𝑡 
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 The early 8.8-hour plasma half-life in Figure 2 was calculated based on the time 
points from 3 to 30 hours, and the longer ‘apparent’ terminal plasma half-life of 82.3 hours 
was calculated on the 54-to-120-hour time points and the late ‘apparent’ doubling time on 




Figure 2.3.1.3 RMTC Safety Factors vs Effective Plasma Concentration
 
Figure 3.2.1 shows the safety factors of various compounds compared to their EPC as 
calculated based on the pharmacological parameters reported by Toutain. 
The other factor to take into account – the health and welfare of the animal – is well-
characterized by the opposite end of the spectrum, guaifenesin.  Guaifenesin is 
therapeutically used in both humans and horses as an expectorant to help clear mucus from 
the airways in the lungs.  However, it also acts as a centrally acting skeletal muscle relaxant.  
As such, it may ‘mask’ an animal’s health issues if it is not truly sound and allow a horse 
to race whenever it has a higher potential for catastrophic injury.  This is in turn an 
argument for the much higher safety factor taken for guaifenesin when comparing the 







RMTC Safety Factors vs Effective Plasma Concentration
Mean Safety Factor Median Safety Factor
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Table 2.3.1.2 Statistical Summary of Naproxen Positives 
 
Table 2. Statistical summary of the dataset inclusive and exclusive to the original extreme 




Figure 2.3.1.4 Outlier Analysis of Naproxen Positives 
 
Figure 3. (A) Outlier analysis of the data of Table 1. (B) Outlier analysis of the data after 
removal of the 4,200 ng/ml point. Outlier fences are shown for ‘mild’ (dotted line) and 




 The data set was initially inspected as an entire set, with its statistical summary 
indicated in Table 2. Using the entire dataset, the 5-number summary of the data was 
calculated, and outliers were determined one-directionally using the Tukey method (Q3 + 
1.5×IQR for mild outliers and Q3 + 3.0×IQR for ‘extreme’ outliers) (Figure 3A). These 
results yielded ‘fences’ at 160 ng/ml for ‘mild’ outliers and 243 ng/ml for extreme outliers, 
which figure we rounded up to 250 ng/ml. Upon analysis via Tukey’s method for outliers 
(and with reasonable belief that it was not due to environmental contamination as the others 
potentially were), the highest datapoint of 4,200 ng/ml was removed from the set and a 
secondary statistical analysis was performed on this new dataset (Table 2, Figure 3B). 
Although noticeably different, it still contains an extreme outlier and two moderate outliers, 
leaving open the question of the genuine distribution to be expected. 1/10,000 one-sided 
probability puts a likely point at 208 ng/ml. Due to the small sample size for this 
determination, the historical threshold of 1000 ng/ml, and the known ability for Naproxen 
to persist and contaminate environments 250 ng/ml seems appropriate as a threshold until 
further information is obtained. 
 
Discussion 
 In contrast to human sports, in competitive events involving animals, it is critical 
that they not compete under the pharmacologic influence of pain mitigating substances 
(Toutain and Lassourd, 2002b). At the same time, regulation of medication must take into 
consideration low levels of substances due to environmental transfer. This is addressed in 
human sports by established decision limits for threshold substances (WADA, 2017). Few 
such screening limits/decision limits for environmental substances exist in equine 
sports. 
 Review of the data in Table 1 with the assumption that all data points at or below 
161 ng/ml are identifications associated with environmental origin demonstrates that the 
SLOD must be greater than 161 ng/ml, leading to a first approximation of 200 ng/ml. Next, 
we performed a Tukey outlier analysis on the entire data set, which suggested that the 161 
ng/ml identification was a ‘mild’ outlier and the 4,200 ng/ml value an ‘extreme’ outlier, 
consistent with the results of our inspection and other analyses. Given the 243 ng/ml value 
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of the extreme outlier fence in this analysis, we rounded this figure up to 250 ng/ml as a 
proposed Interim SLOD. 
 With regard to the lower screening limit for the dataset excluding the 4,200 ng/ml 
identification, a limit of 208 ng/ml is calculated. However, the higher 250 value we 
consider appropriate and present for a number of reasons. The first is the relatively small 
size of the dataset, indicated to us that it may be best to err on the side of caution using a 
higher value, as the presence of two mild outliers in such a small set raises the question of 
how representative the population studied herein is. Secondly, the current long in place 
threshold for Naproxen in the Mid-Atlantic States is 1000 ng/ml in plasma, indicating that 
other geographically related jurisdictions are using higher Naproxen thresholds. Also, the 
ratios of the pharmacologically based thresholds, as presented by Toutain et al. (2002b) 
and currently in place ARCI regulatory thresholds for therapeutic medications are in 
overall good agreement with an interim SLOD for Naproxen of 250 ng/ml. Further, in vitro 
pharmacodynamic studies demonstrate that 2,300 ng/ml Naproxen is required 
for the suppression of platelet aggregation in horses (Johnstone, 1983); support the concept 
of a no-effect SLOD of 250 ng/ml. Based on the Stevenson et al dose schedule and our 
pharmacokinetic model, it would take a similar therapeutic administration approximately 
5 days to decline to this SLOD, on average. 
 Having identified the figure of 250 ng/ml for the Interim SLOD, the next question 
was how this Interim SLOD compares with other regulatory thresholds in place in North 
America. To perform this evaluation, we elected to compare the Association of Racing 
Commissioners International (ARCI) thresholds for controlled therapeutic medications 
with the 16 scientifically defined irrelevant plasma concentrations (IPCs) for the ARCI 
controlled therapeutic medications as presented by Toutain and Lassourd (2002a, b). In 
this work, Toutain and Lassourd use a pharmacokinetic analysis and a conservative safety 
factor to calculate their ineffective plasma concentrations (IPC) values for about 36 
therapeutic medications, below which IPC value they considered that there was no 
possibility of pharmacological effect. 
 Reviewing this analysis, we note that the Toutain IPC for Naproxen is, at 26 ng/ml, 
about tenfold lower than our proposed Interim SLOD. However, when we compare the 
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ratios of the Toutain IPCs with the ARCI regulatory thresholds, as presented in Figure 4, 
we note that this 10-fold ratio for our interim Naproxen SLOD to the Toutain 
IPC is very close to the overall 9.6 ratio of Toutain IPCs to ARCI thresholds. Simply put, 
the ARCI regulatory thresholds are, on average, about 9.6-fold higher than the highly 
conservative Toutain and Lassourd IPC values, with the ratios ranging from less than one 
for Guaifenesin to 200-fold above the Toutain IPC for Phenylbutazone and 294-fold above 
the Toutain IPC for Omeprazole. 
 The next question that we addressed is the matter of the amount of environmental 
exposure that could give rise to these 161 ng/ml or lower plasma concentrations of 
Naproxen reported in the Charles Town samples. We therefore calculated the total daily 
exposure to Naproxen required to produce the plasma concentrations of Naproxen observed 
in these Charlestown samples. As shown in Figure 5, the smallest concentration identified, 
6.3 ng/ml, required a Naproxen intake of little over 2 mg per day, in the order of 1/5,000 
of the high-end 10 g daily dose required to produce a pharmacological effect in a horse. To 
produce the 161 ng/ml plasma concentration, the highest concentration assigned to an 
environmental origin, would require an intake of about 56 mg per day, or 1/178th of a 
clinical dose. In evaluating these data, we again draw attention to the post 80-hour data of 
Figure 1 from the Canadian research, where we note that essentially all of these Charles 
Town values are well below the post 80-hour Naproxen values that are most likely 
associated with reuptake of residual environmental Naproxen. The trace level plasma 
concentrations reported in the Charles Town samples are therefore quite consistent with 
residual traces in animals either treated with Naproxen or exposed to environmental 




Figure 2.3.1.5 RMTC-to-Toutain-IPC Ratio 
 
 
Figure 4. RMTC/Toutain IPC ratios. This figure presents the ratios of the Toutain 
irrelevant plasma concentrations (IPCs) to the Racing Medication and Testing Consortium 
(RMTC) thresholds for the listed controlled therapeutic medications. In all but one case, 
Guaifenesin, the Toutain IPC is more conservative than the corresponding RMTC 
threshold. The ratios range from 1.5× more conservative for Dexamethasone to about 
300× more conservative for Omeprazole. The proposed interim screening limit of 
detection of 250 ng/ml in plasma for Naproxen is close to 1/50th of the Toutain effective 
plasma concentration (EPC) and makes this interim screening limit of detection for 
Naproxen more conservative than those for Phenylbutazone and Flunixin and close 
agreement with the overall 9.6-fold ratio between the RMTC thresholds and the more 




Figure 2.3.1.6 Estimated Plasma Concentration based on input of Naproxen 
 
Figure 5. Relationship of daily intake to plasma concentrations of Naproxen. The plotted 
concentrations were calculated assuming a steady-state concentration was measured from 
environmental exposure with the following equation: Css × CL = R0, where Css is the 
reported concentration, CL is the Clearance reported by Toutain (32 ml/ (kg h), and R0 is 
the calculated rate of input (in ng/(kg h)). Mg/day was calculated assuming a 1000 lb (454 
kg) animal. Oral bioavailability (approximately 87%) (Cagnardi et al., 2011) is not 
included in this calculation. 
Review of the Naproxen identifications reported in 2016 and 2017 offers strong 
support for the hypothesis that these trace level identifications are associated with minimal 
and pharmacologically insignificant residues retained in horses coming into Charles Town 
from neighboring Mid-Atlantic States. Of the 11 identifications reported, only one was 
from a horse stabled at Charles Town. The other ten horses all shipped in from neighboring 
Mid-Atlantic States, 3 from Laurel Park, 1 from a VA training center and all of the other 
horses from farms in Virginia (4), and 2 from farms of unknown location. The horses 
yielding these trace level Naproxen identifications were therefore with one exception 
coming from neighboring Mid-Atlantic States with more tolerant Naproxen regulations, 
accounting for the finding of these trace levels concentrations of Naproxen in the plasma 
samples from these horses. The horsemen involved are, as a practical matter, likely 
completely unaware of the ability of Naproxen to persist in the environment and to 
therefore be present at trace levels in horses for an uncertain period after the last therapeutic 
administration. 
These horses have therefore either inadvertently become exposed to small 
environmental amounts of Naproxen, the amounts of Naproxen being in the order of one 
200th or less of a single clinical dose of Naproxen or have been treated previously some 
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time ago such that the amount of Naproxen present is no longer pharmacologically 
relevant. Alternatively, since the time post the last Naproxen administration for a horse to 
‘clear’ a test of the sensitivity of the current Charles Town testing is unknown, these 
identifications could also be the completely ineffective last traces of a therapeutic 
administration administered up to an unknown number of days before shipping to Charles 
Town. However, whatever the source of these identifications, they are completely unlikely 
to be associated with a pharmacological effect, and as such of no regulatory or forensic 
interest. 
This phenomenon of inadvertent stall contamination driven exposure to equine 
therapeutic medications has been reported previously in the equine regulatory literature, 
starting with the 13th International Conference of Racing Analysts and Veterinarians 
(ICRAV) in Cambridge, UK. At this conference Norgren et al. (2000) showed Flunixin to 
give rise to stall contamination problems, which analysis was later confirmed when Popot 
showed Flunixin to be recycled in stalls via contaminated hay (Popot et al., 2011). 
Similarly, Russell and Maynard (2000) showed the presence of Isoxsuprine in a stall 
environment, i.e., food, bedding, wood scrapings, cobwebs, and the feeding manger of a 
horse. In this case, the Isoxsuprine administration had ended a full three weeks prior to the 
event in which the horse tested positive, with the stall sampling occurring at some 
significant further time after the race in question. Also, at this Cambridge conference, 
Williams et al. (2000) showed Ibuprofen to be to be detectable in the urine of horses whose 
feed had been prepared by contaminated human hands, and we have already referred to the 
Wennerlund et al. (2000) report on Naproxen. 
The take home message is that equine treatment stalls inevitably become 
contaminated with the treatment medication. If the dose/amount of the medication is 
significant, if the substance is stable in the stall environment and absorbed orally, then the 
horse remaining in the treatment stall may be at risk of a medication identification for an 
undefined period of time. If such a treated horse is likely to be medication tested it is 
therefore wise to move the horse to a fresh stall, so that ongoing post-treatment background 
exposure of the horse to the treatment medication does not occur, and a realistic time for 
the horse to go ‘testing negative’ can be estimated. For example, in the present matter based 
on our pharmacokinetic model of Naproxen plasma levels, we estimate it would take a 
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standard therapeutic administration of Naproxen five or more days to on average fall below 
this proposed SLOD. 
Other examples of inadvertent exposure of horses to human use substances are the 
now well-understood circumstances of exposure to trace amounts of morphine, generally 
in feedstuffs and appearing in equine urines as morphine glucuronides (Camargo et al., 
2005). Other such substances are cocaine, appearing in post exposure urines as the major 
urinary metabolite benzoylecgonine (Camargo et al., 2006) and caffeine, appearing in post-
race urine samples as parent caffeine and its various metabolites (Budjahara et al., 2007). 
Additionally, given the circumstances of this current Charles Town situation, where 
neighboring states had higher regulatory thresholds for Naproxen, one practical regulatory 
approach is an appropriate SLOD so that medications identifications are not reported based 
on pharmacologically insignificant trace levels of the medication in question, as has been 
the case in most of the inadvertent exposure circumstances described above. 
 
Conclusions 
 As well as being of no pharmacological significance, it is also equally clear that the 
identification and reporting of these low concentration Naproxen identifications has been 
a direct result of the application of highly sensitive plasma testing for Naproxen. As such, 
this sequence of sporadic low concentration identifications commenced essentially 
immediately after testing transferred to a laboratory using highly sensitive testing for 
Naproxen. The immediate solution to this problem, therefore, is to introduce an interim 
SLOD for Naproxen in the order 250 ng/ml Naproxen (or 1.09 uM), as we have outlined 
in this communication. 
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CHAPTER 3. CONCLUSION 
3.1 Biologically relevant cut-off determination 
Perhaps the model example of determining a physiologically-relevant cut-off is the 
system proposed by Toutain – that is, the determination of Effective Plasma Concentrations 
[EPCs] and their related regulatory Irrelevant Plasma Concentrations [IPCs].  The 
calculation of an EPC is straightforward – divide the standard dose (per dosing interval) by 
the plasma clearance (per dosing interval).  Toutain, in his original article published in the 
International Conference of Racing Analysts and Veterinarians calculated the EPC for 
thirty-six compounds.  Unfortunately, many of the compounds listed by the ARCI are not 
previously calculated, but when the pharmacokinetic data is available for a compound, such 
a calculation is rudimentary.  For example, for the non-steroidal anti-inflammatory drug 
ketoprofen, the dose (in mg/kg) is 2.200, the dosing interval (in hours) is 24, and the 
clearance (in mL/kg/h) is 300.  Taking these values, then, we can determine an EPC of 306 
ng/mL in plasma, as shown below. 
𝐸𝑃𝐶 =
2.2 𝑚𝑔/𝑘𝑔 𝑝𝑒𝑟 24 ℎ𝑜𝑢𝑟𝑠







 = 306 ng/mL 
An IPC then, is determined by dividing the EPC by some safety factor that should be 
determined by a regulatory body.  For Toutain’s initial paper, a safety factor of five hundred 
(500) was used in his example calculations, though he notes that it is up to regulators to
determine the factor that is most appropriate for a given therapeutic compound.  As was 
shown in the naproxen threshold paper, the RMTC’s current regulations vary widely in 
what is effectively the safety factor for their drugs (ranging from a safety factor of roughly 
1200 (guaifenesin) to a safety factor of approximately 1.7 (omeprazole).  However, 
generally the safety factors tended to be around the value of fifty (50), indicating that when 
other considerations are excluded, this is a reasonable level to set the EPC: IPC safety 
factor ratio. 
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3.2 Determining an appropriate safety factor 
What outside factors are likely a source of concern for regulators?  Ultimately, there 
are two major categories of factors to take into consideration: the potential impact on the 
fairness of a race, and the protection of the animal’s health.  Those compounds that may 
impart a competitive advantage to an animal may be more stringently regulated than those 
that offer little to no benefit on race day, and those compounds which are likely to have a 
minimal impact on a race are likely to be allowed a closer safety factor.  For example, the 
relatively high value allowed threshold for omeprazole (10 ng/mL in plasma) compared to 
its calculated EPC (17 ng/mL) may partially be attributed to the fact that there are no known 
performance enhancing effects of the compound on aerobic performance in performance 
horses (Kollias-Baker, et al 2001). 
3.3 Thresholds vs Cut-offs 
Pharmacologically therapeutic compounds are perhaps the most straightforward to 
regulate in such a manner and testing limits on these are referred to as ‘thresholds.’  
However, other compounds may be present due to environmental, dietary, or naturally 
occurring within the animal that may be of regulatory relevance to the industry.  These 
compounds are deemed Environmental, Dietary, and Endogenous [EDE], and may require 
a more subtle approach, as the pharmacokinetics of many of these compounds are less 
likely to be studied or their pharmacology may prove irrelevant to the establishment of 
practical regulatory limits (called ‘cut-offs’ for these types of compounds).  The naproxen 
paper discussed in Chapter 2.3 demonstrates this as well.  Sporadic ‘positives’ called by 
regulatory bodies often indicate a source of unknown or uncontrolled contamination by 
horsepersons, such as was likely with the naproxen ‘positives’ called out of Charles Town 
Races.  Using statistical outlier methods, screening limits may be established for such 
compounds to determine what is likely the result of a therapeutic dose compared to an 
environmental exposure.  These data may take time to gather, as it relies upon sporadic 
exposure events to make a horse test ‘positive’, but they offer good insight into a practical 
cut-off.  Whenever this type of data is not accessible, environmental contamination studies 
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may be necessary (such as occurred at Charles Town Racing), or for the case of endogenous 
substances, such as testosterone, population models must be properly constructed. 
3.4 The “Zero-Tolerance” dilemma 
Ultimately, a zero-tolerance approach is not only impossible to test for, but 
impractical to enforce as modern detection methods push the limits of analytical sciences.  
One example of easy visualization can be thought of as follows.  Using reported data for 
naproxen, as an example.  A five-gram oral dose will reach its terminal recorded half-life 
of 80 hours after approximately 72 hours, with about 50 milligrams of the compound 
remaining in the animal.  With a molecular mass of 230.259 g/mol, that is approximately 
1.31E+20 molecules remaining in the horse.  Assuming the reported terminal half-life 
remains constant from 72 hours onwards, it would take approximately 222.75 additional 
days for the compound to fully clear the animal’s system (225.75 total days).  As the RMTC 
does not list this common therapeutic as having a threshold, a horseperson then would be 
expected to withdraw their animals for more than half of a year after the administration of 
a single well-recommended therapeutic NSAID.  Obviously, this level of therapeutics 
restriction goes too far if taken to this extreme. 
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Figure 2.3.1.1 Time to ‘Zero Tolerance’ Acceptable Levels of Naproxen after Dosing 
Figure  shows the expected molecule count of naproxen over time upon reaching a total 
body dose of 50mg, based upon measured and reported terminal half-life. 
Some compounds, however, remain within the realm of ‘zero detection’ limits 
having use.  For instance, synthetic anabolic steroid may be of interest in that they 
negatively impact the health of the animal while giving it an advantage when racing on the 
track even when it is below detectable limits by gaining a large amount of muscle mass 
during training.  For compounds such as these and other long-term performance-enhancing 
drugs, a zero-tolerance policy may be appropriate.  However, it is worth noting that such 
policies should always be the exception rather than the rule due to the sensitivity of modern 
testing (which will only continue to become more sensitive) and it may be necessary in the 
future for thresholds for such substances to be implemented. 
3.5 No Mediating Bodies 
One of the primary challenges facing regulation in the horseracing industry is the 
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scientists, horsepersons, and regulators together.  Forensic equestrian scientists may be 
experts in the field of isolating and identifying pharmacological compounds in the media 
presented to them, but they are rarely well-equipped to also understand the underlying 
physiological effects for what a specific compounds concentration represents.  Likewise, 
regulators may have great understanding of what rules exist and how they are being applied 
within their jurisdiction, but they are not necessarily experts at understanding neither the 
analytical science behind the detection event itself, nor the underlying physiological 
relevance of said call.  What perhaps would best be proposed is a mediating body through 
which regulators and analysts may communicate.  Such a body could be staffed by 
veterinary scientists that are well trained in both the regulatory desires as well as the 
science, both analytical and veterinary.  Fortunately, an example of just such a body is 
readily available to study, as the human drug-testing standards within the United States go 
through such a body, as established by the Substance Abuse and Mental Health Services 
Administration [SAMHSA] and their Medical Review Officers [MROs]. 
3.5.1 How it works in humans – SAMHSA 
The Substance Abuse and Mental Health Services Administration was formed in 
1992 as part of a reorganization of governmental bodies due to the abolition of the Alcohol, 
Drug Abuse, and Mental Health Administration [ADAMHA].  It was directed to effectively 
target drug abuse and mental health services to the people most in need, with a focus on 
translational research in those areas.  Initially, SAMHSA was directed to test for five 
commonly abused drugs – amphetamines, cocaine, marijuana, opiates, and phencyclidine 
[PCP].  Today, they test for a total of nine (9) compounds for governmental organizations 
as well as for the public – Methamphetamine (d-Methamphetamine/d-Amphetamine), 
Marijuana (THCA, 11-nor-Δ9-THC-COOH), Cocaine (Benzoylecgonine), Opiates 
(Codeine/Morphine), PCP (Phencyclidine), Heroin (6-Acetylmorphine, 6-AM), Ecstasy 
(MDMA/MDA), Vicodin/Dilaudid (Hydrocodone/Hydromorphone), and OxyContin 
(Oxycodone/Oxymorphone).  Each of these substances has a screening cutoff, as shown in 
the following table: 
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Table 3.5.1.1 SAMHSA Cut-offs for Regulated Substances in Humans 







Cocaine Benzoylecgonine 150 
Opiates Codeine/Morphine 2000 
PCP Phencyclidine 25 
Heroin 6-Acetylmorphine (6-AM) 10 







Several of these screens require secondary confirmation of specific analytes to be 
considered a positive test.  In all cases that a cut-off/threshold is exceeded, however, 
immediate action is not taken, but the data is forwarded to a Medical Review Officer, a 
physician (MD) who has trained in understanding substance abuse, the methods for testing, 
and analysis of the data from such tests.  At this point, the medical review officer will 
request a valid prescription or physician’s verification of medical treatment in support of 
the positive drug test.  Failure to provide such results are likely to result in the reporting of 
the test as a ‘positive’ to the relevant authorities (whether governmental or otherwise). 
However, of import is that a well-trained Medical Review Officer has some level of 
discretion for which to proceed.  This, coupled with his understanding of the testing 
facilities and regulations, enables him to have a good understanding of the situation in cases 
of ‘borderline’ positives, sparing the time, energy, and money of both the subject of the 
test and those ordering such a test.  While for certain areas this discretion may be greatly 
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reduced (for instance, in testing of prison inmates), in others it may be more broadly applied 
(in the case of private employers, for example). 
One of the other points to note for the SAMHSA model is that the values for these 
cut-offs is noticeably higher than those for the equine industry.  This is reasonable when 
one considers that humans are often subjected to a much less controlled environment than 
a racehorse (public transportation, shared housing, etc.), but the degree to which 
compounds are reported as ‘positive’ in the equine industry is orders of magnitude lower 
than in human testing, as demonstrated by Brewer, et al in their paper covering the several 
‘positive’ methamphetamine call in Toronto for concentrations (200, 56, and 340 
picograms-per-milliliter of urine).  That paper supports a practical interim screening limit 
(threshold) of 15 nanograms-per-milliliter, due to the chance of environmental 
contamination (as was shown to be the cause by investigators in that case).  This is still a 
factor of thirty lower than testing for humans, but a reasonable approach considering that 
equine exposure to contaminated environments is likely minimal compared to the risk 
humans face of coincidental exposure. 
3.6 Summation of Research 
The design and implementation of appropriate pharmacokinetic studies, both for 
general administration of therapeutic compounds and for those which may be 
environmental contaminants is critical to the development of appropriate regulations 
regarding pharmacologically relevant compounds in the performance sports horse.  Critical 
to these types of studies are the novel syntheses of references standards as well as stably 
isotopically labelled internal reference standards and the availability of such compounds to 
the public.  The work undertaken for this thesis has focused on all of these aspects. 
As a summation of the specific work, those cited as primary authorships include 
the following syntheses: xylazine-d6, barbarin, and barbarin-d5.  Those studies which 
focused on trace therapeutic medication overages: mepivacaine, methylprednisolone, and 
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betamethasone.  Finally, a paper on the environmental contamination as a source of 
naproxen positives was also included. 
These studies have focused on substances that have confounded regulators for some 
time, due to both improvements in sensitivity in testing as well as the sporadic nature of 
environmentally sourced substances.  However, more work has been completed since that 
time as well and following are collaborations that have come forward either as a direct 
result, or alongside this thesis’ primary course of study. 
The development of a novel synthesis for xylazine-d6 led to a collaborative study, 
headed by Dr. E. Macomber making a recommendation of a threshold of 200 pg/mL in 
plasma for a withdrawal time of 48 hours.  Prior to such pharmacokinetic research, the 
regulatory threshold for this withdrawal guideline was 10 pg/mL.  Today, the RMTC 
recommends the suggested 200 pg/mL threshold, showing the value of such studies in 
guiding the regulatory bodies.  This research was not only communicated with the RMTC, 
but also submitted to the Veterinary Journal for publication (Macomber, et al 2017). 
Similarly, our work with betamethasone also helped with another collaborative 
study focusing on betamethasone’s isomer: dexamethasone.  This study, led by Dr S. 
McClure indicated that a daily dose of intravenous dexamethasone demonstrates no 
accumulation, and so withdrawal guidelines for horsepersons should not change based on 
multiple dosings.  While that may seem insignificant, the animals that will continue to 
receive appropriate medical treatment without their owners fearing for an accidental 
overage is of great importance.  This study also led to an interesting environmental 
contamination study reported in the same paper, in which it was shown that urine 
containing dexamethasone (the form by which it is excreted in the horse) in the 
environment is concentrated enough to be detectable in the blood untreated horses that are 
exposed.  This study was published in Comparative Exercise Physiology (McClure, et al 
2021). 
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Several articles have also been published in non-scientific trade journals based upon 
our research.  These include a review of the Charles Town Ship-In Stalls and the 
contamination found within them.  This study found that seventeen of twenty-one stalls 
tested at Charles Town Racing tested positive for environmental contamination of 
pharmacologically relevant compounds.  This included twenty-five total substances, some 
of therapeutic value for both humans and horses as well as human recreational substances.  
Personal communications also indicated that all stalls that housed animals tested positive 
for detectable levels of naproxen, though only those above a specific threshold were 
reported as positive.  This underscores the importance of developing thresholds for most 
substances, as it is an inevitability that animals have the potential to be exposed to said 
compounds in their environment, regardless of the hygienic practices of their owners and 
trainers (Fenger, et al. 2017). 
Similar to Charles Town’s stall contamination, a series of tramadol positives was 
reported on, which is believed to be the result of trace transfers between horsepersons and 
their animals.  Tramadol, an opioid pain medication, is a common prescription for elderly 
horsepersons as they often continue to lead physically demanding lives.  Often prescribed 
in the form of a transdermal patch that the patient wears, contamination on the fingertips 
after application may result in positive tests when they go on to use equipment such as 
tongue ties.  It is also possible that human urine could be one of the transmission methods 
for tramadol, as it is common practice to relieve themselves in the stalls of the animals 
when finding a restroom may prove inconvenient (Brewer, et al 2018). 
The first publication that the author was a contributor to, was in fact a case of trace 
contamination resulting a ‘positive’ call.  Environmental exposure does not only pertain to 
therapeutic and naturally occurring compounds.  One such example is with the illicit 
methamphetamine.  Methamphetamine is not a therapeutic that has any legitimate use in 
equestrian sport, however a trainer and owner at Ajax Downs, Toronto, Ontario had 
‘positives’ called against them when their horses competed.  Of the four horses that ended 
their races in the money, three of them tested positive for methamphetamine at remarkably 
low urinary levels, approximately between fifty and three-hundred-fifty picograms-per-
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milliliter.  For comparison, in the United States, humans are generally tested by the 
standards of the Substance Abuse and Mental Health Services Administration [SAMHSA], 
which denotes that amphetamine, and its derivatives have a testing threshold of 500 
nanograms-per-milliliter in urine, a factor of approximately five orders of magnitude more 
than what was detected in the racing horses. 
However, the trainer was held accountable.  Having appealed the decision, an 
investigation was undertaken.  The three animals that tested positive all were shipped from 
Atlanta to Toronto in the same trailer while the one that had tested ‘clean’ was in a separate 
trailer.  Examination of the trailer showed trace levels of methamphetamine contamination 
– likely due to it being used as a mobile meth lab before being purchased by the horse
owner.  Charges were eventually dropped by the commission as it appeared that the trainer 
and owner had no way of knowing about the contamination.  A suggested fifteen 
nanogram-per-milliliter threshold was suggested based on this data, still very conservative 
compared to those used in human testing (Brewer, et al. 2016). 
Finally, perhaps the most interesting single line of research, the novel syntheses of 
barbarin and its deuterated variant, culminated in the positive identification of a common 
weed (Barbarea vulgaris) as a potential source of aminorex positives appearing in the urine 
of horses.  This research, led by Dr. G. Maylin, showed that horses will readily eat this 
plant, containing glucobarbarin – the glucosinolate precursor of barbarin – when it is mixed 
with their food, and upon its consumption their urine will in fact have detectable levels of 
aminorex present.  Furthermore, it is likely that several other species that have been 
identified as producers of barbarin may likely also cause potential aminorex ‘positives’ 
should they be consumed by the animal (Maylin, et al 2019). 
3.7 Conclusion 
Ultimately, it is studies such as these that will allow for the better regulation and 
protection of equine athletes.  However, for such studies to have any impact, regulators 
must understand the need for thresholds in protecting the health of the animals as well as 
the sport.  The first step of this consists of identifying pharmacologically relevant 
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substances in the environment.  Most often, this occurs whenever a series of low-level 
‘positives’ appear within the regulatory environment in a relatively short period of time.  
This may be due to changing of internal regulatory methods (as was the case in West 
Virginia whenever they changed analytical laboratories), seasonal crop/plant growth 
exposing the animals to environmental contamination (as may be the case for some 
aminorex positives linked to B. vulgaris), or other sources.  However, it can generally be 
understood that if wrongdoing is being undertaken by horsepersons, a ‘positive’ should act 
as a warning flag and future positives should not continue to appear sporadically as they 
often do with environmental contaminants. 
Upon recognition of such a substance, the analytical methodologies for its 
characterization and detection need to be developed.  While these methodologies are often 
straightforward, the availability of reference standards and internal standards is often quite 
scarce for many pharmacologically relevant compounds and their metabolites.  As such, 
the novel syntheses of both the parent compound, the metabolite, and stably-isotopically-
labelled versions of these substances is of paramount importance in maintaining the 
integrity of the testing environment.  Such syntheses have been undertaken for the 
production of xylazine-d6, barbarin, and barbarin-d5, all of which are now available as 
reference standards to the regulatory and research communities. 
Once suitable reference standards are available, pharmacokinetic studies are of 
utmost importance in describing the ability of a compound to remain within the body of 
the horse at detectable levels.  As analytical techniques improve, these levels will be pushed 
to smaller and smaller quantities, with regulations commonly on the pg/mL scale, with 
some substances having regulatory ‘positives’ at the fg/mL scale.  At these concentrations 
in the body, it is likely that the elimination is much slower than reported in previous studies, 
as it reaches a different rate of metabolism.  This has been shown to be the case for several 
compounds, notably mepivacaine, methylprednisolone, and betamethasone having 
substantially longer measurable terminal half-lives than previously reported. 
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The importance of accurate terminal half-lives is difficult to understate with regards 
to equine therapeutic regulation.  That is because the current system within the United 
States is designed around ‘withdrawal guidelines’ that offer a time by which a horse should 
no longer test above the established testing threshold.  Unfortunately, many of these 
thresholds were determined rather arbitrarily low (or at least with little to no scientific 
evidence publicly available), and the methodologies used to determine the relevant 
withdrawal guidelines often failed to capture the terminal half-life associated with such 
small concentrations. 
Not only must long terminal half-lives be properly identified and published, but the 
possibility for urinary-oral reabsorption should be considered for environmentally stable 
or highly bioavailable compounds.  The potential for such compounds to contaminate the 
area around the animal via urine and then be reabsorbed has been shown to a potentially 
confounding variable which should be addressed by racing regulators whenever possible.  
Naproxen is one such example, as shown. 
One of the most practical ways to help regulators prepare their rules for the future 
is to focus on thresholds that are based on physiologically relevant concentrations, rather 
than arbitrary detection limits and withdrawal timelines.  To do this is straightforward, only 
requiring the calculation of an Effective Plasma Concentration and then determining an 
appropriate safety factor for the compound by which to produce an Irrelevant Plasma 
Concentration to act as a threshold for said substance.  For most compounds, a safety factor 
of fifty seems appropriate, though individual substances should be considered against their 
own class of pharmaceuticals, their potential to influence the fairness of a race, and their 
need for the health of the horse. 
Finally, regulators may be advised to consider the development of a mediating body 
between themselves and the analytical/forensic laboratories that test these samples.  These 
mediating bodies would be comprised of specialists that would understand the intersections 
of analytical chemistry, veterinary sciences, and the regulatory structure of the horseracing 
commissions.  They would understand the field to ascertain what concentrations are likely 
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a problem and those that are likely irrelevant, notice any trends developing with certain 
medication overages, and act to guide regulators to efficient and useful rulings should a 
‘positive’ be identified.  Likewise, these review officers could act within a specific 
jurisdiction and so understand the geographical trends that may develop, avoiding 
misunderstandings whenever testing facilities are changed with differing internal 
thresholds, and more. 
Ultimately, the horse racing industry relies upon the testing facility and their 
regulations to maintain a level playing field for all involved, assure the public and bettors 
of the horsepersons’ honesty, and most importantly, protect the health and wellness of the 
equine athletes.  However, without proper regulatory adjustments, it will only be a matter 
of time before another high-profile case, as has happened with Medina Spirit, brings the 
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Regulatory thresholds for xylazine; review and analysis based on recent 
pharmacokinetic data 
Abstract: Xylazine is an α2-adrenergic receptor agonist and a short acting 
sedative/analgesic widely used in equine practice since its original approval by the FDA in 
1988. Closely related agents include Detomidine, Medetomidine, Romifidene, Amitraz and 
Guanabenz.  Xylazine is the shortest acting member of this group and is a Racing 
Medication and Testing Consortium (RMTC) "Controlled Therapeutic Medication” 
(version 2.2); the RMTC interim threshold for xylazine was set at 10 pg/ml plasma with a 
48-hour withdrawal and no defined dose. Application of this regulatory threshold in
Washington State led rapidly to an apparent therapeutic overage of about 75pg/ml 
following a 200 mg dose IV at 54 hours prior to post.  Based on Toutain's reported 
Irrelevant Plasma Concentration (IPC) for xylazine (2013) and the very short duration of 
action of xylazine, an interim 300 pg/ml regulatory threshold for xylazine was proposed.  
Pharmacokinetic data for xylazine up to 12 hours post administration shows that the 
terminal elimination of xylazine slows markedly from 6 hours post-administration, leading 
to a flat terminal half-life. The result of this flat terminal elimination curve for xylazine is 
that it can be detected in plasma for hours to days beyond any pharmacologic effect of the 
drug.  Based on these considerations, the regulatory threshold for xylazine in Washington 
State was adjusted upwards to 200 pg/ml on an interim basis.  Following this adjustment, 
review of reported plasma concentrations of xylazine in Washington State post-race 
samples suggests that this 200pg/ml in plasma adjusted interim regulatory threshold is 
likely a more appropriate and clinically relevant 48-hour post administration regulatory 
threshold for xylazine.   
Introduction:  Xylazine is one of the oldest and most commonly used analgesic and 
sedatives in the horse industry.  It’s rapid onset and brief duration make it ideal for use 
alone or with the coadministration with other agents.  It has been shown to have a peak 
effect within ten minutes of intravenous administration, with return to clinical normalcy 
after only 90 minutes.  Unlike detomidine, the Variable Interval Responding technique 
(used to determine subtle drug effects after the primary effect has worn off) has been shown 
to have no measurable change in response from normal after twenty-four hours.  Other 
pharmacological effects of α2-adrenergic receptor agonists (decrease in packed cell 
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volume, protein, and increase in glucose) have all been shown to return to normal faster 
for xylazine (within approximately sixty minutes).  All of these indicate that xylazine is 
and should remain one of the primary analgesic/sedatives used in the equine industry. 
At the time of writing, the recommended threshold by the RMTC was 10 pg/mL, with a 
withdrawal time of 48 hours.  No dose was defined at that time. 
Positive cases that were for reasonably low doses (200mg via IV bolus; the recommended 
dose by the manufacturer is approximately 1mg/kg, roughly 450mg in an animal) resulted 
in racetrack positives at times greater than the 48-hour withdrawal timeline.  The plasma 
concentrations reported were seven to nine times higher (a split sample returned a 
concentration of 0.093 ng/mL, or 93pg/mL).  With that in mind, a review of the literature 
was determined to be necessary for a more appropriate screening limit. 
Due to data published by Noble, along with Toutain’s published Irrelevant Plasma 
Concentration data, an interim threshold of 200pg/mL was recommended and adopted by 
the Washington State Horse Racing Commission, and eventually by the Racing Medication 
& Testing Consortium as well. 
Conclusion: Review of the pharmacokinetic data for xylazine suggested a terminal plasma 
half-life considerably longer than previously understood, and no publication was provided 
or referenced in the previous threshold of 10pg/mL.  Field experience to date seems to 
indicate that the newly adopted 200pg/mL threshold is more appropriate, both 
pharmacologically and forensically. 
Citation: Macomber, E., Noble, G., Machin, J., Morales, B., O’Connell, M., Stirling, K., 
… & Tobin, T. (2017) Regulatory Thresholds for xylazine; a review and analysis based on 
recent pharmacokinetic data. Submitted to the Veterinary Journal. 
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Dexamethasone serum concentrations after intravenous administration in horses 
during race training 
Abstract: Dexamethasone (DXM) sodium phosphate is a widely used corticosteroid for 
inflammatory conditions in horses, regulated in racing jurisdictions in the United States 
by a 0.005 ng/mL serum/plasma threshold. This study seeks to describe serum 
concentrations of DXM at 48 and 72 hours after intravenous administration of 20 mg 
DXM sodium phosphate over 1 to 5 days, and to identify a possible source of DXM 
overages. Seventy-four horses (39 Thoroughbreds, 13 Standardbreds, 22 Quarter Horses) 
in active race training received 20 mg DXM sodium phosphate. Serum was collected 
before injection, at 48 and 72 hours post last injection, and analyzed by LC/MS-MS 
(Limit of Quantitation (LOQ) = 2.5 pg/mL). No differences were identified by ANOVA 
(p ≤ 0.05) for racing breeds, age, gender or the number of days of DXM sodium 
phosphate administration, so data were pooled for each time point. The DXM serum 
concentration at 48 hours (mean ± standard deviation, SD, range) was 2.18 ± 1.56 pg/mL. 
(<2.5 to 40 pg/mL).  Summary statistics could not be derived for 72-hour DXM serum 
concentration owing to censored data but ranged from <2.5 to 95.8 pg/mL.  There was 
one extreme outlier (Tukey) at 48 hours, and two extreme outliers at 72 hours.  A 
separate study was conducted using sedentary experimental horses to determine the 
likelihood that positive DXM samples could result from environmental transfer.  Urine 
was collected from a mare 2 to 3 hours post administration of 20 mg DXM.  Hay with 
100mL of DXM (17 ng/mL) containing urine was offered to each of six experimental 
horses and blood was collected at 0, 4, 8, 12, 16, 20 and 24 hours.  All six horses had 
plasma DXM concentrations above the LOD and five of six had plasma DXM 
concentrations above the LOQ for at least one sample time. 
Experimental:  Privately owned animals (Thoroughbred, Standardbred, and Quarter 
Horse racehorses) were used throughout the study.  Training adhered to standard 
regimens consistent with the type of racing specific to the racing discipline.  Inclusion 
criteria included a full clinical examination by a veterinarian.  Exclusion criteria were 
injections with Betamethasone or DXM within 7 days, or any other medication within 24 
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hours prior to blood collection.  Blood samples were drawn into 10mL serum separator 
vacuum tubes immediately preceding the first dose of DXM and at 48 and 72 hours after 
the last dose of DXM.  These were allowed to clot, refrigerated, and centrifuged within 4 
hours before being stored at -70 Centigrade.  Serum Analysis was performed via LC-
MS/MS using Selective Reaction Monitoring.  Statistical/Pharmacological analyses were 
used, including a Robust Regression on Order and General Linear Model statistical 
methodologies. 
The contamination experiment was performed by dosing Lucerne hay with urine that was 
collected from a mare previously administered 0.05mg/kg DXM IV.  Blood samples from 
these six sedentary horses were then collected up to 24 hours after the exposure to the 
hay, and samples were analyzed by a more sensitive LCMS methodology with a Limit of 
Detection of 0.5pg/mL. 
Conclusion:  Results indicate that a daily dose of 20mg IV of DXM demonstrates no 
accumulation, and so withdrawal guidelines should not change for an animal requiring 
multiple dosings.  The threshold of 5pg/mL at 72 hours shows an experimental positive 
test risk of approximately 2.7%.  Similarly, environmental contamination from urine was 
shown to result in detectable levels of DXM in the blood of the horse. 
Citation: McClure, S., Fenger, C., Kersh, K., Brown, B., Maylin, G., Duer, W., ... & 
Tobin, T. (2021). Dexamethasone serum concentrations after intravenous administration 
in horses during race training. Comparative Exercise Physiology, 17(3), 263-272. 
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An In-Depth Look at Stall Contamination: A Total of 28 Substances Were 
Identified in Charles Town Ship-In Stalls as a Mix of Human Medications and 
Recreational Substances with Some Actual Equine Medications  
Summary:  A series of low-concentration positives being ‘called’ in West Virginia led to 
an investigation into the possibility of stall contamination.  Of the stalls swabbed, only 
four of the twenty-one tested were not considered to test ‘positive’ for at least a single 
drug – categorized as human recreational, human therapeutic, or equine therapeutic.  This 
indicates a large chance of environmental contamination in any ship-in stall, and as 
testing becomes more and more sensitive it will be more and more important for 
thresholds to be established to avoid just such exposures resulting in a ‘positive’ that 
could otherwise end careers. 
Citation: Fenger, Clara; Catignani, Maria; Machin, Jake; and Tobin, Thomas, "An In-
Depth Look at Stall Contamination: A Total of 28 Substances Were Identified in Charles 
Town Ship-In Stalls as a Mix of Human Medications and Recreational Substances with 




Tramadol: A Human Therapeutic Medication and an Environmental Substance 
Occasionally Identified in Equine Drug Testing 
Abstract: Tramadol is a centrally acting synthetic opioid analgesic prescribed for acute and 
chronic pain in human and veterinary medicine. The human dose is 50-100 mg at 4-6 hr 
intervals, not to exceed 400 mg Tramadol per day. For optimal activity Tramadol must be 
metabolized to O-DesMethylTramadol (ODMT), which has 200-500-fold more opiate 
receptor activity than Tramadol.  Horses rapidly metabolize ODMT to an inactive 
glucuronide metabolite, which renders Tramadol much less therapeutically effective in the 
horse.  In horseracing, Tramadol is classified as an Association of Racing Commissioners 
International (ARCI) Class 2, Penalty Class A substance [Version 11.00 December 2015].  
Tramadol is chemically stable in the environment and has been found at significant 
concentrations in urban wastewater. 
Recently, equine drug testing laboratories have been reporting low concentration urinary 
ODMT ‘identifications/positives’, which may result in significant penalties for trainers 
and owners.  In horses, Tramadol is metabolized to ODMT, which is then rapidly 
glucuronidated and excreted at high concentration in equine urine.  Tramadol therefore 
has marginal therapeutic efficacy in horses but since Tramadol persists in the 
environment and its metabolite, glucuronidated ODMT, is very effectively concentrated 
in equine urine, Tramadol is highly likely to yield environmentally driven low 
concentration identifications (‘positives’) in the urine of horses exposed to Tramadol 
containing environments, as recognized in a number of jurisdictions. 
Review of Tramadol/ODMT ‘positives’ shows a number of low concentration 
identifications in the urine from horses associated with individuals prescribed Tramadol.  
Given the medical reasons for prescribing Tramadol to humans and the marginal 
therapeutic efficacy of Tramadol in horses, the calling of ‘positives’ for 
pharmacologically ineffective trace concentration identifications of ODMT in post-race 
urine samples is difficult to justify and may selectively penalize older horsepersons who 
are more likely to be prescribed Tramadol for chronic pain. We believe a more equitable 
approach is to specify a urinary ODMT (screening or cut-off level) (we propose 50 
177 
ng/mL) below which regulatory action is not warranted, as has been done for morphine 
and other human associated environmental substances (Tobin et al., 2012). 
Conclusion: The widespread use of Tramadol by humans, it’s chemical stability in the 
environment, ready oral absorption by equines, marginal activity in horses, and very 
efficient excretion into the urine as ODMT glucuronide, it is unsurprising to find low 
level Tramadol ‘positives’ occurring sporadically.  While oftentimes it can be determined 
to be related to a human exposure, it may also be from its persistence in the environment 
around a horse.  As such, we recommend a 50ng/mL ODMT urinary ‘cut-off’ based on 
current reported concentration levels in ‘positive’ findings. 
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A Cluster of Trace-Concentration Methamphetamine Identifications in Racehorses 
Associated with a Methamphetamine-Contaminated Horse Trailer: A Report and 
Analysis 
Abstract: Three low concentration methamphetamine “positive” tests were linked to use 
of a methamphetamine-contaminated trailer to transport the affected horses. This incident 
establishes methamphetamine as a human-use substance that can inadvertently enter the 
environment of racing horses, resulting in urinary methamphetamine “positives;” an 
interim regulatory cut-off of 15 ng/mL for methamphetamine in post-race urine is 
proposed. 
Conclusion:  Based on current regulations and the high potential for environmental 
contamination of methamphetamine, a 15 ng/mL threshold is proposed until further 
studies can determine a more appropriate cut-off.  This is noticeably lower than the 500 
ng/mL cut-off used by the US Department of Health and Human Services. 
Citation: Brewer, K., Shults, T. F., Machin, J., Kudrimoti, S., Eisenberg, R. L., Hartman, 
P., ... & Tobin, T. (2016). A cluster of trace-concentration methamphetamine 
identifications in racehorses associated with a methamphetamine-contaminated horse 
trailer: a report and analysis. The Canadian Veterinary Journal, 57(8), 860. 
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Aminorex identified in horse urine following consumption of Barbarea vulgaris, a 
preliminary report 
Abstract: Aminorex, (RS)-5- Phenyl-4,5-dihydro-1,3-oxazol-2-amine, is an 
amphetamine-like anorectic and in the United States a Drug Enforcement Administration 
[DEA] Schedule 1 controlled substance. Aminorex in horse urine is usually present as a 
metabolite of Levamisole, an equine anthelmintic and immune stimulant. Recently, 
Aminorex identifications have been reported in horse urine with no history or evidence of 
Levamisole administration. Analysis of the urine samples suggested a botanical source, 
directing attention to the Brassicaceae plant family, with their contained GlucoBarbarin 
and Barbarin as possible sources of Aminorex. Since horsepersons face up to a 1-year 
suspension and a $10,000.00 fine for an Aminorex identification, the existence of natural 
sources of Aminorex precursors in equine feedstuffs is of importance to both individual 
horsepersons and the industry worldwide. 
Results 
Testing the hypothesis that Brassicaceae plants could give rise to Aminorex 
identifications in equine urine we botanically identified and harvested flowering 
Kentucky Barbarea vulgaris, (“Yellow Rocket”) in May 2018 in Kentucky and 
administered the plant orally to two horses. Analysis of post-administration urine samples 
yielded Aminorex, showing that consumption of Kentucky Barbarea vulgaris can give 
rise to Aminorex identifications in equine urine. 
Conclusions 
Aminorex has been identified in post administration urine samples from horses fed 
freshly harvested flowering Kentucky Barbarea vulgaris, colloquially “Yellow Rocket”. 
These identifications are consistent with occasional low concentration identifications of 
Aminorex in equine samples submitted for drug testing. The source of these Aminorex 
identifications is believed to be the chemically related Barbarin, found as its precursor 
GlucoBarbarin in Kentucky Barbarea vulgaris and related Brassicaceae plants worldwide. 
Experimental: Flowering Barbarea vulgaris were harvested, cleaned, and administered to 
horses with pre- and post-administration blood/urine test samples collected.  
Administration was performed by offering to horses as feed, which was initially declined.  
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Upon being mixed with sweet feed, however, the plant material was readily taken up by 
the horses.  Analyses were performed via LC-MS.  No aminorex was detected in the 
plasma samples, but urinary concentrations were estimated to be approximately 10 
ng/mL. 
Conclusion: “Yellow Rocket” plant (B. vulgaris) has been shown to be a causative agent 
in the production of detectable levels of aminorex in equine urine when consumed.  
Further studies are needed to elucidate the exact chemical responsible, though barbarin is 
a primary candidate. 
Citation: Maylin, G., Fenger, C., Machin, J., Kudrimoti, S., Eisenberg, R., Green, J., & 
Tobin, T. (2019). Aminorex identified in horse urine following consumption of Barbarea 
vulgaris, a preliminary report. Irish veterinary journal, 72(1), 1-8. 
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